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Abstract
  Collagen  induced  arthritis (CIA)  is a  mouse  model  of  autoimmunity that 
closely resembles human rheumatoid arthritis (RA), a debilitating  disease with no 
cure. This study has been undertaken to generate  antigen-specific tolerance to  an 
autoantigen implicated in RA and immunodominant in animal models. Gene therapy 
protocols  for  RA that  have  gone  to  clinical  trial  have  been  designed  to  drive 
expression of therapeutic molecules at the site of inflammation, but not to modulate 
the immune response to key autoantigens.
This study has shown that lentiviral vectors (lvv) expressing fusion proteins 
(FP-lvv) confer antigen-specific tolerance in CIA. Fusion proteins comprised of an 
endosomal-targeting domain coupled to the immunodominant CII259-273 peptide and 
an eGFP tag, were  expressed in APCs. Confocal  microscopy revealed  substantial 
colocalisation with endosomes and lysosomes. Expression of the fusion proteins in 
APCs resulted in MHCII-presentation of the immunodominant CII259-273 peptide to 
CII259-273-reactive CD4+ T cell hybridomas. Furthermore, co-transduction with a lvv 
expressing the enzyme lysyl-hydroxylase 3 enhanced glycosylation of the expressed 
CII construct.
  Administering  mice  iv with  FP-lvv one  month  prior  to  disease  induction 
reduces by half the arthritic score during the first two weeks of clinical symptoms in 
CIA, providing partial but significant protection. The use of suitable controls showed 
that  this  effect  is  antigen-specific  and  measurements  of  α-CII  IgG  show  a 
significantly lower titre in treated animals.
  This study provides evidence that lvv-mediated MHCII-presentation can be 
tolerogenic  and  hence,  this  approach  could  form  an  important  part  of  future 
treatments for autoimmune diseases.17
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Chapter 1.  Introduction23
1  Introduction
1  Tolerance and immunity
  The  immune system  serves to protect an organism  from  disease. Multiple 
mechanisms act to detect and react to pathogens as diverse as foreign cells, infected 
or  altered  self  cells,  virus  particles  and  other  harmful  particles  or  molecules. 
Classically divided into innate and adaptive immunity, the interface between what 
was once regarded as two separate systems is now known to be critical in shaping 
the  adaptive  response.  This  project  can  be  viewed  as  an  investigation  of  how 
inducing  an  interaction  between  innate  and  adaptive  systems  can  modulate 
subsequent immune reaction to a model antigen.
  Phagocytic cells have an “innate” capacity to recognise and ingest harmful 
materials, and those endowed with antigen presenting abilities such as dendritic cells 
(DCs) and macrophages (MΦ) not only remove and digest the offending substance, 
but  also  present  digested  fragments  to  a  particular  subset  of  lymphocytes  that 
constitute  the  “adaptive”  arm,  alerting  them  to  the  threat.  It is at  this  interface 
between  the  innate  and  adaptive  systems,  where  presented  antigens  prime  the 
adaptive response that can largely determine the nature of the response to particular 
antigens.
  Lymphocytes use antigen receptors to mediate adaptive immunity, and there 
is  an  almost  infinite  variety  of  antigen  receptors,  generated  through  random 
rearrangement of Ig  genes in B lymphocytes and T cell receptor (TCR) genes in T 
lymphocytes. The ability to generate so vast a range of antigen receptors is crucial 
for the recognition of epitopes present in any immunological challenge, but because 
the  generation  of  diversity  in  antigen  receptors  is  random,  many  lymphocytes 
develop  with  antigen  receptors  that  react  against  the  host’s  own  constituents. 
However, harmful immune reactions against the host are rare because another series 24
of mechanisms exist to tolerise the immune  systems to host antigens,  preventing 
autoimmunity (Goodnow et al. 2005).
  This  project has  shown  that  by expressing  chimeric  proteins  that  traffic 
antigens to the endosomal pathway in antigen presenting  cells (APCs) the adaptive 
system  can  be  primed  to  respond  to  subsequent challenge  from  that  particular 
antigen  much  less  severely.    Chimeric  protein  expression  was  driven  by  self 
inactivating (SIN) lentiviral vectors.
  This study, therefore, shows that induction of antigen presentation using this 
method tolerises and may prove to have important applications in the treatment of 
autoimmune diseases.
1.1  Tolerance induction in the healthy immune system
  In a ‘normal’ immune system, tolerance to self antigens and other innocuous, 
non-infectious environmental antigens is achieved by silencing the immune response 
in an antigen-specific manner. This, as discussed below, can be done centrally or in 
the periphery, by a number of overlapping  mechanisms such as clonal deletion or 
desensitisation of  autoreactive  lymphocytes  (Nossal  1994),  or by immunological 
suppression  by regulatory T cells  (Treg  cells)  specific  to  the  innocuous  or  self 
antigen  (Kronenberg  &  Rudensky 2005). As there  is no  direct way to determine 
whether a particular molecule has originated from the host, the context in which the 
immune system encounters an antigen shapes the response and subsequent responses 
to that antigen.
1.1.1  Central tolerance
  The first point at which self-reactivity can be silenced is during lymphocyte 
development that happens in the central lymphoid organs of the bone marrow and 
thymus, during which strongly reactive lymphocytes are deleted or altered so as not 
to respond aggressively to the stimulating  antigen. In this way, the immune system 
uses  the  context of  centralised  antigen  recognition  as  a  marker  of  self.  B  cell 25
receptors react with antigens in their native form (eg folded peptide epitopes) wheras 
T cells react with antigens presented on Major Histocompatibility (MHC) molecules 
such as MHC class II (MHCII) (figure 1.1)
Figure 1.1 Antigen processing and presentation
MHCII molecules fold in the Endoplasmic Reticulum (ER) in complex with the 
Invariant  Chain,  Ii,  which  includes  a  CLIP  domain  that  excludes  other 
endogenous peptides in the ER from occupying the antigen-binding groove of 
MHCII  (top  left).  The  trimeric  complex  is  trafficked  to the  lysosomes/late 
endosomes where cathepsins degrade  the invariant chain (top right) and  also 
captured  antigens.  HLA-DM  (H2-DM  in  mice)  is  a  chaperone  molecule, 
structurally  related  to  MHCII,  which  acts  to  facilitate  CLIP  exchange  for 
processed antigen (above left). The MHCII-antigen complex then moves to the 
plasma membrane for presentation to CD4+ T cells (above right).26
  Both  B  and T cell  progenitors  originate  in  the  bone  marrow,  but  whilst 
important steps in the deletion or inactivation of autoreactive B cells occur in the 
bone marrow, T cell progenitors travel to the thymus to continue their development. 
Medullary epithelial  cells  (MECs)  present  peptides  from  a  wide  array  of  host-
derived peripheral tissue antigens (PTAs), usually found only in specific tissues, on 
MHC molecules (Westerberg, Klein, & Snapper 2008). Interaction between the T-
cell  receptor  and MHC-peptide complex  is  crucial  for  the  positive selection  and 
survival of the thymocyte (Fowlkes & Schweighoffer 1995) because this ensures that 
the  mature  T  cell  will  recognise  peptides  presented  on  self-MHC  molecules. 
However,  T-cell  clones  that  strongly  react  to  MHC/self-peptide  complexes  are 
deleted (Kappler, Roehm, & Marrack 1987;Kisielow et al. 1988;Kishimoto & Sprent 
1997)  by  induced  apoptosis  (clonal  deletion)  (Surh  &  Sprent  1994)  or  can  be 
induced  to  develop  down  the  lineage  of  regulatory T  (Treg)  cells  (Itoh  et  al. 
1999;Picca & Caton 2005) which will be discussed further below. The importance of 
central deletion of strongly reactive T cells in the thymus is illustrated when PTA 
expression is abrogated. Although its precise regulatory mechanism remains unclear, 
the autoimmune regulator gene Aire (Aaltonen et al. 1997;Nagamine et al. 1997), 
expressed  at high levels  in  MECs (Anderson et  al.  2002;Anderson et al.  2005), 
promotes  ectopic  expression  of  PTAs.  Mutations  in  this  gene  lead  to  the  rare 
condition  autoimmune  polyendocrinopathy-candidiasis-ectodermal  dystrophy 
(APECED).  In  Aire-knockout mice,  the  self-reactive  lymphocytes  escape  clonal 
deletion  and  are  able  to  egress  from  the  thymus,  migrating  to  the  periphery 
(Anderson et al. 2005)  resulting  in multi-organ autoimmunity (Mathis & Benoist 
2007).  Hence, the  ability of  the  immune  system  to recognise  a  variety of  self-
antigens  in  the  context  of  central  presentation  is  crucial  for  generating  central 
tolerance.
  As many as 75% of early immature B cells have been found to express self-
reactive antibodies (Wardemann et al. 2003), but most of these are removed during B 
cell  maturation.  Developing  autoreactive  B  cells  are  silenced  within  the  bone 27
marrow by three known mechanisms (Meffre & Wardemann 2008). Strongly self-
reactive B cells maturing in the bone marrow are either deleted (Nemazee & Burki 
1989;Cornall, Goodnow, & Cyster 1999) or the self-reactive B-cell receptor (BCR) 
can be  internalised and edited to replace the light chain with a version that is no 
longer  self-reactive  so  as  to  escape  clonal  deletion  (Tiegs,  Russell,  &  Nemazee 
1993;Halverson, Torres, & Pelanda 2004). This is thought to occur in at least 25% of 
developing  B cells in normal individuals (Retter & Nemazee 1998;Casellas et al. 
2001).  Thirdly,  B  cells  that  chronically bind  self-antigen  may become  anergic, 
defined as functional inactivation to further signals through their BCR (Hippen et al. 
2005), a state initially described in 1988 (Goodnow et al. 1988). Finally, B cells can 
be inherently unresponsive due to ignorance of their autoantigen if the  antigen is 
inaccessibly sequestered in a cellular compartment.
  Clonal  deletion,  or  conversion  from  potentially  dangerous  autoreactive 
lymphocytes into either non-autoreactive lymphocytes, or into immunosuppressive, 
autoreactive  Treg  cells,  silences  the  immune  response  from  cells  with  antigen 
receptors that bind strongly in the primary lymphoid organs; strong reactivity in the 
context  of  developing  lymphocytes  in  the  central  lymphoid  organs  is  used  to 
centrally silence potential autoimmune reactions. Some self antigens, however, may 
not have  access to  developing  lymphocytes  (Lo  et al.  1989)  and  these  clonally 
ignorant lymphocytes may encounter  their  cognate autoantigens after  leaving  the 
central  lymphoid  organs. Additonally,  some  autoreactive  lymphocytes  escape  the 
mechanisms for central tolerance (Bouneaud, Kourilsky, & Bousso 2000). There are 
a  plethora  of mechanisms in the  periphery that prevent autoreactive  lymphocytes 
from mounting a destructive response against the host, many of which are still being 
elucidated.  Below is an overview of  peripheral  immune  regulation,  focussing  on 
antigen  recognition  by CD4+  T cells  that are  pivotal  in  the  deployment of  the 
adaptive immune response. Again, the context in which the thymocyte encounters its 
cognate antigen determines the nature of any subsequent immune responses.28
1.1.2  CD4+ T cells are pivotal in the deployment of the adaptive immune response
  Tolerisation  of  CD4+  T cells is  critical  in  avoiding  autoimmune  disease. 
Often  termed helper T cells (Th  cells),  CD4+ T cells do not generally exert any 
direct  cytotoxic  action  against  pathogens  but  instead  ‘help’  other  arms  of  the 
immune  system  by  activating  other  effector  cells,  inducing  them  to  mount  an 
appropriate  response.  The  exceptions  are  regulatory  CD4+  T cells  (Tregs)  that 
express  the  forkhead/winged-helix  transcription  factor  FoxP3  (Hori,  Nomura,  & 
Sakaguchi 2003). 
  Th  cells  were  historically divided  into  two  classes  namely Th1  and  Th2 
(Mosmann & Coffman 1989) according  to their cytokine profile that is critical  in 
activating a particular branch of the immune system. Antigen-specific MΦ activation 
by gamma-interferon  (IFN-γ) producing  CD4+  T cells (helper  class  1, Th1)  are 
required for the induction of antimicrobial  mechanisms against many intracellular 
pathogens (Stout & Bottomly 1989), whilst interleukin-4 (IL-4) producing helper T 
cells (Th2) are required for B cell activation in most cases (Parker 1993). Even the 
cytotoxic response to infection, mediated by CD8+ cytotoxic T lymphocytes (CTLs) 
involves regulation from CD4+ T cells (Novy et al. 2007) and CD4+ T cell help is 
especially important in the generation and maintenance of memory CD8+ T cells 
(Ramsburg et al. 2007).
  More recently a third group of effector CD4+ cells have been described that 
have  been shown to be  distinct from  Th1/Th2,  denoted Th17 cells  that produce 
IL-17  (Aggarwal et al. 2003).    IL-17 contributes to the  pathogenesis of  arthritis 
(Lubberts 2003) and it has been shown that IL-17-deficient mice are less susceptible 
to CIA, partly due to impaired CII-specific IgG2a production (Nakae et al. 2003). 
Th17  cells were initially thought to be  induced by IL-23,  a  member  of  the  IL-6 
superfamily of cytokines (Oppmann et al. 2000) and data showing  IL-23-deficient 
mice to be resistant to experimental autoimmune encephalomyelitis (EAE) (Cua et 
al. 2003) and CIA (Murphy et al. 2003) supported this. Naïve T cells, however, do 
not express high levels of the IL-23 receptor (IL-23R) (Parham et al. 2002) and it 29
has  since  been  shown  that  whilst  IL-23  is  necessary  for  the  maintenance  and 
pathogenicity of Th17 cells (McGeachy et al. 2007), IL-23 does not actually induce 
Th17 differentiation.
  Three studies published in 2006 showed that Th17 cell differentiation is not 
induced by IL-23 but instead by Transforming growth factor-β (TGF-β) in concert 
with IL-6 (Bettelli et al. 2006;Veldhoen et al. 2006;Mangan et al. 2006). IL-23 was 
instead found  to be  necessary for Th17 cell  survival  and expansion. The  role  of 
TGF-β in inducing Th17 cells, so important in autoimmunity, contrasts with its role 
in  the  delineation  of  Treg  cells  when  present  without  IL-6  (Hori,  Nomura,  & 
Sakaguchi 2003;Chen et al. 2003).
  Secreted  by Treg  cells  and usually regarded as a key immunosuppressive 
cytokine, TGF-β has an inhibitory effect on effector T cell  proliferation (Li et al. 
2006) but,  conversely, induces production of auto-immunogenic Th17 cells when 
present together with IL-6. TGF-β  can be an inducer of immunosuppressive Treg 
cells or immunogenic Th17 cells depending on IL-6 concentration. Hence, either cell 
type,  but  not  both  are  produced.  The  implications  of  this  so-called  reciprocal 
relationship  between  Th17  cells  and  Treg  cells  (Bettelli  et  al.  2006)  will  be 
considered below.
1.1.3  Peripheral tolerance
  Effector CD4+ T cells of each subtype initiate an adaptive immune response 
after  they  become  activated,  which  causes  clonal  expansion,  and  enables  the 
activated T cells to access sites of inflammation (Sallusto et al. 1999). Classically, 
the Two Signal model has been used to describe the conditions required to achieve T 
cell activation (Mueller, Jenkins, & Schwartz 1989); ligation of TCR with cognate 
antigen presented on MHC molecules, and costimulation provided by either surface 
molecules such as CD40 and CD80/86, expressed on mature (activated) APCs, or 
pro-inflammatory cytokines such as interleukin-2 (IL-2), or both.30
  Autoreactive T lymphocytes that have  escaped  the  mechanisms  of  central 
tolerance may encounter their specific antigen in the periphery, but if this occurs in 
the  absence  of  other  inflammatory  signals,  the  T  cell  is  unlikely  to  initiate  a 
damaging  autoimmune  reaction;  if  TCR  ligation  occurs  in  the  absence  of 
costimulatory signals the T cell cannot become strongly activated (Bour-Jordan & 
Blueston 2002;Zhou et al. 2002), and should induce no response. Although the non-
inflammatory context of TCR ligation in the absence of costimulation prevents the 
T cell from  mounting  an autoimmune  response, the  two-signal  model  for T cell 
activation  can  present a  problem  in  the  ability to  distinguish  dangerous foreign 
antigens from  innocuous or self antigens when a  self peptide is presented  in the 
presence of pro-inflammatory cytokines that had been produced by other activated 
immune cells (the bystander effect), or by an antigen presenting cell that has become 
activated by another stimulus.
  Immature  dendritic  cells continually survey the  extracellular environment, 
capturing  innocuous  material  from  dead  cells (Steinman  &  Nussenzweig  2002). 
Subsequent encounter with pathogenic  microorganisms at a  site  of infection will 
activate DCs through interaction with pattern recognition receptors (PRR) such as 
Toll-like  receptors  (TLRs)  (Medzhitov  2001;van  Vliet  et  al.  2007)  inducing 
maturation which leads to increased processing and presentation of peptides derived 
from  both  the  pathogen  and  the  innocuous  material,  as  well  as upregulation  of 
costimulatory signals. Any T cell  that had escaped deletion in the thymus and is 
reactive against an epitope from an innocuous antigen captured by the DC before 
maturation has the potential to be activated by the mature DC. However, potentially 
dangerous autoimmune reactions induced by autoreactive peripheral CD4+ T cells 
are thought to be avoided in three main ways.
  After  activation  by  a  mature  DC  that  is  presenting  self  antigen,  if  the 
autoreactive  T cell  subsequently encounters  an  immature  or  non-activated  APC 
presenting the same epitope in the absence of costimulatory signals, it can be deleted 
through  activation  induced  cell  death  (AICD)  (Kabelitz,  Pohl,  &  Pechhold 31
1993;Hildeman  et  al.  2002;Krammer,  Arnold,  &  Lavrik  2007)  although  it  was 
recently shown that Th17 cells are largely resistant to AICD (Yu et al. 2009).
  T  cell  anergy can  be  defined  as  a  state  of  long-lasting,  partial  or  total 
unresponsiveness  induced  by  partial  activation  (Lechler  et  al.  2001)  that  is 
maintained in vivo by continuous antigen exposure (Pape et al. 1998). When a TCR 
is ligated but only low levels of costimulatory molecules are present on the APC, a 
naïve T cell will be anergised, and unable to express IL-2 or proliferate (Quill  & 
Schwartz 1987;Schwartz 2003) even if it subsequently encounters a  fully mature 
APC presenting  its cognate antigen along  with costimulatory signals. It has been 
shown in vivo that when cells in which the pro-apoptosis Bim protein - essential for 
AICD - has been eliminated, are  continually exposed to self antigen, anergisation 
results in those cells that would otherwise have been deleted by AICD (Barron et al. 
2008).  In  this  study  anergising  self-reactive  peripheral  T  cells  was  enough  to 
maintain tolerence.
1.1.4  Treg cells
  The  third  mechanism  by which  autoreactive  T  cells  are  prevented  from 
inducing an autoimmune response, even when presented with their specific antigen 
in the presence of strong  costimulation, is through antigen-specific suppression by 
CD4+ regulatory T cells. Protection from autoimmunity can be conferred to animals 
deficient  in  these  cells  by  transfer  of  Tregs  from  healthy,  syngeneic  animals 
(Sakaguchi et al. 1995). Prevention of antigen-specific autoimmunity by Treg cells is 
an active, dynamic and multi-pronged process (Sojka, Huang, & Fowell 2008).
  Treg cells inhibit proliferation and IL-2 secretion of effector CD4+/CD25- T 
cells  (Thornton  &  Shevach  1998).  Northern  blot  analysis  revealed  IL-2  mRNA 
levels in the responder CD4+/CD25- T cells was undetectable after co-culture with 
Tregs. Addition of exogenous IL-2 or other costimulation in the form of anti-CD28 
rescued proliferation  in  responder T cells. Whilst this suppression  appears  to  be 
contact-dependent  (Thornton  &  Shevach  1998;Takahashi  et  al.  1998),  IL-2   32
deprivation may contribute. Treg cells have been shown to absorb IL-2 via CD25, 
their high-affinity IL-2 receptor α-chain (de la Rosa et al. 2004;Barthlott et al. 2005). 
Apoptosis of effector T cells induced by cytokine deprivation has been demonstrated 
(Pandiyan et al. 2007).
  Although IL-2 downregulation is often used as a primary readout of target 
cell  suppression  by Tregs (Sojka,  Huang,  &  Fowell  2008),  comparison  of  gene 
expression profiles between Treg-suppressed target cells and other non-proliferating 
T cells showed expression of many genes associated with growth arrest or inhibition 
of  proliferation  (Sukiennicki  &  Fowell  2006).  Destabilisation  of  the  interaction 
between  responder  T cell  and APC  by the  Treg  may play a  significant role  in 
immunosupression (Tadokoro et al. 2006). A recent report has shown that platelet 
glycoprotein-specific Tregs can mediate  their suppressive  activity by modulating 
DCs pre-pulsed with platelet glycoprotein. These modulated DCs displayed reduced 
levels of CD86 and MHC class II and were unable to stimulate platelet glycoprotein-
specific responder T cells (Zhang et al. 2009).
  Another  contact-dependent mechanisms  is one  of  transfer  of  cAMP from 
Tregs directly into responder T cells via gap junctions resulting in strongly reduced 
proliferation and inhibition of expression of key cytokines IL-2 and IFN-γ (Bopp et 
al. 2007).
  Despite  the  initial  focus  on  contact-dependent  Treg  action  (Thornton  & 
Shevach 1998;Takahashi et al. 1998) and in vitro studies showing that elimination of 
IL-10 and TGF-β did not abrogate Treg function (Dieckmann et al. 2001;Jonuleit et 
al. 2001), these immunosuppressive cytokines, secreted by many Tregs, have been 
shown  to  be  crucial  for  Treg  function  in  many in  vivo  systems  (Powrie  et al. 
1996;Asseman et al. 1999;Hara et al. 2001;Kingsley et al. 2002;Strauss et al. 2007). 
IL-35, identified in 2007, found to be secreted constitutively by Tregs, but not other 
CD4+ T cells, was required for maximal suppressive activity (Collison et al. 2007). 
IL-35 production by Tregs is increased by contact with effector T cells, suggesting 33
that  cell  contact  may  be  essential  for  the  initiation  but  not  maintenance  of 
suppression (Collison et al. 2009).
1.1.5  Generation of Tregs
  When Tregs are  induced in the  thymus,  a  strong  affinity for  the  MHCII-
peptide  complex  is  required  to  select thymocytes  to  develop down  this  lineage 
(Jordan et al. 2001) to become what are now called natural Tregs (nTregs). In the 
periphery, naïve CD4+/CD25- T cells can be converted to CD25+/FoxP3 induced 
Tregs (iTregs) by weaker MHCII presentation in the presence of TGF-β (Kretschmer 
et  al.  2005b)  along  with  costimulation  from  CD80/86  (Liang  et  al.  2005)  and 
CTLA-4  (Zheng  et al. 2006). TGF-β has been  shown  to be  the  key cytokine  in 
generating  iTregs from CD4+/CD25- T cells in vitro when present at the  time of 
TCR ligation (Chen et al. 2003;Fantini et al. 2004). TGF-β, however, far from being 
a solely immunosuppressive cytokine is also crucial for the development of Th17 
cells that are important in both human RA (Shahrara et al. 2008) and CIA in mice 
(Nakae  et al. 2003). Naïve CD4+ T cells will differentiate into Th17 cells in the 
presence of TGF-β in concert with IL-6 (Bettelli et al. 2006) through expression of 
the  transcription  factor RORγt (Ivanov  et al.  2006).  TGF-β also upregulates the 
IL-23  receptor  conferring  responsiveness  to  IL-23  (Mangan  et  al.  2006)  thus 
assisting  in  the  survival  of  Th17  cells.  This  iTreg/Th17  paradigm  presents  an 
interesting immunological pivot upon which damaging autoimmune reactions could 
be  triggered or  avoided.  The cytokine  environment, in particular  the  presence  or 
absence of  IL-6 at the time  of TCR  ligation  could  make  the  difference  between 
differentiation of an autoreactive naïve CD4+ T cell into an autoimmunogenic Th17 
cell or an immunosuppressive iTreg. By blocking IL-6 signaling in mice using anti-
IL-6R mAb, inflammatory IL-17 responses are inhibited and arthritis is suppressed 
(Fujimoto et al. 2008). The humanised mAb against the IL-6 receptor, tocilizumab, 
as produced by Roche under the name RoACTEMRA, can be used as an effective 
adjunct therapy for rheumatoid arthritis in combination with methotrexate.34
1.1.6  Methotrexate in the treatment of RA
  First  synthesised  in  the  1940s  and  described  as  an  analogue  of 
Pteroylglutamic (folic) acid (Seeger et al. 1949), methotrexate inhibits the enzyme 
dihydrofolate  reductase  (DHFR)  that  is  essential  in  tetrahydrofolate  synthesis. 
Tetrahydrofolate is a single carbon donor in many biosynthetic pathways including 
those that ultimately produce purines and pyrimidines for DNA and RNA molecules 
and is therefore necessary for cell proliferation. Methotrexate’s inhibitory action on 
DHFR  reduces tetrahydrofolate  synthesis  ultimately limiting  the  cell’s  ability to 
synthesise DNA, thus preventing  it from undergoing  mitosis. Extensively used in 
treating neoplastic diseases, the rational for using methotrexate for the treatment of 
RA was the inhibition of proliferation of the lymphocytes and other inflammatory 
cells in the affected joints (Cutolo et al. 2001). 
  In  the  years  after  several  trials  found  methotrexate  to  be  an  effective 
treatment for  RA (Thompson  et al.  1984;Weinblatt et  al.  1985)  several  lines  of 
evidance suggesting  that methotrexate does not simply act as an anti-proliferative 
started to emerge. Indeed, methotrexate had been shown to act when administered in 
pulses (Andersen et al. 1985). It was difficult to imagine how a therapeutic effect 
might be achieved by anti-proliferative levels of methotrexate being present for only 
a short time each week.
  Anti-inflammatory  mechanisms  of  action  have  been  suggested  (Kremer 
1994) and recent discussions of the mechanisms of methotrexate’s therapeutic action 
include  triggering  the  release  of  endogenous  adenosine  (that  itself  has  anti-
inflammatory effects)  and  suppressing  production  of  pro-inflammatory cytokines 
IL-4,  IL-6,  IL-13, TNF-α  and  IFN-γ  (Gerards et al.  2003;Wessels,  Huizinga,  & 
Guchelaar 2008).
  Other mechanisms by which methotrexate exerts an anti-proliferative effect, 
particularly on  lymphocytes,  have  also  been  proposed;  alteration  of  intracellular 
levels of reactive oxygen species and increased sensitivity of activated T cells to 35
CD95 have  been shown  to lead to apoptosis of the  autoreactive T cells (Strauss, 
Osen, & Debatin 2002;Wessels, Huizinga, & Guchelaar 2008).36
1.2  Collagen Induced Arthritis
  CIA is  an  autoimmune  condition  that  can  be  induced  in  mice,  rats  and 
monkeys. It is a well-characterised model of autoimmunity in general but also shares 
many key features with human Rheumatoid Arthritis.
1.2.1  Disease induction
  It was first shown in 1977 that rats injected intradermally with collagen II 
(CII) derived from human, chick, or rat cartilage (that contain identical amino acid 
(aa) residues 256-272) in either complete  Freund’s adjuvant (CFA),  that contains 
inactivated  and  dried  mycobacteria  emulsified  in  mineral  oil,  or  in  incomplete 
Freund’s adjuvant (IFA), composed of the same oil but without the mycobacterial 
component, caused about 40% of rats to develop a  chronic inflammatory arthritis 
(Trentham, Townes, & Kang  1977). It was also noted that injection of either CII 
without adjuvant, collagen type I or type III with adjuvant, or adjuvant alone was 
unable  to  induce  arthritis in  any rat.  This is not  surprising  given  that the  only 
collagen present in cartilage is CII, itself forming the major constituent of articular 
cartilage (Brand, Kang, & Rosloniec 2004). Encoded by the single gene COL2A1, 
located on the long arm  of chromosome 12, CII is found only in cartilage,  in the 
vitreous humor of the eye and in the inner ear. 
  When collagen induced arthritis in mice was first described (Courtenay et al. 
1980), the disease was again shown to be induced by CII, (in this case of bovine 
origin) but not collagen I. Arthritis induction in the DBA/1 mice used in this study 
required a second, booster injection of CII emulsified in acetic acid administered 
intraperitoneally (ip) on day 21. All male mice  initially administered with CII  in 
CFA developed clinical arthritis in one or more joints by 14 days after the booster 
administration. About 90% of female mice develop clinical disease by 14 days, and 
all by 28 days. Of mice initially administered with CII emulsified with IFA, 70% of 
males and just 40% of females developed clinical arthritis in one or more joint at 28 37
days post booster injection, and just 80% of males and 50% of females when the 
experiment was terminated 62 days after initial immunisation.
  Autologous CII in CFA induces an arthritic condition in male but not female 
DBA/1 mice which more closely resembles human rheumatoid arthritis, with a more 
gradual  onset,  and  periods  of  remission  and  relapse  (Holmdahl  et  al.  1985a); 
(Holmdahl et al. 1986) however, a generally later but widely varying time of onset of 
clinical  disease, along  with large variability in histological data and key markers 
such  as anti-CII titre  between  individual  mice (Holmdahl  et al.  1986) limits the 
usefulness of using mouse CII-induced arthritis as a robust and repeatable model of 
autoimmunity.
  The present study has induced arthritis in male DBA/1 mice by intradermal 
administration of 100µg rat CII emmulsified in CFA followed 21 days later by an ip 
booster injection of 100µg rat CII in IFA.
1.2.2  Antibody response
  In 1981 Wooley et. al observed high titres of anti-CII antibodies not only in 
B10-Q and DBA/1 mice that developed arthritis, but also in other strains of mice 
that had received exactly the same immunisation, but that never developed clinical 
signs of inflammation (Wooley et al. 1981) suggesting  that the  presence  of anti-
collagen  antibodies  is  not itself  sufficient  to  cause  disease.  Only mouse  strains 
bearing  the  MHCII I-Aq haplotype  were  susceptible  to CIA. The Th1-associated 
IgG2a isotype was the only antibody to show raised serum levels in arthritic mice 
but not non-arthritic mice, and these antibodies are essential for the establishment of 
joint inflammation which is mediated by their ability to fix complement (Watson & 
Townes 1985).
  Whilst  transfer  of  sera  or  purified  anti-CII  Abs  from  mice  that  have 
developed CIA to recipient mice rapidly initiates severe arthritis (Holmdahl et al. 
1990), an effect termed α-collagen antibody induced arthritis (CAIA), this effect is 
not dependent on the host MHCII I-A haplotype but on the presence of a functional 38
complement  pathway  (Nandakumar  &  Holmdahl  2006)  such  that  complement 
protein C3 can be activated (Banda et al. 2007). This demonstrates that binding of 
arthritogenic  immunoglobulins  to  collagen  contributes  to  arthritis  development. 
However, the necessity for the donated immunoglobulins to be of the complement-
fixing subtypes, and the restriction to mice of particular I-A haplotypes of the ability 
to produce large amounts of these antibodies in response to exogenous CII implies 
that initiation of arthritis is dependent on properties of the immune system upstream 
of B cell maturation and antibody production. It is clear that the antibody response is 
a necessary part of the pathogenesis of CIA as B cell-deficient mice do not develop 
CIA (Svensson et al. 1998).
  Arthritogenic mouse monoclonal anti-collagen antibodies recognise surface-
exposed epitopes present on native, triple helical, but not denatured collagen that 
share  a  common  “proline-glycine-hydrophobic”  amino  acid motif  (Schulte  et al. 
1998). Human IgG in sera from RA patients have been found to recognise to the 
same epitopes as arithritogenic mouse mAbs from CIA (Burkhardt et al. 2002) and 
antibodies purified from RA patients can cause a  transient arthritis when injected 
into  mice  (Wooley  et  al.  1984).  As  discussed  in  1.2.6,  CII  is  heavily  post-
transcriptionally modified. This actually increases recognition by IgG in sera from 
RA patients compared to binding to unmodified CII.
1.2.3  Clinical and histological manifestations
  Murine CIA is characterized by an intense synovitis that corresponds with 
the clinical onset of arthritis (Brand, Kang, & Rosloniec 2004). Following  an early 
phase  in  which  T cells  and  MHC  class  II-expressing  macrophages infiltrate  the 
synovial lining, oedema accompanies infiltration of large numbers of granulocytes 
before  formation  of  a  pannus  that  marks  the  beginning  of  cartilage  and  bone 
destruction  (Holmdahl,  Tarkowski,  &  Jonsson  1991).  Immunohistopathologic 
analysis of arthritic joints from CIA display important similarities with rheumatoid 
joints,  with  the  formation  of  synovial  pannus  tissue  being  the  prototypical 39
morphologic feature (Trentham 1982). Fibrin deposition occurs, and there is often 
symmetrical  joint  involvement  persistently  affecting  peripheral  joints  causing 
synovial hyperplasia (Joe & Wilder 1999). As in RA, the pannus, which contributes 
to cartilage and bone erosion, includes many macrophages, activated dendritic cells 
and granulocytes (Holmdahl et al. 1988;Holmdahl, Tarkowski, & Jonsson 1991), a 
small number of CII-specific CD4+ T cells (Arai et al. 1996;Latham et al. 2005) as 
well as osteoclasts (Gravallese 2002) which are the only bone resorbing  cell type 
and are involved in bone erosion when activated.
1.2.4  The restriction of CIA susceptibility to mice possessing certain MHC class II 
  alleles suggests a critical role for CD4+ T cells in disease initiation 
  It was noted in the 1981 Wooley paper that the only mouse strains capable of 
developing  clinical CIA bear the MHCII I-Aq haplotype (Wooley et al. 1981). The 
same group later showed that such mice were susceptible to chick, bovine, deer, rat 
and human type II collagen, but were largely resistant to arthritis induced by porcine 
type  II  collagen  whilst mice  that express the  MHCII  I-Ar  allele  develop CIA in 
response  to  bovine,  deer,  and  porcine  collagen  (Wooley  et  al.  1985)  Arthritis 
induction  using  autologous (mouse)  CII results in  a milder disease, described  in 
1.2.2. It was postulated that the I-Aq class II molecule might bind and present one 
arthritogentic  epitope  present on chick,  deer,  rat and  human  CII  whilst the  I-Ar 
molecule might present a different arthritogenic epitope present on porcine CII and 
that both epitopes may be present on bovine and deer CII. Further work elucidating 
these immunodominant epitopes will be described below.
  The  I-Ap  molecule  only  differs  from  I-Aq  by  four  amino  acids,  the 
substitution  of  which  then  confers  susceptibility to  CIA on  H-2p  mice  that are 
otherwise refractory (Brunsberg et al. 1994). This provides direct evidence for the 
critical nature of MHCII-antigen interactions for disease induction.
  Peptides presented in the context of MHCII molecules are bound by TCRs 
with an affinity for the peptide-MHCII complex such that the T cell may be primed 40
to respond to subsequent TCR ligation in an immunostimulatory fashion. Given the 
role of CD4+ T cells in the initiation of adaptive immune responses and in antibody 
switching, this early data strongly suggested that for a mouse to be susceptible to 
disease  induction,  the ability to  present CII-derived epitopes to  activate  CD4+ T 
cells is critical. 
  Adoptive transfer of expanded CII-specific helper T cells can induce arthritis 
in syngeneic recipients (Holmdahl et al. 1985b;Kakimoto et al. 1988). The crucial 
role of CD4+ T cells is further supported by observations showing removal of CD4+ 
cells  renders mice  resistant to CIA. Mice  administered  with  rat anti-mouse-CD4 
immunoglobulins the  day before CII immunisation, which results in depletion of 
90% of CD4+ T cells, prevented 8 out of 10 mice from developing arthritis (Ranges, 
Sriram, & Cooper 1985). Anti-T cell receptor antibodies were subsequently shown to 
be an effective treatment after arthritis induction in both rats (Yoshino, Cleland, & 
Mayrhofer 1991) and mice (Chiocchia, Boissier, & Fournier 1991). Knockout mice 
for the tcrb locus that encodes the TCR β-chain lack any CD4+ cells at all and are 
completely resistant to CIA (Corthay et al. 1999). CD4 -/- mice are not completely 
refractory to CIA however (Tada et al. 1996;Ehinger et al. 2001) although this could 
be due to an abnormally high number of CD4-CD8-TCR+ cells, many found in the 
joints of these mice after immunological challenge with CII, that may contribute to 
disease (Tada et al. 1996).
1.2.5  A CII-derived peptide, recognised by the MHCII-I-Aq allele, was shown to be 
an immunodominant epitope, and renders mice resistant to CIA when exposed to it 
during early development
  Building  on work that showed that the  only cyanogen bromide  digestion 
fragment from  chick  CII  able  to  induce  arthritis  in  DBA/1  mice  was  CII245-270 
(Terato et al. 1985), Myers’ group in the early 1990s used amino acid substitutions 
on synthetic peptides to show that an immunodominant 11-mer CII260-270 drives a 
Th1-like response when incubated with splenocytes cultured from DBA/1 mice pre-41
immunised  with  chick  CII  (Myers  et al.  1992).  They further  demonstrated  that 
administering the same peptide to neonatal mice induces collagen-tolerance, making 
them refractory to CIA. This peptide is not recognised by mouse strains that do not 
express  the  I-Aq  allele  (Gustafsson  et al. 1990;Myers et  al.  1993).  Rat,  bovine, 
human and chick are identical at positions 256-273 (figure 1.2).
  256  259         264  266      270
  |      |          |    |        |
Rat:  G  E  P  G  I  A  G  F  K  G  E  Q  G  P  K  G     E  T 
Bov:  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -   -      -      P 
Mus:  -  -  -  -  -  -  -  -  -  -  D  -  -  -  -   -      -      -
Hum:   -  -  -  -  -  -  -  -  -  -  -  -  -  -  -   -      -      P
Chic:  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -   -      -      -
Pig:   -  -  -  -  -  -  -  -  -  -  -  -  -  -  -   -      -      P
Figure 1.2  Sequence  alignment  of  amino acid  residues  256-273  of  CII. 
Comparison of 6 species – rat, cow, mouse, human, chicken and pig.
  Further  evidence  supporting  the  immunodominance  of  this  collagen 
determinant is provided by experiments showing  that rat CII is unable to induce 
arthritis in transgenic mice that express the CII256-270 fragment in their Collagen type 
I (CI), denoted TSC mice. 
  Draining lymph node cells from TSC mice are unable to respond to rat CII 
whereas draining  lymph node  cells from  MMC-1  mice  that have  point mutation 
D266E, the one amino acid residue in the CII256-270 epitope that differs between mice 
and  human,  rat,  bovine  and  chick  CII,  do  produce  IFN-γ  and  normal  anti-CII 
immunoglobulin levels but do not proliferate in response to rat CII suggesting that 
the CII256-270-reactive T cells were not eliminated, but tolerised (Malmstrom et al. 
1996). This difference in the magnitude of tolerisation induced by either expression 42
of the  heterologous CII256-270 epitope ectopically in the systemically occurring  CI 
molecule  or  in  place  of  the  autologous  CII  epitope  in  MMC-1  mice  (that  still 
develop severe arthritis in response to rat CII, albeit with a halved rate of incidence) 
is thought to be  due  to only peripheral  part-tolerisation  that can be  achieved  by 
expressing the heterologous epitope in CII which is resident only in cartilage and the 
vitreous humour of the eye. It was later shown that chick CII can induce arthritis in 
TSC  mice  dependent on the  subdominant, I-Aq-restricted  chick-CII190-200  epitope 
(Malmstrom, Kjellen, & Holmdahl 1998).
  The arthritogenic response of I-Ar-bearing mice focuses on another collagen 
epitope, CII442-455, but the susceptibility of I-Aq mice is heavily focussed on TCR 
recognition of the CII256-270 epitope bound in the peptide-binding groove of Class II 
I- Aq molecules (Rosloniec et al. 1996;Kjellen et al. 1998).
  The  CII256-271  epitope  is  likely  important  in  RA.  Peripheral  blood 
mononuclear cells (PBMCs) of RA patients react to CII256-271 and its overlapping 
variants (Ohnishi et al. 2003).
1.2.6  Posttranslational  modifications of  CII  by  enzymes such  as LH3  alter the 
immunogenicity of the immunodominant epitope
  Lysine residues at the Yaa position of the Gly-Xaa-Yaa  triplet of collagen 
molecules  are  hydroxylated  at  varying  frequencies,  converting  Gly-Xaa-Lys  aa 
sequences to Gly-Xaa-Hyl, a process essential for inter-molecular cross-linking that 
endows  fibrils  with  strength  (Reiser,  McCormick,  &  Rucker  1992).  Some 
hydroxylysine  (IUPAC  name  2,6-Diamino-5-hydroxyhexanoic  acid,  formula 
C6H14N2O3)  residues  are  then  further  modified  by  addition  of  carbohydrates 
(glycosylation).
  The structure of the major glycan on collagen was solved in 1967 as being α-
glucosyl-1,2-β-galactopyranose  (Glc(α1-2)Gal(β1-O))  (Spiro  1967).  Lysyl-
hydroxylase  3 (LH3) can perform both the initial hydroxylation (Valtavaara et al. 
1998) and has been reported to further modify collagen via a glycosyl-transferase 43
domain  distinct  from  the  hydroxylating  site,  conjugating  a  β-galactopyranose 
monosaccharide  (Gal(β1-O))  or  a  Glc(α1-2)Gal(β1-O)  disaccharide  to  the 
hydroxylated  lysine  residue  (Heikkinen  et al.  2000).  Such  modifications  of  the 
Lys264 residue  of the immunodominant peptide of CII (CII259-271) have important 
implications for  the  recognition  by CD4+  T cells of  the  MHCII-bound  peptide. 
Although recent reports suggest the glycosyl-transferase activity of LH3 is modest 
(Schegg  et al. 2009), the present study has shown that coexpression of LH3 with 
fusion proteins that include the CII peptide domain can enhance glycosylation of the 
CII259-271 peptide.
  Four  post-transcriptional  modification  states  of  the  Lys264  residue  exist, 
namely  the  unmodified  (naked)  lysine  residue,  hyroxylysine,  Gal(β1-O)-
hydroxylysine, and Glc(α1-2)Gal(β1-O)-hydroxylysine. When bound in the Class II 
pocket, these Lys264 variants result in at least four different T cell-determinants, the 
Gal(β1-O)-hydroxylysine version being recognised by the majority of T cell clones 
from immunised mice (Corthay, Backlund, & Holmdahl 2001). Analysis of clonally 
expanded  (and hybridised) T cells from  two strains of I-Aq+ mice  strains found 
20/29 specifically recognized CII(256–270) glycosylated with the monosaccharide 
Gal(β1-O) suggesting that this glycopeptide is immunodominant in CIA (Corthay et 
al. 1998). Removing the sugar moiety by biochemical methods disrupts recognition 
of the MHC-peptide complex by certain T cell hybridomas, showing the importance 
of glycosylation in inducing a response from these T cell lines (Michaelsson et al. 
1994).
  Incidence  and  mean  arthritic  score  in  (B10.QxDBA/1)F1  male  mice 
immunised with biochemically de-glycosylated rat CII is reduced as compared to 
untreated rat CII, and time of onset is also delayed (Michaelsson  et al. 1994). A 
similar dependence on glycosylation state of the tolerising potency of the CII259-273 
peptide  has been  demonstrated  when  using  it bound  within  the  peptide-binding 
groove of soluble I-Aq molecules. Such peptide-MHC complexes have preventative 44
and therapeutic effects in CIA model only when the CII259-273 peptide is glycosylated 
in the 264 position (Dzhambazov et al. 2006).
  It has been suggested that where PTAs are post-transcriptionally modified in 
the periphery, they may not be presented by MECs in the thymus in all isoforms, and 
the  glycosylation  of  collagens  may  be  one  scenario  (Malmstrom,  Trollmo,  & 
Klareskog 2004) where the negative selection of autoreactive T cells may not extend 
to  those T cells that recognise  the  epitope in all  its post-translationally modified 
isoforms.45
1.3  Clinical need for tolerance induction
  Autoimmunity, graft rejection and graft-versus-host disease are three major 
clinical conditions that are currently treated with immunosuppressives as a first-line 
measure.  Whilst this  can  be  effective  in  controlling  symptoms,  it  can  leave  the 
patient vulnerable  to  infection  and  does not address the underlying  cause  of the 
undesirable immune reaction. Hence, induction or restoration of tolerance are major 
therapeutic goals.
1.3.1  Experimental induction of antigen-specific tolerance
  The first report of experimentally generated tolerance by Medawar in 1953 
showed that ip injection of allogeneic cells into fetal mice facilitates acceptance in 
adulthood of skin grafts from mice of the cell-donor strain (Billingham, Brent, & 
Medawar  1953).  Similar  results  were  obtained  in  chickens and  the  induction  of 
tolerance in this way was shown to be dependent on the exposure to foreign antigens 
whilst the  host’s  immune  system  is  still  in  an  immature  state  (ie  before  birth). 
Induction of specific tolerance to allogeneic bone marrow graft in adult mice was 
described by Slavin et al in 1977 by total  lymphoid irradiation of recipient mice 
prior  to  infusion  of  bone  marrow  cells  from  donor  mice  resulting  in  specific 
tolerance to skin grafts of donor-strain origin (Slavin et al. 1977). A year later, the 
same group showed that tolerance to BSA following total lymphoid irradiation and 
subsequent ip BSA administration was mediated by antigen-specific suppressor cells 
(Zan-Bar, Slavin, & Strober 1978). Immunosuppressive T lymphocytes were finally 
characterised in 1995 as coexpressing CD4+ and CD25+ and were called Treg cells 
(Sakaguchi et al. 1995).
  Many experimental  strategies to develop protocols for tolerance  induction 
have  focussed on Treg  induction and expansion. There  are multiple subclasses of 
Treg  cells,  some  of  which  can  be  generated  or  expanded  in  an  antigen-specific 
manner.46
  Treg  cells can be  induced both in the thymus (Jordan et al. 2001;Picca  & 
Caton 2005) and in the periphery (von Herrath & Harrison 2003;Kretschmer et al. 
2005b) and there have been many reports of conversion of CD4+/CD25- T cells into 
CD4+/CD25+/FoxP3+ Tregs in vitro (Zheng et al. 2002;Zheng et al. 2004;Zheng et 
al. 2006).
  Conversion of CD4+/CD25- T cells into Tregs can be achieved by targeting 
minute doses of cognate peptide to DCs for suboptimal activation, thus generating 
large  numbers of antigen-specific  immunosuppressive cells (Mahnke  et al. 2003). 
Over 50% of CD4+/CD25- T cells can be converted to Tregs (Bettelli et al. 2006). 
  Antigen-specific regulatory T cells that do not express FoxP3,  termed Tr1 
cells can be induced by culturing  murine or human CD4+ T cells with antigen or 
alloantigen in the presence of exogenous IL-10 (O'Garra & Vieira 2004;Vieira et al. 
2004).  CD25-negative  Th3  cells are  also  experimentally induced  in  an  antigen-
specific manner via TCR ligation during transient overexpression of TGF-β (Carrier 
et al. 2007), but mediate suppression by secreting TGF-β and so are suppressive in 
an  antigen-independent  manner,  thereby  potentially  giving  rise  to  “bystander 
suppression”(Weiner 2001). Nonetheless, this, along with each of the other methods 
for  generating  antigen-specific  Treg  cells,  have  potential  uses  in  establishing 
antigen-specific  tolerance  in  transplantation  and  autoimmune  diseases  including 
autoimmune arthritis (Thomson & Robbins 2008).
  A method of expanding  nTregs in  the periphery of live mice  has recently 
been  reported  (Swee  et  al.  2009).  Achieved  by  injection  of  supra-physiologic 
injection  of  Fms-like  tyrosine  kinase  3  ligand,  a  cytokine  required  for  DC 
homeostasis that results in massive DC expansion when present at these levels, this 
indirectly induces a two-fold increase in nTregs as a result of the 18-fold expansion 
of DCs. Whilst the expanded nTregs were demonstrably one fraction of previously 
existing  nTregs in the periphery that had  been induced to proliferate, there  is no 
selectable antigen specificity of these cells.47
  Whilst FoxP3+ Treg  cells have been generated in vitro by using TGF-β in 
concert  with  TCR  costimulation  (Chen  et  al.  2003),  antigen  presentation  by 
immature  dendritic  cells  in  the  “steady state”  is increasingly implicated  in  Treg 
generation  (Yamazaki  et  al.  2003;Gaudreau  et  al.  2007).  Even  experimentally-
matured DC’s can stimulate Treg generation in an antigen-specific fasion (Gilliet & 
Liu 2002;Lau et al. 2008).
  Antigen-specific tolerogenic DCs, prepared by pulsing  immature DCs with 
influenza  matrix  peptide (MP) has been used to induce MP-specific tolerance  in 
human test subjects when injected subcutaneously (Dhodapkar et al. 2001). This was 
found to induce suppressor CD8+ T cells, and the silencing of CD8+ effector cells 
was found to be specific for MP-reactive T cells. Antigen-specific Tregs that may 
have  important uses  in  transplant  patients  have  been  generated  by culture  with 
allogeneic DCs in the presence of IL-10 (Levings et al. 2005).
  Such methods may represent a viable approach for the conversion of antigen 
specific conventional T cells into Treg cells in situ in the periphery in a similar way 
as de novo generation in the periphery via conversion of truly naïve CD4+ helper 
cells  has  been  achieved  by targeting  small  amounts  of  specific  antigens  to  be 
presented by immature DCs (Mahnke et al. 2003;Kretschmer et al. 2005a;Jaeckel et 
al. 2006). In this way, it is hoped, by expanding antigen-specific regulatory T cells, 
antigen-specific tolerance could be generated. 
  An alternative  method  for antigen-specific tolerance induction, rather than 
trying to generate Tregs directly, or by using tolerogenic DCs has been to perform 
systemic administration of soluble antigen. This has been done by single or multiple 
iv or ip injections in the absence of adjuvant. This has been shown to be effective in 
both Experimental  autoimmune  encephalomyelitis (EAE) (Levine et al. 1972) and 
type  1  diabetes  (Tisch,  Wang,  &  Serreze  1999;Atkinson  &  Leiter  1999). 
Mechanisms include anergy (Gaur et al. 1992) due to TCR ligation in the absence of 
costimulation usually provided by adjuvant (Boussiotis et al. 1993) and   Treg  cell 
induction (Thorstenson & Khoruts 2001). Beneficial effects in clinical investigations 48
of antigen therapy for allergy and chronic progressive multiple sclerosis at the end of 
the  1990s,  however,  were  disappointing  (Warren,  Catz,  &  Wucherpfennig 
1997;Norman et al. 1997;Bousquet et al. 1998).
  The  oral route  of antigen exposure  can also be  effective in preventing  the 
induction of autoimmune diseases (Khoury et al. 1990;Zhang et al. 1991). In 2007 
the  CII250-270  peptide,  administered  via  the  oral  route,  was  shown  to  be 
immunosuppressive in CIA (Zhu et al. 2007). Several mechanisms that mediate this 
effect have been suggested including  deletion and anergisation of CD4+ cells and 
Treg induction (Mowat et al. 2004). No significant beneficial effects were observed 
in  phase  II clinical  trials that attempted to induce  oral  tolerance  using  bovine  or 
chicken  CII  in  RA  patients  however  (Trentham  et  al.  1993;McKown  et  al. 
1999;Staines et al. 2004) although oral insulin administration did delay the onset of 
diabetes in high-risk patient populations (Chaillous et al. 2000).
  Altered peptide ligands (APL) are peptides that vary from immunodominant 
epitope peptides by one or two amino acids. Such peptides have been shown to act 
“antagonistically”  to  T  cell  clones  (Sloan-Lancaster  &  Allen  1996)  and 
administration of such peptides has been shown to be effective inhibitors of EAE in 
mice  (Franco  et  al.  1994).  Whilst  administration  of  APL  at  the  time  of  EAE 
induction profoundly suppressed disease, because the immune response in humans is 
polyclonal, a ligand that acts as an  antagonist to one  T cell clone may stimulate 
another. A phase II clinical trial for the use of myelin basic protein APL was halted 
when disease was exacerbated in some MS patients (Bielekova et al. 2000).
1.3.2  Gene therapy approaches for antigen-specific tolerance induction
  Gene  therapy  has  been  used  in  imaginative  and  diverse  ways  to  drive 
antigen-specific tolerance in experimental animals. Loosely defined as the transfer 
of genetic material into cells for therapeutic gain (see 1.5.5 Gene therapy in humans, 
below),  a  slightly narrower  definition  is the  insertion  of  a  gene  into a  cell  –  a 
definition that excludes oligonucleotide delivery such as some RNAi technologies. 49
Whilst  two  oligonucleotide  therapies  undergoing  human  clinical  trials  will  be 
mentioned briefly in section 1.5.7 Gene therapy for rheumatoid arthritis below, this 
overview  of  gene  therapy approaches  for  inducing  antigen-specific  tolerance  in 
experimental animals will only consider studies that insert recombinant genes.
  The  simplest form  of gene therapy involves transfer of plasmid DNA into 
cells. Typically injected intramuscularly, often into the quadriceps, naked plasmids 
are  cytophagocytized,  and  their  encoded  genes  expressed  (Wolff  et  al.  1992). 
Expressed genes can be presented on MHC class I by myocytes or on MHCII by 
neighboring  APCs.  Because  such  presentation  occurs  without inflammation,  the 
vaccine can be tolerising due to the lack of costimulatory molecules. DNA vaccines 
encoding  a peptide  fraction of myelin proteolipid protein have been shown to  be 
protective against EAE (Ruiz et al. 1999), and plasmids expressing mouse CII (Ho et 
al. 2006) or chick CII (Song et al. 2009) were protective against CIA in mice and 
rats respectively.
  Of critical importance to the design of this project was a publication from 
2006 on transfecting DCs with DNA vaccines (Maksimow et al. 2006). By fusing 
the endosomal-trafficking motif from LAMP-1 onto the OVA model antigen, DCs 
expressing  this fusion construct did not prime an immune response  against OVA-
expressing  lymphoma  cells in recipient mice but rather attenuated the response  – 
tolerance to OVA was actually enhanced. This was shown to be Treg cell-mediated. 
Also included on the fusion construct was an eGFP domain, immediately proceeding 
the  LAMP-1  signal  sequence  at the  3’-end, that enabled  the  authors to  identify 
transfected DCs and optimize their transfection protocol. The authors conclude that 
by driving OVA antigen presentation in the context of MHCII, tolerance to OVA was 
induced.
  The  use  of  viruses in  gene  therapy allows  efficient and  sometimes  cell-
specific  DNA transfer.  Of  particular  interest to  this  introduction  are  the  family 
retroviridae that includes lentiviruses. The genome of retroviruses is single-stranded 
RNA that is reverse-transcribed within the cell and the resultant DNA is integrated 50
into the host genome. This has the advantage of guaranteeing permanent presence of 
the  transgene  both within the  transduced  cell and in any daughter cells should it 
divide. HIV-1-based lvv are the gene-delivery vectors used in this study.
  Retroviral  gene  therapy has been used  transduce bone  marrow cells  with 
antigen-expressing vectors to induce antigen-specific tolerance for over fifteen years 
(Sykes et al. 1993;Ally et al. 1995). It was shown that by simply expressing a model 
antigen in re-infused bone marrow cells, T cells that were reactive to that antigen 
were deleted (Ally et al. 1995). Retroviruses have also long  been used to express 
chimeric  proteins that display either  whole  antigen  or  immunodominant  epitope 
fused to the extracellular domain of IgG heavy chains in either bone marrow (Kang 
et al. 1999) or LPS-stimulated B cells (Zambidis & Scott 1996;Agarwal et al. 2000). 
Whilst this type of antigen presentation was shown to mediate Treg expansion (Song 
et al. 2004), the exact mechanism for this is unclear.
  Gene and cell therapy can be used in combination to induce antigen-specific 
tolerance.  Some  such  strategies  rely  on  generating  an  antigen-specific  cell  that 
homes  to  the  site  of  inflammation  by  virtue  of  its  acquired  specificity  but  is 
engineered to deliver an immunotherapeutic payload. Alternatively, APCs presenting 
self antigen have been engineered to deliver apoptotic signals to any effector T cell 
that interact with them: Collagen presenting DCs, generated in vitro by pulsing with 
CII, were transduced with adenoviruses that express TRAIL, an apoptosis-inducing 
ligand. In this way, CII-reactive lymphocytes that interact with the modified DCs 
will  undergo  apoptosis.  Treatment of  DBA/1  mice  with  such  DCs  significantly 
reduced CIA disease and splenic T cell response to bovine CII (Liu et al. 2003).
  Recent  reports  have  used  lentiviral  vectors  to  induce  antigen-specific 
tolerance. Ex vivo transduction of DCs with lvv encoding the  OVA model  antigen 
under control of a novel DC-specific promoter (DC-STAMP) resulted in deletion of 
most OVA-reactive CD4+ T cells and also some deletion of OVA-reactive CD8+ T 
cells. Lenti-vectors have also been used by our group (iv) (Gjertsson et al. 2009) and 
others  (ex  vivo)  (Eixarch  et  al.  2009)  to  express  immunodominant  peptide 51
autoantigens in chimeric Ii in place of the CLIP domain. This strategy ensures that 
the peptide epitope will be positioned in the MHCII peptide-binding groove. These 
studies have shown the antigen-specific tolerogenic effects of using lentiviral vectors 
to drive MHCII-presentation of autoantigens. The work from our group has shown 
that presentation of the CII259-273 epitope on MHCII has protective effects in CIA.
  The present study has also shown that by using lentiviral vectors iv to induce 
MHCII-presentation  of  the  CII259-273  peptide  in  mice,  specific  tolerance  to  the 
CII259-273 is induced without the need for ex vivo transduction of APCs. The chimeric 
proteins in this study, however, have not directly inserted the CII259-273 peptide into 
the MHCII peptide-binding groove by virtue of Ii-chimeras but, rather, constructed 
rationally designed  fusion proteins that include  endosomal-trafficking  motifs  and 
proteolytic cleavage sites such that the CII259-273 peptide is released and loaded onto 
MHCII  molecules  via  pathways present  in APCs.  Mice  administered  with  these 
vectors were partially but significantly protected from clinical arthritic symptoms of 
CIA, namely inflamed joints.
1.3.3  Fusion  proteins  used  in  this  study,  designed  to  induce  antigen-specific 
  tolerance
  The  fusion constructs used by the  present study were rationally designed, 
based on the Maksimow strategy (Maksimow et al. 2006), to present the CII259-273 
peptide on MHCII molecules of APCs. They are comprised of the signal  peptide 
from LAMP-1 (which is cleaved prior to egression from the ER) fused to eGFP, the 
CII259-273 epitope of interest,  and finally the lysosyme-localisation transmembrane 
tail of LAMP-1 or HLA-DM that is at the carboxy-terminal end (figure 1.3). Also 
included are cathepsin S cleavage sites (Ruckrich et al. 2006) flanking the CII259-273 
epitope to facilitate efficient release for loading onto the MHCII molecule; leucine, 
arginine, methionine and lysine on the N-terminus side, and glutamate, asparagine, 
leucine and lysine on the C-terminus side. The inclusion of eGFP in these chimeric 52
proteins enables both the identification of cells positive for construct expression and 
for imaging the intracellular location of the protein product.
Figure 1.3 Cartoon of LAMP1-targeted fusion protein 
  Proteins destined for the cytosol are encoded by free ribosomes whilst those  
estined  for  secretion,  for  the  lumen  of  the  ER,  Golgi  or  lysosomes,  or  for  the 
membrane of any of these organelles or the plasma membrane are synthesized on the 
membrane bound ribosomes of the rough ER (Blobel & Dobberstein 1975). They are 
then targeted to the appropriate cellular compartment.
  Secretory and membrane protein targeting is thought to be largely regulated 
during  translocation through the  ER. Nearly all  proteins destined for  any of the 
locations reached by the secretory pathway are targeted to the ER membrane as they 
are  synthesized,  a  process  called  cotranslational  translocation.  In  cotranslational 
translocation,  signal  sequences  within  a  nascent  polypeptide  are  recognized  by 
universally conserved factors in the cytosol and membrane to mediate their selective 
targeting,  translocation,  and/or  membrane  insertion  (Hegde  &  Kang  2008).  This 
process is initiated when the hydrophobic core of a signal sequence or TMD emerges 
from the ribosome and is recognized by the signal recognition particle (SRP). The 
SRP-bound  ribosomenascent  chain  complex  (RNC)  is  then  targeted  to  the  ER 53
membrane  via  an  interaction  with  the  SRP  receptor  (SR).  The  RNC  is  then 
transferred to an adjacent translocon and the SRP – SR complex dissociates. The ER 
signal sequence is cleaved off from most secreted proteins by a signal peptidase on 
the  lumenal  side  of  the  ER  membrane.  These  steps,  collectively referred  to  as 
targeting (Shan & Walter, 2005), result in the delivery of translocation substrates to 
sites of translocation at the ER.
  Proteins  synthesized  on  ER-bound  ribosomes  go  to  the  cell  surface  by 
default,  unless  they  are  specifically  directed  to  other  compartments  by  special 
signals. Proteins that are to be retained in the ER or Golgi, or that are to be directed 
to  specialized  secretory vesicles,  or  to  the  lysosome  must be  sorted from  those 
constitutively secreted (Atkinson 2006). Discrete signals on the target protein that 
are  recognized by specific receptors actively mediate sorting  of the target protein 
(Marks  et  al.  1996).  Most such  signals  consist  of  short linear  sequences  of  aa 
residues. Some, referred to as tyrosine-based sorting signals, are based on NPXY or 
YXXO (where  ‘O’ denotes an  hydrophobic  residue)  motifs whilst others,  called 
dileucine-based signals fit DEXXXLLI or DXXLL consensus motifs (Bonifacino & 
Traub 2003).
  LAMP-1  is  a  type-1  transmembrane  protein so  the  signal  peptide  that is 
responsible for inverting the protein into the ER during translation is present at the 
amino terminus (the 5’ end of the mature mRNA), whilst the intracellular trafficking 
of LAMP-1 to the lysosome relies upon a tyrosine-based lysosomal targeting signal   
GYQTI on the cytoplasmic tail mediates sorting into vesicles (Fukuda 1991; Honing 
et al. 1996). 
  The first chimeras constructed during this project used the N-terminus signal 
sequence from  IL-2, as included upstream  from the multiple cloning  sites of the 
plasmid pFUSE-hIgG4-Fc2, Invivogen (San Diego, CA), which, being derived from 
a secretory protein should direct the polypeptide to the ER and enable cleavage and 
trafficking  through  the  endosomal  pathway.  These  constructs  were  generated  as 
described in Materials and Methods below, and were shown to induce a pattern of 54
eGFP expression within transiently transfected cells, but the lentiviral vectors that 
were  made  for  stable  delivery of  these  constructs were  unable  to  demonstrably 
transduce cells. The IL-2 signal sequence was then replaced with the signal sequence 
from LAMP-1 after which the lentiviral constructs, described below, were successful 
in stably transducing fibroblast cell lines.
  The second set of constructs were generated using the endosome/lysosome-
targeting moiety from mouse H2-DMβ (Potter et al. 1999), the membrane-anchored 
subunit of the molecular chaperone that is responsible for facilitating the loading of 
antigen fragments onto the MHCII molecules in the lysosomes (Vogt et al. 1999).
  Lentiviral  vectors  were  deemed  to  be  ideal  for  this  research  project. 
Lentiviral transduction integrates the transgene into the host genome of even non-
dividing cells, and does not alter DC maturation or function (Esslinger, Romero, & 
MacDonald 2002;Breckpot et al. 2003). Hence, terminally differentiated APCs will 
express the transgene whether they themselves are directly transduced, or if a parent 
precursor cell was transduced prior to division and differentiation. The biology of 
lentiviruses and of retroviruses in general will now be discussed, and their uses for 
gene therapy will be considered.55
1.4  Viruses
  Viruses are the most abundant biological entities on the planet. Most viruses 
infect  bacteria  and  are  called  phages,  outnumbering  bacteria  by  an  order  of 
magnitude  in  most  environments  (Wommack  &  Colwell  2000).  Viruses  are 
genetically extremely diverse  and  there  is  no  single  gene  common  to  all  viral 
genomes (Edwards &  Rohwer 2005). All  viruses do, however, consist of a  viral 
genome protected by coat proteins, and some viruses also  have a  lipid  envelope. 
Many viruses are pathogenic to humans causing diseases ranging from the common 
cold to cancer and AIDS.
  Viral  genomes  are  comprised  of  DNA  or  RNA molecules  that  use  the 
standard  genetic  code  that ultimately translates into  peptide  sequence  and  thus, 
protein structure. Larger viruses such as Herpes Simplex  virus can have genomes 
that  encode  over  100  proteins,  whilst  small  RNA  viruses  such  as  the  MS2 
bacteriophage, that has a genome length of 3,569 bp, encodes just 4 proteins. The 
genome of an RNA virus can be double-stranded or single stranded which can act as 
a direct template for protein synthesis exactly as host mRNA does (+ssRNA virus) or 
require synthesis of complementary RNA, by an RNA-dependent RNA polymerase, 
that then acts as the template  for transcription (-ssRNA virus).  Retroviruses  also 
contain an RNA genome but are often not classed as RNA viruses because the RNA 
genome undergoes reverse transcription to synthesise the DNA sequence that is then 
integrated into the host genome.
  The  integration  processes makes retroviruses particularly useful  for many 
types  of  gene  therapy  –  if  retrovirus-based  vectors  are  used,  not  only  is  the 
therapeutic  transgene  delivered  into  the  cell,  but  also  integrated  into  the  host 
genome. The key stages of virus life-cycle and biology will  be  considered below 
with special attention paid to HIV, on which the lentiviral vectors used in this study 
were  based.  Gammaretrovirus  MLV,  a  simple-genome  retrovirus  will  also  be 
considered as gammaretroviral vectors have been widely used for gene therapy. The 56
advantages and disadvantages of genomic integration will also be discussed in the 
section on Retroviral vectors below.
1.4.1  Viral entry
  Viruses  enter  the  cell  by  a  variety  of  pathways;  endocytosis,  membrane 
fusion, or, in the  case of many bacteriophages, direct RNA injection. HIV enters 
following  adsorption  to  and  fusion  with  the  cell  membrane  (figure  1.4). 
Adenoviruses and Adeno-associated virus (AAV) enter the cell via endocytosis that 
follows binding of viral coat proteins with host cell receptors and integrins (Waehler, 
Russell, & Curiel 2007). AAV then requires an acidic environment to escape from 
the  early endosomes and  into  the  cytosol  (Bartlett,  Wilcher, &  Samulski  2000). 
Retroviruses enter the cytoplasm via fusion of the envelope with a cell membrane. 
HIV-1 surface glycoproteins interact with the CD4 molecule of T cells (Dalgleish et 
al. 1984) and also require interaction with chemokine receptors CXCR4 (Feng et al. 
1996) or CCR5 (Dragic et al. 1996).
  Pseudotyping is the exchange of viral envelope and attachment proteins from 
one viral strain to another (Waehler, Russell, & Curiel 2007). This can confer altered 
viral  tropism  and higher  viral  titres, hence,  it is widely used  in  generating  viral 
vectors for gene delivery. It was first shown in 1972 that VSV-G could be used to 
pseudotype  viruses  (Zavada  1972),  and  this is  the  most common  retroviral  and 
lentiviral pseudotyping  envelope protein used for vector production as it results in 
high titre vector production and a broad tropism  (Cronin, Zhang, & Reiser 2005) 
although VSV-G pseudotyped retroviruses do require endocytosis and acidification 
of endocytosed vesicles for membrane fusion to occur (Campbell et al. 2007).57
    Figure 1.4 Cartoon of HIV life-cycle. HIV envelope (Env) protein gp120 
  binds  CD4  leading  to  further  interactions  between  gp120  and 
  CCR4/CXCR5. Viral and cell membranes fuse releasing the viral core into 
  the cytoplasm and reverse transcription is initiated, generating viral cDNA. 
  Following transport into the nucleus,  viral cDNA is inserted into the host 
  genome  by  the  viral  protein  Integrase.  Transcription  of  viral  cDNA 
  generates genomic RNA and mRNA that is translated into the HIV envelope 
  protein Env  and  immature  polyproteins  Gag and Gag-Pol,  that,  together 
  with genomic RNA are assembled as viral progeny that bud from the cell 
  membrane. Picture taken from www.nature.com/nrc.58
  1.4.2  Uncoating and RTC formation
  Once the viral membrane has fused with a cellular membrane, the viral core 
(capsid) is released into the cytoplasm. For some retroviruses, the disassemblement 
of the viral capsid appears to be essential before reverse transcription of retroviral 
genome can proceed.
  In HIV infection, the host protein cyclophilin A (CypA) binds to CA and it 
was initially thought that this interaction could be involved in either viral entry or 
uncoating (Luban et al. 1993). Recent studies suggest that the CypA-CA interaction 
is important in uncoating the viral core after entry (Yamashita & Emerman 2009;Arfi 
et al. 2009). The remaining complex of viral genome and viral proteins are termed 
the reverse transcription complex (RTC). Whilst the uncoating process is relatively 
rapid in HIV, in  MLV  the  CA protein is associated  with the  RTC  and is present 
throughout  reverse  transcription  (Fassati  &  Goff  1999).  Even  in  HIV-1  where 
uncoating  is rapid, reverse transcription is thought to commence together with, not 
after uncoating  (Arhel  et al.  2007). The RTC always contains IN and  RT and  in 
HIV-1  also  contains MA,  NC  and  Vpr (Nermut &  Fassati  2003).  The  genomic 
structure  of  retroviruses  determines  the  process  of  reverse  transcription  and 
arrangement of the resulting  dsDNA genome that is ultimately integrated into the 
host genome.
1.4.3  Retrovirus genome structure
  Most retroviral genomes contain three main open reading  frames, gag, pol 
and  env downstream  from  the  repeat (R)  and  unique  5’ (U5) sequences. Almost 
directly adjacent to  the  U5  region  is  the  primer  binding  site  (PBS)  from  which 
reverse transcription is initiated. Complex  retroviruses such as lentiviruses include 
several  other  reading  frames  that  encode  regulatory  and  accessory  proteins. 
Downstream  from  the  coding  regions is a  poly-purine  tract (PPT),  a  3’ unique 
sequence (U3) and a second R sequence. The U3 sequence contains the promoter 59
and enhancer elements, thus, these are only upstream of the coding sequences after 
reverse transcription (Shinnick, Lerner, & Sutcliffe 1981).
  The R sequences are important in the second step of the reverse transcription 
process where the first part of synthesized DNA (complementary to the 5’ end of 
viral RNA) transfers to the 3’ end of the viral RNA by complementarity with the R 
sequence there. The R sequences ultimately comprise the central region of the long 
terminal repeats (U3, R, U5) that flank the dsDNA provirus that is integrated into the 
host genome.
1.4.4  Reverse transcription
  Reverse transcription is initiated by binding of host tRNA to the PBS. While 
reverse  transcription  proceeds  in  the  cytoplasm  of  the  infected  cell,  tRNA-PBS 
binding  can  occur  within  the  virion  (Trono  1992)  because  retroviral  virions 
encapsulate many host tRNAs. Different host tRNA molecules are used by different 
retrovirus genera to initiate  reverse transcription; HIV uses tRNALys3 (Jiang  et al. 
1993) while MLV uses tRNAPro (Peters et al. 1977).
  The  viral  enzyme reverse transcriptase  (RT), using  the  tRNA as a  primer, 
begins synthesis of the  minus-strand DNA complementary to the  U5  and then R 
regions at the 5’ end of  the  RNA genome. As well as DNA polymerase  activity 
(Baltimore  1970),  RT  also  possesses  a  ribonuclease-hybrid  (RNase  H)  domain 
(Molling et al. 1971) that degrades template RNA after it is reverse transcribed. This 
initial DNA transcript is called the minus strand strong stop DNA (-sssDNA). Once 
its template RNA has been degraded  the  –sssDNA “jumps” to the  3’ end of the 
remaining  RNA genome where the R sequence of the –sssDNA pairs with the  R 
sequence at the 3’ end of the remaining RNA genome (Mitra et al. 1979).
  RT, now using  the  –sssDNA as a primer, reverse  transcribes the  template 
RNA in the 5’ direction, thus encoding the viral genes into DNA, and also degrading 
the template RNA with the exception of the PPT that acts as the primer for plus-
strand DNA (+DNA) synthesis using the –DNA as a template (Smith, Cywinski, & 60
Taylor 1984). Additionally, in   some retroviruses, other RNA template regions are 
left undegraded (such as the central poly-purine tract, cPPT, in HIV) and are used as 
primers to synthesise other, discontinuous +DNA strands (Charneau & Clavel 1991). 
Synthesis of the +DNA proceeds up until the tRNA which is then degraded by the 
RNase H activity, enabling  a second, intramolecular jump such that the PBS at the 
3’ end of the –DNA strand anneals with the newly synthesized PBS on the +DNA 
strand  allowing  each strand to prime  off each  other. The  resulting  dsDNA viral 
genome has a  Long  Terminal Repeat (LTR) at each end that is blunt-ended  and 
serves as a substrate for integration (Brown et al. 1989).
  In HIV, the region of the +DNA strand synthesized from the cPPT becomes 
displaced by the +DNA strand primed from the PPT. The +DNA strand primed from 
the PPT does not completely displace the cPPT-primed strand because of a central 
termination  sequence  that prevents  full-length  +DNA synthesis. This results in  a 
single-stranded DNA flap. Although the mechanism is not known, the DNA flap is 
needed  for  efficient  entry into  the  host cell  nucleus  (Arhel,  Souquere-Besse,  & 
Charneau  2006).  The  cPPT  was  added  to  the  transfer  plasmid  of  many  later 
generations of lvv to improve transduction efficiency of non-dividing cells (Sirven et 
al. 2000).
1.4.5  Nuclear import
  Once reverse transcription is completed, the complexes are regarded as being 
integration-competent (Nisole & Saib 2004) and termed the pre-integration complex 
(PIC). In 2006 an elegant method of labeling HIV integrase (IN) was reported (Arhel 
et al. 2006). Insertion of a small tetracysteine tag (CCRECC) onto the C-terminal of 
HIV-1 IN allowed labeling  of the  RTC/PIC  with the  Fluorescein Arsenical Helix 
binder (FlAsH). Images of the translocation of the RTC/PIC through the cell were 
obtained. There was evidence  for cytosolic translocation along  both microtubules 
and  the  actin cytoskeleton. The  paper  then  reports an  attachment to the  nuclear 61
membrane  that  they  refer  to  as  docking,  and  while  occasional  intranuclear  IN 
molecules were visualized, the mechanism or route of entry was still unknown.
  While gammaretroviruses only infect dividing cells because they require the 
cell to undergo mitosis to access the nucleus, lentiviruses can enter the non-dividing 
cell  nucleus.  It  is  thought  that  transcription  factors bind  LTR  enhancers  in  the 
nucleus  before  integration,  synergizing  with  IN  in  tethering  retroviral  PICs  to 
enhancer-containing  domains  of  transcriptionally  active  chromatin  (Felice  et  al. 
2009). Lentiviral entry via direct disruption of the nuclear membrane by accessory 
protein Vpr  has been proposed (de  Noronha  et al. 2001) but recently a report of 
direct  binding  of  IN  with  the  nucleoporin  NUP153C  domain  strongly suggests 
nuclear  entry is via  interaction  with the nuclear pore  complex  (Woodward et al. 
2009).
1.4.6  Integration
  Integration  of  the  reverse  transcribed  dsDNA  viral  genome  into  host 
chromosomes is an important step in the retroviral life-cycle because it ensures that 
the integrated provirus will be replicated when the cell divides and will be present in 
both daughter cells.
  The viral IN protein is key for integration. It is a 32kDa cleavage product of 
the gag-pol polyprotein and although the exact crystal structure is yet to be solved, it 
is known to contain three main domains (Jaskolski et al. 2009). The  zinc binding 
domain  contains  an  HHCC  putative  zinc  finger  motif  (Burke  et  al.  1992)  that 
promotes multimerisation of IN thus increasing enzymatic activity (Zheng, Jenkins, 
& Craigie 1996). The catalytic central domain contains the D64-D116-E152 motif, 
commonly called DX39-58DX35E or DD35E (Ellison et al. 1995; Shibagaki & Chow 
1997)  while  the  DNA-binding  domain  resides  at  the  C-terminus  (Mumm  & 
Grandgenett 1991).
  Two catalytic  steps are  required  for integration;  both are  catalysed by IN. 
Cleavage and removal of a dinucleotide adjacent to the att sites at the end of the viral 62
DNA (Katzman  et al.  1989), known as  3’ processing  is essential  for  subsequent 
integration into host DNA in the nucleus, but actually occurs within the PIC in the 
cytoplasm (Chen & Engelman 2000). The second catalytic step, known as “joining” 
or “strand transfer” happens in the nucleus. IN catalyses a nucleophilic attack by the 
free 3’-hydroxyl group of the viral DNA on host DNA phosphodiester linkages. The 
3’ viral  ends are  ligated to the  5’-O-phosphate  residues of  the  target DNA in  a 
transesterification reaction (Bushman & Craigie 1991).
  The final integration steps involve removal of unpaired dinucleotides from 
the 5’ end of the viral DNA and repair of single-strand gaps between the viral 5’ end 
and the target DNA. These steps are probably performed by cellular factors (Van & 
Debyser 2005). The integrated viral genome is commonly termed the provirus.
  Interestingly, it was known as early as the mid-1970’s that non-integrated 
(extrachromosomal) viral DNA can also exist in the nucleus of retrovirus-infected 
cells as linear or circular DNA molecules (Gianni, Smotkin, & Weinberg 1975). The 
circular DNA molecules can form via homologous recombination between the two 
LTRs (giving rise to one-LTR circles) or via non-homologous end-joining, producing 
two-LTR circles (Ju & Skalka 1980). After it became apparent that these circular, 
extrachromosomal viral genomes could support transcription and contribute to the 
production of viral proteins, IN-defective HIV-1-based lvv were developed that are 
able to deliver the transgene to the nucleus but unable to integrate the transgene into 
the  host  chromasomes  (Vargas,  Jr.  et  al.  2004;Yanez-Munoz  et  al.  2006).  The 
advantages and disadvantages of non-integrating vectors will be discussed below.
1.4.7  Retroviral transcription and nuclear export
  Once  integrated  in  the  host genome,  the  provirus  relies  on  host  cellular 
machinery for  transcription.  The  cis-acting  elements  that  interact with  the  host 
transcriptional machinery are  present in the viral LTR. Transcribed  by host RNA 63
polymerase II, the full-length genomic RNA transcript starts at the 5’ end of the R 
sequence of the 5’ LTR. Transcription terminates at the 3’ end of the R sequence of 
the 3’ LTR thus generating the viral RNA genome flanked by the R sequences.
  In simple retroviruses such as MLV, transcription is regulated by host factors 
alone  so  viral  RNA  levels  depend  on  cell  cycle  and  differentiation  stage. 
Transcription  of  complex  retroviruses  such  as  HIV  are  also  regulated  by  viral 
proteins such as Vpr (Kino et al. 2002) and Tat that can phosphorylate host RNA 
polymerase  II, causing  it to be  more  active  (Parada  &  Roeder  1996) as well  as 
binding the trans-activation response region (TAR) present in the LTR.
  Host mRNA molecules are modified by 5’ capping, 3’ polyadenylation and 
excision of introns by splicing. Unspliced molecules are normally being retained in 
the nucleus. Retroviral RNA is also 5’ capped and 3’ polyadenylated but full-length 
genomic  RNA  must be  exported  for  packaging  into  virions  as  well  as  spliced 
transcripts for translation of viral proteins. Retroviruses have evolved a number of 
mechanisms that allow nuclear export of incompletely spliced viral RNA. Simple 
retroviruses contain sequences such as the constitutive export element (CTE) on the 
3’ UTR of Mason-Pfizer monkey virus that interacts with host Transporter associated 
with antigen processing (TAP) to directly export the viral RNA (Ernst et al. 1997). 
Complex  retroviruses have evolved additional export mechanisms (Harris & Hope 
2000). HIV-1  utilises the  Rev-RRE system  in which  the Rev protein recruits the 
nuclear export factor RanGTP (Fornerod et al. 1997) via interactions with importin 1 
(Neville  et al.  1997) to  the  incompletely spliced RNA facilitating  export via  the 
nuclear  pore  complex.  It has  been  shown  that addition of  the  CTE  to HIV  can 
facilitate Rev-independent nuclear export (Wodrich & Krausslich 2001).
1.4.8  Translation of viral proteins
  Once  in  the  cytoplasm,  viral  RNA can  be  used  for  both  packaging  into 
virions and as a template  for translation of viral proteins (Butsch & Boris-Lawrie 
2002).  The  viral  mRNA  species  in  the  cytoplasm  are  heterogeneous  as  many 64
retroviruses including  HIV contain splice  sites that are designed to be  inefficient 
(Staffa  &  Cochrane  1994).  All  viral  transcripts  are  templates  for  translation 
including  full length genomic RNA the translation of which generates the gag  and 
gag-pol  polyproteins.  Readthrough  of  the  stop codon  is  achieved  differently by 
different retroviral strains. During  translation of MLV genomic RNA the ribosome 
can  mis-read  the  amber  stop  codon  as  a  glutamine  (Yoshinaka  et  al.  1985). 
Ribosomal frame-shift is used by a majority of retroviruses including  HIV. In this 
case the ribosome “slips” back a single nucleotide and contiguously translates pol 
(Jacks & Varmus 1985).
  Env is translated from a separate reading frame. In HIV, Env is produced as a 
result of leaky scanning from mRNA that contain env as the second or third reading 
frame (Schwartz et al. 1990). Following  oligomeric assembly and transport to the 
golgi compartment, Env is proteolytically cleaved by cellular furin to form TM and 
SU proteins (Stein & Engleman 1990). Regulatory and accessory proteins, present in 
complex retroviruses, such as HIV-1, are generated through splicing to produce open 
reading frames on additional transcripts (Bolinger & Boris-Lawrie 2009).
1.4.9  Assembly, budding and maturation
  Infectious virions are formed when gag, gag-pol and env assemble together 
with genomic RNA at the plasma membrane. Present on the RNA is a  packaging 
signal (Ψ). Ψ is a sequence that forms a secondary structure that interacts with gag to 
facilitate  incorporation  into  the  virion.  In  HIV-1  the  Ψ  sequence  is  located 
approximately 300 nucleotides from the  5' end and is necessary and sufficient to 
promote  RNA dimerization  (Darlix  et  al.  1990)  leading  to  NC-interactions  and 
ultimately incorporation into virions.
  Vpr  is  packed  into  HIV  virions  through  an  interaction  with  gag  (Lu, 
Spearman, & Ratner 1993) and while Vif and Nef are thought to be incorporated 
non-specifically, Nef requires myristylation for efficient inclusion (Camaur & Trono 
1996;Bukovsky et al. 1997)65
  The gag polyprotein is largely responsible for virion assembly in HIV. When 
HIV particles form and bud from the plasma membrane the spherical arrangement of 
gag  proteins  associated  with  the  inner  viral  membrane  of  immature  virions  are 
proteolytically processed by the viral protease giving rise  to matrix  (MA) nuclear 
capsid (NC) and capsid (CA) proteins that rearrange to form conical or sometimes 
cylindrical capsid structures in mature, infectious virions (Ganser-Pornillos, Yeager, 
& Sundquist 2008). It is this capsid core of the virus particle that is released into the 
cytoplasm of an infected cell.
1.5  Retroviral vectors
  Transgene  integration into host DNA is the  desirable feature  of retroviral 
vectors, however, they have also been shown to be oncogenic due to insertion within 
or adjacent to proto-oncogenes, a phenomenon known as insertional  mutagenesis. 
The two main types of retroviral vectors have been derived from gammaretrovirus 
and lentivirus. The advantage particular to lentiviruses is that they can infect non-
dividing cells.
  Retroviral vectors are designed such that the transgene of interest replaces 
the coding region of viral RNA genome (gag-pol-env) on a plasmid known as the 
transfer  vector.  Cis  elements  Ψ,  PBS,  PPT  and  viral  LTR  are  still  included  to 
facilitate  RNA  encapsidation,  reverse  transcription  and  integration.  All  proteins 
needed for vector production are supplemented in trans (on separate plasmids). This 
spacial segregation renders the vector capable of one round of replication only.
 
1.5.1  Gammaretroviral vectors
  Gammaretroviral vectors are most commonly based on the Moloney murine 
leukaemia  virus (MLV). In  the  simplest transfer vectors,  the  transgene  is  placed 
between  Ψ and  the  PPT with  transcription being  regulated  by the  enhancer  and 
promoter in the 5’ LTR and the polyadenylation signal being provided by the 3’ LTR.66
  The first strategy for providing gag, pol and env genes in trans to produce 
MLV  particles  used  a  DNA plasmid  encoding  the  viral  genome  missing  the  Ψ 
sequence (Mann, Mulligan, & Baltimore 1983). While this packaging plasmid was 
able  to  drive  virus  production,  after  ten  days,  replication-competent  infectious 
viruses  were  detected.  This  was  because  of  recombination  between  the  transfer 
vector  and  the  packaging  construct.  This  lead  to  the  development  of  second-
generation MLV-based retroviral vectors.
  To greatly reduce the risk of homologous recombination between the transfer 
vector and the  packaging  construct, in second-generation gammaretroviral vectors 
the 3’ LTR, the PPT and part of the U3 region on the 5’ LTR as well as the Ψ signal 
were  removed  from  the  packaging  plasmid  (Miller  &  Buttimore  1986).  Further 
improvements  in  safety  derived  from  separating  env  onto  a  third  plasmid  also 
allowed the development of pseudotyping by providing  an heterologous env gene 
from another virus (Danos & Mulligan 1988).
  As discussed below in the section on Gene therapy in humans, MLV-based 
vectors were used in successful clinical trials to treat SCID-X1 (Cavazzana-Calvo et 
al.  2000;Gaspar  et  al.  2004).  By using  pseudotyped  gammaretroviral  vectors  to 
express a functional copy of the common gamma chain (γc) in haematopoietic stem 
cells, sustained phenotypic and functional immunological correction was achieved. 
However, because  transgene  expression  is driven by the  viral  LTR that contains 
enhancer elements, proto-oncogenes near to sites of integration were activated  in 
some cases leading to leukemia. The risk of such insertional mutagenesis is reduced 
by insulating  transcriptional  activation  to  within  the  transgene.  Self-inactivating 
(SIN)  vectors  utilise  internal  promoters  rather  than  viral  LTRs  and  can  include 
chromatin insulator elements (Arumugam et al. 2007).
1.5.2  Self-inactivating (SIN) vectors
  The  rationale  behind  the  design  of  SIN  vectors  is  that  by  deleting  the 
enhancer element from the U3 region of the 3’LTR on the transfer vector, the U3 67
will be absent from both LTRs in the dsDNA following reverse transcription. Hence, 
transgene expression is dependent on the inclusion of an internal promoter that can 
be carefully chosen. This is believed to increase the biosafety of such vectors by 
further reducing the possibility for homologous recombination between the transfer 
vector and the packaging plasmids (Zufferey et al. 1998) and by reducing the chance 
of enhancing expression of host genes proximal to the integration site. Additionally, 
it removes the possibility for transcriptional interference between internal promoters 
and viral LTRs.
  SIN gammaretroviral vectors were the first to be described (Yu et al. 1986). 
A 299bp deletion in  the U3 region that contained the  enhancer and  included the 
CAAT  box  was  used  to  eliminate  virus-derived  promoter  activity.  An  internal 
inducible promoter was instead used to drive transgene expression.
  SIN lentiviral vectors have also been generated in a similar way – by deleting 
400bp of the U3 region including the TATA box  and leaving just 38bp on the U3 
5’end that contain attachment sites for integrase and 18bp from the 3’ end (Zufferey 
et al. 1998). One problem with both types of SIN retroviral vector is that by deleting 
large  sections of the U3 region, the likelihood of transcriptional read-through and 
thus insertional mutagenesis is actually enhanced (Zaiss, Son, & Chang 2002). This 
can be reduced be the addition of polyadenylation elements to improve 3’ processing 
(Schambach et al. 2007)68
1.5.3  Lentiviral vectors
  Lentiviruses, able to infect non-dividing cells, have a major advantage over 
gammaretroviruses  for  use  as  gene-delivery vectors  as  gammaretroviral  vectors 
require cell division for transgene integration into the host genome (Miller, Adam, & 
Miller 1990). However, because wild-type HIV-1 is a human pathogen that causes 
aquired  immunodificiency syndrome  (AIDS),  numerous modifications  had  to  be 
made for the generation of HIV-1-based vectors that are safe for general laboratory 
use.
  The most important safety feature of a retroviral vector system is that it must 
be replication-defective. A similar approach was used to achieve this for lentiviral 
vectors as was used for gammaretroviral vectors, namely the segregation of essential 
viral proteins onto  separate  plasmids to greatly reduce  the  chance of  replication-
competent viruses forming via homologous recombination.
  First-generation lentiviral vectors were constructed using a single packaging 
plasmid that encoded seven of the total of nine HIV-1 proteins, excluding only Vpu, 
an  accessory  protein  involved  in  the  downregulation  of  CD4,  required  for  the 
maintenance of viral infectivity of HIV-1 (Tanaka et al. 2003), and Env, needed for 
HIV-1 binding and entry to the host cell. The vector instead was pseudotyped with 
the vesicular stomatis virus glycoprotein (VSV-G) which conveys a broad tropism 
(Naldini et al. 1996).
  It was shown in 1997 that  none of the four HIV-1 accessory genes vif, vpr, 
vpu,  or  nef  were  required  for  efficient  formation  of  VSV-G-pseudotyped  vector 
particles (Zufferey et al. 1997). Second generation lentiviral vectors use a packaging 
construct containing just gag, pol, rev and tat and commonly the VSV-G coat protein 
on a  separate  plasmid.  Third  generation vectors have further segregated  rev to  a 
fourth plasmid and deleted tat  from  the packaging  plasmid  as the vector plasmid 
contains a tat-independent promoter (Dull et al. 1998).
  The transfer vectors used in this study has the deletion in the U3 region of the 
3’ LTR eliminating  promoter activity. It is therefore  said to be  a self-inactivating 69
(SIN) vector. A WPRE element is included, which has been shown to increase viral 
titre  (Zufferey  et  al.  1999)  and  a  central  polypurine  tract/central  termination 
sequence (cPPT/CTS) element to enhance transduction in non-dividing cells (figure 
1.5).  Transgene  expression  is driven  by the  spleen  focus  forming  virus (SFFV) 
promoter that strongly promotes expression in many cell types including fibroblasts 
and cells of myeloid lineage (Baum  et al. 1995). The packaging plasmid encodes 
both  rev to  mediate  nuclear export and  tat  to  enable  transcription in  the  vector 
plasmid LTR. This means that these vectors are second generation SIN vectors.
MCS
promoter-enhancer
Figure 1.5 Feature map of LNT transfer vector backbone
Features include the internal SFFV  promoter, cPPT and a WPRE downstream 
element that enhances transgene expression. A transgene of interest is inserted   
in the multiple cloning site (MCS) between the SFFV promoter and the WPRE.
1.5.4  Integration and insertional mutagenesis
  Although genomic integration of a transgene is advantageous for long-term 
gene  expression  in  daughter  cells  when  progenitor  lineages  are  transduced,  this 
benefit is balanced by the risk of insertional mutagenesis. The severity of this risk 
has  been  illustrated  by  the  occurrence  of  clonal  T  cell  lympho-proliferative 70
abnormalities in one patient treated for SCID-X1 in London (Howe et al. 2008) and 
four in a similar trial in Paris (Hacein-Bey-Abina et al. 2008) both of which used 
MLV-based vectors. Although it had been suggested that the transgene itself may be 
oncogenic when overexpressed (Woods et al. 2006) experiments in vitro have shown 
that overexpression of LMO2, a proto-oncogene activated by insertion in four of the 
five  leukemic cases,  and not the  γc  itself  that causes aberrant thymocyte  growth 
(Pike-Overzet  et  al.  2007).  The  same  study  shows  that  of  all  the  T-cell  acute 
lymphoblastic leukemia (T-ALL) oncogenes, LMO2 is most highly transcribed  in 
the CD34+ bone marrow cells and suggests this as an explanation for the preferential 
targeting of LMO2 over other T-ALL oncogenes. 
  Experiments designed to assess the risk of insertional mutagenesis derived 
from lvv integration have found them to be safer (Montini et al. 2006) although this 
study compared SIN lvv expressing  eGFP with an viral  LTR-driven eGFP-based 
MLV vector. Both were pseudotyped with VSV-G. A similar cell culture assay that 
compared SIN lvv with HIV-1 LTR-promoter vectors and with MLV-based vectors 
found the SIN vectors to have greatly reduced transforming capacity (Bokhoven et 
al. 2009). A separate  report,  however,  did  find the  integration  of  SIN  vectors  to 
perturb  expression  of  adjacent genes  in  primary,  clonal  murine  beta-thalassemic 
erythroid cells. Perturbed expression was detected in 28% of the transduced clones. 
11% of all  genes contained within a 600-kilobase region surrounding  the vector-
insertion site demonstrating altered expression. This was higher than that observed 
for a lentiviral vector containing a viral long-terminal repeat (LTR) (Hargrove et al. 
2008).
  This  study  uses  SIN  lvv  primarily  as  an  experimental  tool  to  achieve 
sustained transgene expression in cells such as DCs that may not be dividing. Whilst 
the safety profile of such vectors would be of prime concern if the current strategy 
was to be translated into the clinic, the present study instead focuses on a method of 
designing  a  transgene  that  induces  antigen-specific  tolerance.  Many  vector 
modifications are under development in labs across the world that attempt to marry 71
the  stability of lvv-driven transgene  expression  with the  low toxicities associated 
with other gene delivery protocols for use in future human trials.
1.5.5  Gene therapy in humans
  Gene therapy can be defined as the transfer of genetic material into cells for 
therapeutic  gain. The  method of transfer,  can  be  physical (gold  nano-particles or 
therapeutic ultrasound), chemical (non-viral vectors such as liposomes), or in the 
case of viral vectors, biological. Originally intended as a novel treatment for genetic 
diseases by way of correcting missing or mutant genes via addition of a functional 
copy, current applications range from the treatment of fatal acquired diseases such as 
AIDS to gene doping in sport (Trent & Alexander 2006). An index from the Journal 
of Gene Medicine of all worldwide clinical trials to use gene therapy details over 
1,500 past or present trials of which almost 1,000 trials are for cancer diseases.
Figure 1.6 Journal of Gene Medicine index of global clinical trials of gene 
therapy. Data is correct as of march 2009.
  The  first clinical  trial  of gene  therapy,  conducted  in 1989  used retroviral 
vectors  to  transfer  the  neomycin  resistance  gene  into  tumour-infiltrating 
lymphocytes that were  then  infused  into  five  patients with  advanced  melanoma 72
(Rosenberg et al. 1990). Whilst the use of neomycin resistance as a marker enabled 
the group to show that the infused cells infiltrated the tumour and were still present 
in the tumour after 64 days, the wider implications of the study were that retroviral 
vectors could be used to introduce a transgene into cells to be administered to human 
patients  and  that  these  cells  were  able  to  persist  whilst  stably  expressing  the 
transgene. In 1990 the first therapeutic trial was performed in two girls with a severe 
combined immunodeficiency (SCID), in this case an inherited metabolic form of the 
disease called ADA-SCID caused by a mutation in the gene encoding the adenosine 
deaminase  enzyme  (ADA)  (Bordignon  et  al.  1995).  ADA is  involved  in  purine 
metabolism,  de-aminating  both  adenosine  and  deoxyadenosine.  In  patients  with 
ADA-SCID large amounts of deoxyadenosine accumulate in T cells resulting  in a 
lack of T cell and B cell function (Akeson, Wiginton, & Hutton 1989). Retroviral 
vectors were again used to transduce T cells, enabling  them to produce functional 
ADA enzyme and  thus reduce the patients’ dosage of ADA enzyme replacement 
therapy (Blaese et al. 1995). Similar studies that instead focussed on transducing 
autologous CD34+ bone marrow (Bordignon et al. 1995) or umbilical cord (Kohn et 
al. 1998) cells followed, eventually culminating in recent reports in which first one 
(Gaspar et al. 2006) and then 8 out of 10 patients (Aiuti et al. 2009) to receive such 
treatment following  mild  preconditioning  chemotherapy were  able  to  completely 
discontinue costly and potentially immunogenic enzyme replacement therapy.
  Other  reports  of  complete  or  partial  cures  of  human  disease  have  been 
restricted to hereditary conditions and have numbered a small proportion of the total 
number of trials undertaken.  Our  laboratory, simultaneously with a  laboratory in 
Paris, conducted trials on a total of 20 boys with X-linked SCID (Cavazzana-Calvo 
et al. 2000;Hacein-Bey-Abina et al. 2002;Gaspar et al. 2004). This form of SCID, 
denoted  SCID-X1  is  caused  by a  defect  in  the  IL2RG  gene,  located  on  the  X 
chromosome that encodes the γc which forms an integral part of cytokine receptors 
IL-2R, IL-4R, IL-7R, IL-9R, IL-15R and IL-21R resulting in a complete loss of T 
cells  and  NK  cells (Sugamura  et al.  1996).  B cells are  often  present in  normal 73
numbers  but  are  functionally  defective  (White  et  al.  2000).  By  using  a 
gammaretroviral vector encoding the IL2RG cDNA to transduce autologous CD34+ 
bone marrow ex vivo, these cells were re-infused into the patients without any pre-
conditioning.  The  ability  of  successfully transduced  cells  to  signal  through  the 
cytokine  receptors listed  above  confers a  survival  advantage  as  they are  able  to 
respond  to  survival  signals  and  other  signals.  These  transduced  progenitors 
reconstitute the bone marrow and give rise to normal populations of T cells and NK 
cells although there is some variation in this, probably due to patient age at the time 
of treatment as gene therapy for SCID-X1 has been shown to fail in older recipients 
(Thrasher et al. 2005).
  A very different heritable condition that has been treated with some success 
by gene therapy is Leber's congenital amaurosis (LCA) (Bainbridge et al. 2008). In 
this case subretinal delivery of a recombinant Adeno-associated virus (AAV)-based 
vector  was  used to  deliver  human  RPE65  coding  sequence driven  by a  1400-bp 
fragment of the human RPE65 promoter to three patients with defective copies of 
the gene. Patients who have mutations in the RPE65 gene experience  progressive 
degeneration of cone photoreceptor cells that ultimately results in the loss of cone-
mediated vision because the mutated RPE65 cannot convert all-trans retinol to 11-cis 
retinol during phototransduction, which is then used in visual pigment regeneration 
in photoreceptor cells. Although cone photoreceptor cells are responsible for bright-
light colour perception, sufferers of LCA experience a prolonged degeneration of 
visual acuity that often only starts becoming a barrier to leading a normal everyday 
life in the third decade of life and in dark conditions. The youngest of three patients 
in  this study,  a male  in his late  teens showed significant improvements after six 
months in  his visual  function  as  measured  by microperimetry and  dark-adapted 
perimetry and showed vastly improved performance  in a dark-condition mobility-
test obstacle  course. Whilst this  alone  was  an  undisputed  and  widely publisised 
success, the other two patients in the trial did not display significant improvements, 
probably  in  part  due  to  being  of  a  slightly  greater  age  and  stage  of  disease 74
progression. An application for authorization of a similar study in younger patients is 
underway (Smith, Bainbridge, & Ali 2009). Another study has used a similar AAV 
vector to deliver the RPE65 gene this time expressed under control of a constituitive 
(chicken  β  actin)  promoter  rather  than  a  tissue-specific  promoter  and  the  three 
patients here also showed varied but in one case significant improvements in retinal 
sensitivity by various measures (Maguire et al. 2008).
  In 2005 the Chinese government approved the use of the  first comMerck, 
Nottingham,  UKial  gene  therapy product. Intratumoral  injection  of  Gendicine,  a 
replication-deficient  P53-expressing  adenoviral  vector,  used  in  conjunction  with 
radiotherapy to treat head and neck cancers and other solid tumors such as advanced 
hepatocellular  carcinoma,  advanced  lung  cancer  and  soft  tissue  sarcoma  (Peng 
2005). P53 is a tumor suppressor gene that is mutated in at least half of all human 
malignant tumours (Chen et al. 1999). Treatment with Gendicine with radiotherapy 
increases life expectancy of cancer sufferers and induces complete remission in 64% 
of head and neck cancer patients compared to just 19% who received radiotherapy 
alone (Guangyu Ma et al. 2008).
1.5.6  Adverse effects of gene therapy
  Even  some  of  gene  therapy’s  success  stories  have  been  mitigated  with 
serious adverse events including leukemia and death. The trials that have corrected 
SCID-X1, generally regarded as the most significant triumph for gene  therapy in 
curing  human disease, unfortunately reported leukemia development, as discussed 
previously in  section  1.5.5.  Insertional  mutagenesis was  located  near  the  T-cell 
proto-oncogene  LMO2.  All  five  children  received  chemotherapy  to  treat  the 
leukaemia and whilst four are in sustained remission, one subsequently died after 
two bone marrow transplants and further chemotherapy. 
  A protocol similar to that used in these trials by Hacein-Bey-Abina et al. in 
Paris and by Howe et al. in London - ex vivo transduction of bone marrow using 
gammaretroviral  vectors  -  has  been  used  to  successfully  treat  the  myloid 75
immunodeficiency X-linked  chronic  granulomatous  disease  (X-CGD)  (Ott et al. 
2006), but one of the three patients in the study subsequently died. This was due to 
massive  bacterial  infection followed by colon  perforation  and subsequent sepsis. 
Because these complications are known to occur in X-CGD patients, this death is 
attributed to the underlying  disease  as opposed to a side-effect resulting  from the 
gene therapy.
  In 1999, the first death  resulting  from gene therapy occurred. In the now 
famous case of Jesse Gelsinger, a young man with ornithine transcarbamylase (OTC) 
deficiency that can lead to potentially fatal blood levels of ammonia, he underwent 
hepatic  infusion  of  an  adenoviral  vector  carrying  the  OTC  gene.  Despite  high 
toxicity and morbidity of first generation adeno-vectors in rhesus macaques (Nunes 
et al. 1999), a  dose  escalation study of OTC-bearing  third generation adenoviral 
vectors in baboons showed only limited toxicity at the highest doses (Raper et al. 
1998).  Of  the  first 17  human  patients to  receive  a  liver  infusion  of this vector, 
transgene expression was detected in hepatocytes of seven of the patients and only 
three of these subjects from eleven who had symptoms related to OTC-deficiency 
showed improved urea-cycle metabolism (although this was non-significant). Jesse, 
the 18th subject to be enrolled, suffered a fatal reaction that was due to a systemic 
inflammatory  response  leading  to  intravascular  coagulation  and  multiple  organ 
system failure  (Raper  et al. 2002). This fatal  reaction is thought to be  due to  an 
immune response to the capsid of the adeno-vector and although this was largely 
unforeseen, the investigators and regulators involved in planning  and carrying  out 
the trial have since accepted some responsibility (Wilson 2009).
  In 2007 a  37  year old  woman who had received an intra-articular AAV2-
based vector as part of a phase I/II clinical trial of gene therapy for arthritis died 
(Kaiser 2007). The vector expresses a gene product identical to Etanercept, a protein 
therapeutic used for RA and other autoimmune diseases that consists of the human 
type  II Tumour  necrosis factor  (TNF)  receptor fused  to the  Fc  region  of human 
IgG1. Four months after receiving an initial intra-articular injection of 5 × 1013 viral 76
particles into her right knee, she received a second injection and became very sick 
that day with nausea and vomiting followed by diarrhea and abdominal pain. After 
experiencing fluctuating symptoms for ten days, she was admitted to hospital with a 
temperature  of  39.5°C.  Following  treatment  with  antibiotics,  antifungals  and 
multiple blood transfusions, and despite renal replacement therapy for acute renal 
failure, an ultrasound revealed a massive hemorrhage in the left retroperitoneal space 
that  eventually  led  to  compression  of  the  abdominal  organs.  Life  support  was 
withdrawn and the patient died twelve days after admission to intensive care, three 
weeks after the second viral injection. Postmortem examination found Histoplasma 
capsulatum in the liver, lungs, bone marrow, spleen, lymph nodes, thymus, kidney 
and brain. Oddly, the pathological examination found no evidence of RA in either 
knee  (Evans, Ghivizzani, & Robbins 2008) suggesting  that the gene therapy was 
successful in treating the arthritis.
  These lethal adverse effects could have been caused by the AAV vector itself 
or  the  expressed  Etanercept  transgene.  When  taking  such  TNF  antagonists, 
histoplasmosis is a  recognised risk factor  and the  patient lived in  an area  where 
Histoplasma capsulatum is endemic. She had, however, been using TNF antagonists 
already for  5 years prior to the  gene  therapy and  histoplasmosis usually occurs 
within 6 months of TNF antagonist therapy initiation. Nonetheless, it is probable that 
the  patient was infected with  the  fungus at the time  of the second gene  therapy 
injection and that the resulting  immunosupression  due  to reduced TNF signalling 
resulted in acute infection, eventually leading to mycotic aneurysm, retroperitoneal 
bleed and death.
  Trace amounts of vector genomes in the blood, spleen, liver and brain of the 
subject, larger amounts in the tonsils and high copy numbers in the right knee were 
detected  by quantitive  polymerase  chain  reaction  (qPCR)  (Evans,  Ghivizzani,  & 
Robbins  2008).  Rep  gene  sequences,  absent from  the  recombinant vector  were 
detected in the heart, trachea and right knee, but not in the blood, spleen, liver, brain 77
or tonsils. This suggests that replication-competent AAV were present although the 
detected levels were low enough for this to be disputed (Frank et al. 2009).
  Despite the cause of death being uncertain, the FDA lifted the hold on this 
trial in December 2007, and it proceeded with more stringent criteria on enrolling 
and treating patients, being completed in May 2009. One issue that this death raises 
is  the  safety  of  expressing  a  non-specific  immunosuppressive.  Whilst  direct 
administration  of a  drug  such as Etanercept can  be ceased  in the  event of  acute 
infection, expression of such a therapeutic cannot be stopped so easily. As discussed 
below, all other gene therapy trials for arthritis essentially express anti-inflamatory 
peptides, either in  the  form  of antagonists or  soluble  receptors for  inflammatory 
cytokines  such  as  TNF  or  IL-1,  or  directly express  anti-inflamatory  cytokines 
themselves  such  as  TGF-β.  The  present  study  instead  demonstrates  that  an 
alternative strategy can be to induce antigen-specific tolerance using lvv injected iv. 
Rather than restricting the anti-inflammatory effects of transgene expression to the 
location of inflammation, this approach restricts the anti-inflammatory effect to the 
antigen of interest.
1.5.7  Gene therapy for rheumatoid arthritis
  As described above in the case of the Phase I/II clinical trial that used AAV-
based vectors to deliver the Etanercept TNF antagonist, the two primary advantages 
of current clinical trials of gene therapy over directly administered protein therapies 
are; expression of the protein therapeutic can be physically limited to the inflamed 
joint and that endogenous expression of a protein therapeutic results in it’s prolonged 
availability eliminating  the need for repeat dosing  (Evans, Ghivizzani, & Robbins 
2006).
  Recombinant IL-1Ra, called Anakinra, but also marketed as Kineret (Amgen 
Biologicals) is administered by daily sc injection as an effective treatment for RA 
(Fleischmann  et al. 2006). A protocol for introducing  the  IL-1Ra  cDNA into the 
joints of RA patients was proposed in 1996 (Evans et al. 1996), and this was the 78
basis  of  the  first clinical  trial  for  RA gene  therapy. Results from  this  trial  were 
published in 2005 (Evans et al. 2005). Recombinant retroviral vectors expressing 
cDNA for Anakinra were used to transduce autologous synovial fibroblasts ex vivo. 
These  cells were expanded as were untransduced cells. After tests for  replication 
competent  virus,  endotoxin,  mycoplasma,  and  other  adventitious  agents  were 
negative, transduced or untransduced synoviocytes were intra-articularly injected in 
a double-blind fashion into the 2nd-5th metacarpophalangeal joints. 11 out of 12 joints 
that received  the  higher  doses of  transduced  synoviocytes  did  produce  elevated 
levels of IL-1Ra  after they were  surgically removed on day 7, although this was 
insufficient to have a therapeutic effect. Publication of these results was delayed by 
more  than 5  years to give  a  report on longer-term  safety aspects. The  retroviral 
vector used was the same MLV-based vector used in the SCID-X1 trials in Paris and 
London that resulted in leukemia in 5 out of 20 subjects. It was feared that during 
the  week between injection of gene-modified  synoviocytes and their removal via 
surgery  because  some  of  the  subjects  experienced  inflammation  at  the  site  of 
injection,  some  gene-modified  cells may have  egressed  the  intra-articular  space, 
escaping surgical removal and then have the potential to subsequently cause adverse 
effects. There was, however, no clinical or molecular evidence of side-effects and no 
detectable replication-competent retrovirus.
  The first evidence of a clinical response to gene therapy in human arthritis 
was published in February 2009 using an ex vivo transduction protocol based on that 
described above (Evans et al. 2005) to express recombinant IL-1Ra in autologous 
synoviocytes  (Wehling  et al.  2009).  In  this  study,  two  post-menopausal  females 
under the age of 75 that required a surgical synovectomy of metacarpophalangeal 
joints 1-3 on both hands were selected. Approval was originally given to treat six 
patients but due to the report of leukemia as a result of the SCID-X1 trials (Kohn, 
Sadelain, & Glorioso 2003), the trial was unable to be completed. Results only from 
the first two patients, treated before approval was withdrawn, was presented.79
  Synovial  fibroblasts  from  one  hand  were  injected  into  the  joints  of  the 
contralateral  hand.  Again,  untransduced  fibroblasts  were  used  as  intra-patient 
controls. In this study the transduced synovial fibroblasts remained in the recipient 
joint for 4 weeks during which the subject kept a “pain diary”. Patient 1 showed a 
dramatic improvement in pain score in both “high dose”  treated  and “low dose” 
treated joints as measured by VAS Pain Score.  Joint circumference was also found 
to reduce in patient 1, indicating reduced inflammation, even despite a flare of her 
RA  during  the  study  period,  possibly  due  to  cessation  of  methylprednisolone 
administration. Patient 2 also responded albeit less dramatically.
  One feature of the gene therapy protocol in these studies that was identified 
for  obvious  improvements  was  the  time-consuming  and  expensive  nature  of 
performing  ex  vivo  transduction  (Evans  et  al.  2005).  Subsequent  gene  therapy 
protocols for treating RA have concentrated on in vivo gene delivery.
  Preclinical data showed that by injecting naked DNA plasmids encoding the 
herpes simplex  virus-thymidine kinase (HSV-tk) directly into the joint followed by 
iv administration of ganciclovir (a pro-drug that is phosphorylated by HSV-tk) for 
three days reduced swelling  in the knees of rabbits with antigen-induced  arthritis 
(AIA)  (Sant et al. 1998). AIA is  an  animal  model  of  proliferative  inflammatory 
arthritis where the rabbit is immunised to ovalbumin and arthritis is then triggered 
by ovalbumin injection into the joint. Histologic examination of the joint 21 days 
after treatment showed evidence of cytolysis that was confined to the synovial lining 
cells within inflamed synovium. Based on this approach, Roessler’s group initiated a 
human  trial  that  showed  no  adverse  effect  in  its  first  patient  but,  because  it 
overlapped with the death of Jesse Gelsinger, recruitment was disrupted and the trial 
was terminated (Evans, Ghivizzani, & Robbins 2009). 
  Focus has since shifted to using  AAV-based viral vectors because  of their 
very  low  immunogenicity,  improved  manufacturing  protocols  (Grieger,  Choi,  & 
Samulski  2006)  and  self-complementary  genome  configurations  that  enhance 
transduction  efficiencies  (McCarty  et  al.  2003).  A recent  finding,  however,  has 80
suggested  that neutralizing  immune  reactions to AAV-2  might prevent  re-dosing 
(Kay et al. 2009), a phoenomenon that may have contributed to the massive adverse 
reaction that lead  to the  death of  a subject in 2007, discussed  above  in Adverse 
effects of gene therapy. In those trials (a Phase I and Phase I/II, both sponsored by 
Targeted Genetics Corporation) AAV-2-based vectors delivered the cDNA encoding   
etanercept,  a  TNF  antagonist fused to  the  Fc  region  of human  IgG1.  The  dose-
escalation Phase I study found the treatment to be well tolerated (Mease et al. 2009). 
The Phase I/II trial is now closed but as yet unreported. Work to refine this type of 
TNF-inhibitory delivery system is underway. By using AAV-5 vector delivering  a 
TNF inhibitor coupled instead to the Fc domain from mouse IgG1 under control of 
the NF-κB-responsive promoter, a large therapeutic efficacy was observed in the rat 
adjuvant-induced arthritis model (Adriaansen et al. 2007). In this case, expression of 
the fusion protein can be “switched off” by NF-κB blockade. Although not as easily 
controllable as “tet-on” or “tet-off” systems, using a promoter with multiple NF-κB-
response elements has the advantage of enhanced expression in cells responding  to 
inflammatory stimulus.
  A trial for the use RNAi approaches to reduce TNF-signalling are reportedly 
underway (Evans, Ghivizzani, & Robbins 2009) as are trials of the use of decoy 
oligonucleotide  NF-κB inhibitors injected  directly into the  joints of  RA patients   
based on pre-clinical studies by Tomita et al. that found such dsDNA to act as decoy 
cis  elements  to  bind  the  transcription  factor  and  block  the  activation  of  such 
proinﬂammatory cytokine genes as (IL-1) and tumor necrosis factor thus reducing 
the severity of joint destruction.
  Although  lentiviral  vectors  have  been  used  in  animal  trials  treating  and 
preventing arthritis (Gouze et al. 2003;Gjertsson et al. 2009), none of the 21 human 
gene therapy trials currently using lentiviral vectors are for arthritic or autoimmune 
conditions.  Furthermore,  none  of  the  previous  clinical  trials  for  gene  therapy 
approaches  for  RA  have  attempted  to  induce  antigen-specific  tolerance  to 
autoantigens implicated in RA pathogenesis.81
1.6  Bio-electrospray
  The work presented below was intended to be an investigation of the use of 
novel  lvv  for  the  induction  of  tolerance  by the  CII259-273  peptide.  An  important 
component of the fusion proteins expressed by the novel lvv produced in this work is 
the eGFP domain that allowed intracellular images to be taken using fluorescence 
microscopy (presented in chapter 4). In the third year of this work a collaborative 
study was initiated with Dr Suwan Jayasinghe from the Department of Mechanical 
Engineering,  UCL,  who  was  searching  for  live  cells  that  could  be  genetically 
modified and then physically manipulated, being deposited in a controlled way as a 
droplet or thread, by a process known as bio-electrospray (BES). By transducing 
3T3-I-Aq cells with the lvv vCII-LAMP, described in this thesis, we  were able  to 
demonstrate both that this cell line continued to proliferate following  transduction 
and  BES  and  that they also retained the vector-derived function,  namely surface 
presentation of the CII259-273 peptide to MHCII-restricted T cell hybridomas.
  BES  is a method of using electrostatic charge to control the flow of a cell 
suspension through a large-bore needle. By applying a voltage to the needle, the cell 
suspension  becomes  charged  and  is  attracted  to  a  target  cell-culture  vessel  or 
solution contained within a beaker attached to a grounded electrode (electrostatically 
neutral). By varying the flowrate of the cell suspension and the electrostatic potential 
of the  steel, large-bore  needle, the  cell-structures that are  produced  in the  targed 
solution can be precisely controlled. By adding  1% poly(ethylene oxide) (PEO) to 
the solution, we were able to produce cell droplets under high-voltage conditions, 
and threads of cells under lower-voltage conditions (1-5 kV) (a process known as 
Cell electrospinning, (CE)). These results are discussed in chapter 6.
  Potential clinical applications of such a method of generation of multicellular 
structures  could  include  the  generation  of  immunomodulatory  cell-structures 
including  artificial lymph nodes or other large  cell structures that require  precise 
layers or strata of antigen-presenting cells and responder cells. Such structures could 82
be constructed in vitro and implanted at a desired site for particular immunological 
action, for example within the intra-articular space of an inflamed joint. A second 
direct application of the method developed in the present study would be to use gene 
therapy to induce tolerogenic antigen presentation in a population of cells that could 
be incorporated into a multicellular structure. If this were used to induce autologous 
iTreg cells in vitro, the iTreg cells would be easily separated and re-infused without 
the need to expose the patient to any potentially carcinogenic gene-therapy-modified 
cells or tissue.83
Chapter 2.  Materials and Methods84
2  Materials and methods
Table of culture media, buffers and solutions
Buffer/solution Recipe/Manufacturer
4% Paraformaldehyde (w/v) 
(4% PFA)
4 g paraformaldehyde (SIGMA, Poole, UK) dissolved 
in 100ml phosphate-buffered saline (PBS)
PBS-tween (PBS-T) PBS + 0.05% TWEEN20 (SIGMA, Poole, UK)
ELISA/Western blot 
blocking buffer
PBS-T + 5% BSA
ELISA stop solution 1M Nitric acid
ELISA substrate R&D Substrate Reagent Pack
Fc receptor block PBS + 5% heat-inactivated mouse serum
Western running buffer 1 x NuPAGE MES SDS running buffer (Invitrogen, 
Paisley, UK)
Western sample buffer NuPAGE LDS sample buffer (Invitrogen, Paisley, UK) 
+ 1 x NuPAGE Sample Reducing Agent (Invitrogen, 
Paisley, UK)
Western transfer buffer 1 x NuPAGE transfer buffer (Invitrogen, Paisley, UK) 
made according to manufacturer’s instructions
Bacteria culture medium Recipe
LB Broth 20g Luria broth base (Invitrogen, Paisley, UK) + 1 L 
MilliQ H2O + autoclaving
LB/Amp selection medium LB Broth + 100 µg/mL ampicillin (Invitrogen, Paisley, 
UK)
LB/Amp Agar plates 17.5g LB-Agar (Merck, Nottingham, UK) + 500 mL 
MilliQ H2O + autoclaving + 50 mg ampicillin at 50ºC 
before pouring85
2  Reagents and equipment
  All  DNA  restriction  and  modifying  enzymes  were  from  Promega, 
Southampton,  UK,  unless  otherwise  stated  and  oligonucleotides  were  custom-
ordered and generated by Invitrogen, Paisley, UK, UK. All cell culture reagents were 
from (GIBCO/Invitrogen, UK) unless otherwise stated. Polymerase chain reactions 
and  other  thermal  cycling  protocols  were  performed  on  an  UNO-Thermoblock 
(Biometra,  Gottingen,  Germany).  All  DNA  concentrations  were  determined  by 
measuring the absorbance at 260 nm using  a Nanodrop machine (Thermo, Sussex, 
UK).
2.1  Design and generation of fusion constructs
  Initial  fusion  constructs  were  cloned  into  the  pFUSE-hIgG4-Fc2  vector 
(Invivogen, San Diego, CA) that contained a sequence encoding the 20-amino acid 




Figure 2.1 Vector NTI map of pFUSE-hIgG4-Fc2. 
•  hEF1a-HTLV  promoter  is  a  composite  promoter  comprising  the  human 
Elongation Factor-1α(EF-1α) core promoter and the R segment and part of the 
U5 sequence (R-U5’) of the Human T-Cell  Leukemia Virus  (HTLV) Type 1 
Long Terminal Repeat. The EF-1α promoter exhibits a strong activity and yields 
long lasting expression of a transgene in vivo. The R-U5’ has been coupled to 
the EF-1α core promoter to enhance stability of RNA.
• IL2 ss: The IL2 signal sequence contains 21 amino acids and share common 
characteristics with signal peptides of other secretory proteins. The intracellular 
cleavage of the IL2 signal peptide occurs after Ser20.
• Minimal Ori (E.coli): A truncated, minimal E. coli origin of replication to limit 
vector size, but with the same activity as the full-length Ori.
• CMV enhancer / hFerritin LC promoter: This composite promoter combines 
the  human cytomegalovirus  immediate-early gene  1  enhancer  and  the  core 
promoter of the human ferritin light chain gene. This ubiquitous promoter drives 
the expression of the Zeocin-resistance gene in mammalian cells.
• EM2KC E.coli promoter is a bacterial promoter that enables the constitutive 
expression of the antibiotic resistance gene in E. coli. EM2KC is located within 
an intron and is spliced out in mammalian cells.87
• Sh ble Zeocin resistance: Resistance to Zeocin is conferred by the Sh ble gene 
from Streptoalloteichus hindustanus. The same resistance gene confers selection 
in both mammalian cells and E. coli.
•  ßGlobin  3’  UTR:  The  human  beta-globin  3’UTR  and  polyadenylation 
sequence allows efficient arrest of the transgene transcription5.
The  pFUSE-hIgG4-Fc2  plasmid  was  digested  with  NcoI  and  EcoRI  by 
incubating 400 ng  DNA with 1 µL 10 X Buffer D and 0.5 µL of each restriction 
enzyme in a total  volume  of 10 µL incubated at 37C for 90 minutes. The  linear 
vector fragment was purified on a 1% agarose gel. The EcoRI site is present in the 
18th, 19th and 20th codons for the amino acid residues Thr, Asn, Ser of the IL-2 signal 
sequence. A PCR-amplified eGFP fragment that had also been digested with EcoRI 
and NcoI was inserted into 100 ng linearised vector with 1 µL T4 DNA Ligase and 1 
µL 10 x T4 DNA Ligase buffer consisting of 500 mM Tris-HCl, 100 mM MgCl2, 100 
mM  Dithiothreitol  10  mM  ATP,  pH  7.5 (Promega, Southampton, UK) in total 
reaction  volume  of  10  µL  incubated  at  18C  for  4  hours  (below).  This  ligation 
conserves the Thr-Asn-Ser amino acid sequence. 
2.1.1  eGFP
A PCR  fragment encoding  eGFP with  an  EcoRI site  at the 5’ end  and  a 
sequence  encoding  the  first  of  two  4-aa  sequences  that are  highly sensitive  to 
cleavage by cathepsin S (Ruckrich et al. 2006) site Leu-Arg-Met-Lys followed by 
BamHI  and  NcoI  sites  at the  3’ end  was generated  using  the  polymerase  chain 
reaction:
5 µL 10 mM forward primer 5’-ggaattcgatggtcagcaagggcgaggagctgttcacc-3’ 
a n d  5  µ L  1 0  m M  o f  t h e  r e v e r s e  p r i m e r  5 ’ -
gccatggaaaggatcccttcatgcgaagcttgtacagctcgtccatgccgagagtgatccc-3’ (custom ordered, 
Invitrogen, UK) were mixed with 5 µL 10 X PfuUltra HF reaction buffer (Stratagene 
Inc.,  La  Jolla,  CA),  2 units of  PfuUltra  HF (Stratagene  Inc.), 0.32  µL  1 µg/µL 
pEGFP and subjected to a denaturisation step at 95ºC for 5 minutes, 25 amplification 88
cycles of 58ºC for 1 minute, 72ºC for 2 minutes and 95ºC for 30 seconds followed 
by a final extension step at 72ºC for 5 minutes. It was decided to use two varying 4-
aa sequences reported to be substrates for cathepsin S to increase the likelihood of at 
least one being efficiently cleaved. The PCR product was cloned into a TOPO-pCRII 
vector (Invitrogen, Paisley, UK) by mixing  4 µL purified PCR product with 1 µL 
TOPO-pCRII  vector.    and  subsequently  digested  with  EcoRI  and  NcoI.  This 
fragment was ligated into the linearised pFUSE-hIgG4-Fc2 vector by mixing 1 µL 
linearised vector with 1 µL T4 DNA Ligase, 1 µL T4 DNA Ligase buffer and 7 µL 
PCR  products.  Chemically  competent  MACH-1  T1  phage-resistant E.  coli  cells 
(Invitrogen, Paisley, UK) were transformed with the  reaction mix. All chemically 
competent cells were transformed by incubating with 5 µL reaction mixture on ice 
for  30  minutes  followed  by ‘heat shock’ step,  42ºC/30s,  ice/1  minute  and  then 
incubated  at  37ºC  for  1  hour  before  plating  onto  25  µg/mL  Zeocin  plates The 
daughter  plasmid  (denoted  pG10)  was  then  digested  with  NcoI  and  NheI  for 
insertion of the Lamp1 cytosolic/TM domain (below).
2.1.2  LAMP-1
mRNA was extracted from an homogenised mouse spleen using Tri-reagent 
(Applied Biosystems) and chloroform (VWR). Briefly, a mouse spleen sample was 
homogenised  in  500 µL Tri-reagent, incubated  at room  temp for  5  minutes  and 
centrifuged for 1 minute before the supernatant was added and mixed thoroughly. 
After microcentrifugation for 15  minutes,  the aqueous phase  was transferred to  a 
fresh  tube  for  RNA precipitation  and  wash  using  isopropanol  (VWR)  and  75% 
ethanol.  A  cDNA  pool  was  generated  using  MultiScribe  reverse  transcriptase 
(Applied  Biosystems)  by preparing  10  µL 2X  reaction  mix,  placing  on  ice  and 
adding 10 µL mouse spleen mRNA sample. The 2 X reaction mix was prepared by 
adding 2 µL 10 X RT buffer, 0.8 µL 100 mM dNTPs, 2 µL supplied 10 X Random 
Primers, 1 µL  RNase Inhibitor and 1 µL MultiScribe reverse transcriptase to 3.2 µL 
nuclease-free H2O. The reaction mix was incubated at 25ºC for 10 minutes, 37ºC for 89
120 minutes and 85ºC for 5 minutes before incubating  on ice breifly. The reaction 
mix  was  purified  on  a  QiaQuick  column  (Qiagen)  and  RNA was  degraded  by 
incubating with RNase H (New England Biolabs, Hitchin, UK) for 30 minutes at 
37ºC. Second strand synthesis was performed by using the Klenow fragment (NEB, 
Hitchin,  UK) incubated in 1X NEBuffer  2  for 1  hour at 37ºC followed by heat 
inactivation at 75ºC for 20 minutes.
A  DNA  fragment  encoding  the  48  amino  acid  residues  at  the  carboxy 
terminus of mouse LAMP-1 which includes the  cytoplasmic  tail  domain, the TM 
domain, and a short portion of the luminal domain was cloned using forward primer                                     
5’-accatgggagaatctgaaggggtctgtggaagagtgtgttcag-3’  and  reverse  primer                                                   
5’-ggctagcctcgagctagatggtctgatagccggcgtgactcct-3’.  The forward primer includes an 
NcoI site and the second Cathepsin S recognition site Glu-Asp-Leu-Lys at the 5’ end 
(Ruckrich et al. 2006), and the reverse primer includes a stop codon, an XhoI and an 
NheI site at the 3’ end. The 188-bp fragment was cloned into TOPO pCR-II and was 
subsequently digested out with NcoI and NheI and inseted into the pG10 plasmid to 
form pGL1. Restriction endonucleases BamHI and NcoI were used to open pGL1 
between the Cathepsin S  cleavage sequences for insertion of the CII259-273 peptide 
(below).
2.1.3  CII peptide and MOG peptide
Complementary  oligonucleotides  encoding  collagen  residues  259-273 
(CII259-273) with overhanging ends compatible with BamHI and NcoI were obtained 
from Invitrogen, Paisley, UK:
Direct  strand  5’-gatccggcatcgctggcttcaaaggtgaacaaggccccaagggagaacctt-3’, 
and complementary strand 
5’-gccgtagcgaccgaagtttccacttgttccggggttccctcttggaagtac-3’.  These  were 
annealed in 1 x T4 DNA-ligase (Promega) buffer and purified on a 2% agarose gel. 
The  eluted  band  was  resuspended  in  10  µL  1  x  T4  DNA-ligase  buffer  and 
phosphorylated by adding 1 µL polynucleotide kinase (Promega) and incubating at 90
37ºC  for  30  minutes. The  reaction  mix  was  gel  purified,  extracted  and  serially 
diluted  100-fold. For ligation into pGL1  (between  BamHI  and NcoI sites),  1 µL 
linearised  pGL1  (above)  was  mixed  with  1  µL  T4  DNA Ligase,  1  µL  diluted 
phosphorylated oligos and 8 µL H2O. by mixing  to form plasmid pGCL2 (figure 
2.2). Plasmid construct sequences were analysed by test restriction digestions (see 
figure 3.2A) and confirmed by sequencing the fusion construct with internal forward 
primer  5’-gacgacggcaactacaag  -3’  and  internal  reverse  primer  5’-
gctgttgtagttgtactc-3’, complementary to regions of the eGFP sequence,  using  the 
Sanger method (MWG Biotech, London).
Figure 2.2 Features map of vector pGCL2 
• Minimal Ori (E.coli): A truncated, minimal E. coli origin of replication
• hFerritin LC promoter: core promoter of the human ferritin light chain gene
• EM2KC E.coli promoter is a bacterial promoter that enables the constitutive 
expression of the antibiotic resistance gene in E. coli
• Sh ble Zeocin resistance: Resistance to Zeocin is conferred by the Sh ble gene 
from Streptoalloteichus hindustanus91
•  ß-Globin  3’  UTR:  The  human  beta-globin  3’UTR  and  polyadenylation 
sequence
• LAMP-1 TM/cytosolic:  The  188-bp sequence encoding  the  transmembrane 
domain and cytoplasmic tail of the mouse LAMP-1 protein
• CII 259-273: Sequence encoding the collagen 259-273 peptide
• eGFP: Enhanced green fluorescent protein
  A Myelin  oligodendrocyte  glycoprotein 79-90  peptide (MOG79-90  peptide) 
control  for  the  in  vivo  experiments  was generated  in  the  same  way by ordering 
forward primer 5’-gatccggcaaagtgaccctgcgcattcagaacgtgcgctttt-3’ and reverse primer 
5’-catgaaaagcgcacgttctgaatgcgcagggtcactttgccg-3’, annealing  and inserting  into the 
pGL1  plasmid  that  had  been  opened  with  BamHI  and  NcoI  giving  rise  to  the 
daughter  plasmid  pMOG6  that was  sequenced  with  internal  forward  primer  5’-
gacgacggcaactacaag -3’ and internal reverse primer 5’-gctgttgtagttgtactc-3’ using the 
Sanger method (MWG Biotech, London).
2.1.4  H2-DM-targeted fusion constructs
  Chimeric  DNA sequences  designed to encode  fusion  proteins targeted  to 
subcellular  compartments  by  the  TM/cytoplasmic  signal-anchor  sequence  from 
mouse H2-DM rather than LAMP-1 were also generated; a DNA fragment encoding 
the 65 amino acid residues at the carboxy terminus of mouse H2-DMb2 was cloned 
from mouse spleen cDNA using forward primer
5’-accatgggagaatctgaagagcgggacctctgagcccatc-3’ and reverse primer 
5’-cgctagcctcgagctagtgccgtccttctgggtagg-3’. The 223-bp fragment that includes the 
NcoI site and cathepsin S cleavage site on the 5’ end and a stop codon, an XhoI and 
an NheI site  at the 3’-end of the reverse  primer - as for LAMP-1 (above) - was 
cloned into TOPO-pCRII, removed by digestion with NheI and NcoI, and ligated 
into the pG10 plasmid adjacent to eGFP. Annealled, phosphorylated oligonucleotides 
encoding the CII259-273 peptide was then inserted between BamHI and NcoI sites to 
form pGCH1.92
2.1.5  Insertion of construct into lentiviral backbone plasmid
Constructs were  initially inserted into the  Invitrogen, Paisley, UK transfer 
vector backbone pDEST via the Gateway system. The Gateway system is an off-the-
shelf  lvv backbone-generating  procedure  that utilises  homologous  recombination 
between a 3.8 kb pENTR1A plasmid that contains convenient multiple-cloning sites 
and  a  kanamycin  resistance  gene  with  the  sffv-  and  WPRE-containing  lentiviral 
transfer vector that contains an ampicillin-resistance gene. A transgene of interest is 
inserted into pENTR1A, selected on kanamycin plates before  using  Gateway LR 
Clonase,  a  recombinase,  to  catalyse  a  recombination  reaction  that  transfers  the 
transgene into the  pDEST backbone. Prior  to recombination, the pDEST plasmid 
contains the ccdB gene that is toxic to E. coli, preventing them from growing due to 
production of the toxin ccdB that binds to the E. coli DNA gyrase. Hence, E coli 
harbouring unrecombined pDEST plasmids are unable to grow. When the transgene 
from pENTR1a has replaced the ccdB gene in pDEST these successfully recombined 
plasmids enable host E. coli to grow.93
Figure 2.3 Schematic plasmid maps of Gateway Plasmids.
Homologous  recombination  between  attL1  site  (pENTR1A)  and  attR1  site 
(pDEST) and between attL2 site (pENTR1A) and attR2 site (pDEST) resulting 
in LR-catalysed transfer of the transgene from the pENTR1A plasmid into the 
pDEST  plasmid  in  the  correct  orientation.  Figure  adapted  from 
www.invitrogen.com.
pGCL2 and pGCH1 were each digested with SfoI and XhoI to release a ~1 kb 
fragment comprising the entire construct from the start codon preceding the IL-2 ss 
on the 5’ end to a stop codon on the 3’ terminus. This was purified on a 1.5% agarose 
gel. The fragment was inserted into pENTR1A that had been linearised with XhoI 
and XmnI using T4 DNA ligase to form plasmids pGCL8 and pGCH4 respectively. 
The pENTR1A daughter plasmids includes attL1 and attL2 recombination sites on 
each side  of  the gene of interest which recombine  with attR sites present on the 94
pDEST  vector  to  transfer  the  transgene  into  the  pDEST  vector  in  the  correct 
orientation,  downstream  from  the  sffv  promoter,  in  a  reaction  catalysed  by the 
recombinase  LR  Clonase  (Invitrogen,  Paisley,  UK).  Briefly,  200  ng  pGCL8  or 
pGCH4 and 300 ng pDEST vector was reacted using  4 µL LR Clonase in 1X LR 
Clonase reaction buffer, total volume 20 µL, at RT for 1 hour. 2 µL Proteinase K 
solution (Invitrogen, Paisley, UK, provided with LR Clonase reaction kit) was added 
to each reaction to terminate recombination and 2 µL from each reaction was used to 
transform competent E. coli strain DH5α that were plated on LB-agar plates that also 
contained  kanamycin  at  a  concentration  of  100  µg/ml.  Colonies  were  selected, 
amplified  and DNA extracted  to generate plasmids  pGCL12  and  pGCH12.  Both 
pGCH12  and  pGCL12  were  sequenced  with  internal  forward  primer  5’-
gacgacggcaactacaag  -3’  and  internal  reverse  primer  5’-gctgttgtagttgtactc-3’, 
complementary to regions of the eGFP sequence,  using  the Sanger method (MWG 
Biotech, London).
2.1.6  Generation of transfer vector with construct expression driven by the 
  hEF1α-HTLV promoter in place of the sffv promoter
100ng pGCL2 was digested with NotI, a unique site ~100bp upstream of the 
hEF1α-HTLV  promoter by incubating  at 37°C  with  1 µL NotI in 1  X Promega 
reaction buffer D for 2 hours. The  sticky end was filled by adding 1 µL 2.5 mM 
dNTPs and 1 µL T4 DNA polymerase (Promega) and heating at 37°C for a further 5 
minutes,  before  heat-inactivation  of  the  polymerase  by heating  to  65°C  for  20 
minutes. After subsequent digestion with XhoI, the ~1700bp fragment was purified 
on a 1% agarose gel, and was inserted into pENTR1A that had been digested with 
XmnI and XhoI  to generate  the  plasmid pGCL22  containing  the  fusion  construct 
behind the hEF1α-HTLV promoter that was then transferred into a pDEST plasmid 
lacking the sffv promoter in a reaction catalysed by LR Clonase as described above 
to generate transfer vector pGCL29.95
2.1.7  Replacement of the IL-2 signal sequence with LAMP-1 signal sequence
  Multiple attempts to clone the LAMP-1 signal sequence (Lss) from mouse 
spleen cDNA library were unsuccessful, including nested PCR and 20 combinations 
of forward  and reverse  primers.  Eventually a  set of two pairs of complementary 
oligonucleotides were ordered that encode the whole Lss sequence in two halves, 
have  an  8-base  complementary  overhang  in  the  centre  and  4-base  overhangs 
compatible with BamHI at the 5’ end of pair 1 and EcoRI at the 3’ end of pair 2; 
forward  primer  1:  5’-gatccgtcctccggcctcggctgcgtcgcgccatggcggcccccggcgcccgg-3’, 
reverse primer 1:
5’-agcggccgccgggcgccgggggccgccatggcgcgacgcagccgaggccggaggacg-3’,   forward 
primer  2:  5’-cggccgctgctcctgctgctgctggcaggccttgcacatggcgcctcagcactctttgag-3’, 
reverse primer 2:
5’-aattctcaaagagtgctgaggcgccatgtgcaaggcctgccagcagcagcaggagc-3’.
Each pair was annealed, purified on a 100 mL 2% gel agarose  gel stained 
with 1 µL ethidium bromide. Electrophoresis was performed by applysing a potential 
difference of 100 V with the DNA being  loaded into wells placed at the negative-
charge  end  of the  gel. Phosphorylation was performed by mixing  9 µL purified, 
annealed oligos with 1 µL DNA polynucleotide kinase buffer and µL polynucleotide 
kinase  (both Promega,  UK). The primer pairs were  then ligated in an equi-molar 
reaction mix (RT, 1 hour) and run directly on a 2% agarose gel. The 117-base Lss 
was extracted and was then inserted into TOPO-pCRII vector (Invitrogen, Paisley, 
UK) that had been linearised with BamHI and EcoRI to form plasmid pLss39.
  The  pGCL2/pGCH1/pMOG6 EcoRI-XhoI fragments (that exclude the  IL-2 
ss) were  then  each  separately inserted into pLss39 between the EcoRI site and  a 
downstream XhoI site to generate plasmids LssGCL1 and LssGCH1. Finally these 
plasmids were digested with XhoI and then with BamHI for 20 minutes to release the 
full ~1kb LssGCL or LssGCH construct that was purified on a 1.5% agarose gel and 
inserted into pLNT/sffvMCS (figure 2.4 A) that had been opened between sffv and 
WPRE with BamHI and EcoRI.96
  Insertion  of  the  fusion  construct  into  pLNT/sffv/MCS  yielded  plasmids 
pLssGCL12 and pLssGCH12 (Figure 3.8A, B) that were used as transfer vectors on 
virus preparations to generate lentiviral vectors vCII-LAMP and vCII-DM.
  The  MOG-peptide-containing  construct was  inserted  into pLNT/sffv/MCS 
using  the  same  strategy giving  rise  to  vMOG-LAMP.  Each  of these  three  final 
plasmids were sequenced, using the sanger method. The sequences are listed in the 
appendix at the end of this thesis.
Figure 2.4 A Cloning diagram for GCL constructs. Schematic diagram 
showing the complete cloning sequence for the final GCL construct, 
pLssGCL12. LAMP-1 cyt/TM: LAMP-1 cytoplasmic/transmembrane 
domain, L-1 ss: LAMP-1 signal sequence, IL-2ss: IL-2 signal sequence.97
Figure 2.4 B cloning diagram for GCH constructs. Schematic diagram 
showing the complete cloning sequence for the final GCH construct, 
pLssGCH12. H2-DM cyt/TM: H2-DM cytoplasmic/transmembrane domain, 
L-1 ss: LAMP-1 signal sequence, IL-2ss: IL-2 signal sequence.
2.1.8  Generation of LH3-expressing lvv-backbone
  cDNA encoding  LH3  had  been  cloned,  by James  Devitt,  into  a  TOPO 
plasmid from Invitrogen, Paisley, UK but was found after sequencing to contain an 98
adenine-to-guanine  point-mutation  that results in  a  glutamate-to-glycine  missense 
mutation. The  single  base  pair  was  corrected  using  a  QuickChange  II  XL  site-
directed mutagenesis kit (Stratagene, La Jolla, CA, USA).
  A reaction mix using 2.5 mM dNTPs, 1X reaction buffer, 1X quick solution, 
2.5ng/µL forward primer 5’-ggtggctcaagaaggaaatggagaaatatgcagatcagaaagac-3’ and 
2.5ng/µL complementary primer 5’-gtctttctgatctgcatatttctccatttccttcttgagccacc-3’ was 
set up in a total volume of 49 µL. 1 µL Pfu Ultra (supplied with QuickChange kit) 
was added and the reaction was initiated at 95ºc for 1 minute before cycling between 
95ºc for 50 seconds, 60ºc for 50 seconds and 68ºc for six minutes for a total of 18 
cycles before finishing  the reaction at a  temperature  of 68ºc for eight minutes. A 
control reaction was performed without the addition of Pfu Ultra, and both reactions 
were digested with DpnI prior to transformation of competent XL10-Gold cells (also 
provided).
  Approximately a dozen colonies were present on the reaction plate and no 
colonies were present on the control plate. Sequencing of the resulting plasmid preps 
revealed that the single-base missense mutation had been reversed. The corrected 
LH3 cDNA was then cloned into the Xho-BamHI sites of pLNT/sffv/MCS giving 
rise to plasmid pLH3cor63.99
2.2  Generation and titration of lvv’s
2.2.1  Preparation of Lentivirus
  293T cells were  grown  in DMEM medium  with  10%  Fetal  bovine  serum 
(FBS) in 12 x 275 cm2 tissue culture flasks (Nunc, Roskilde, Denmark) to a density 
of approximately 80%. Transfection solution was made  by adding  13 µL  10  µM 
polyethylenimine (PEI) to 65 mL Opti-MEM, which was then passed through a 0.22 
µm filter (Millipore, Bedford, MA, USA), and split into three 21 mL aliquots, any 
excess being discarded. Separately, 200 µg of either pGCL12, pGCH12, pLH3cor63 
or the GFP-expressing control vector SEW, along with both 70 µg pMD.G2 (Plasmid 
Factory)  that  encodes  VSV-G  and  130  µg  pCMVdR8.74  (Plasmid  Factory, 
Bielefield, Germany) that encodes the packaging proteins was added to 20 mL Opti-
MEM and filtered through a 0.22 µm filter, added to one of the 20 mL PEI/Opti-
MEM aliquots and left at room temperature for 20 minutes with occasional agitation. 
After removal of cell medium, cells were washed with Opti-MEM and incubated in 
10 mL transfection solution at 37°c, 5%  CO2. After  four hours, the  transfection 
medium was removed and replaced with 17.5 mL DMEM-10% FBS. This medium 
was  harvested  and  replaced  on day 2  and  harvested  again  on day 3.  Harvested 
medium was centrifuged at 4000rpm for 10 minutes, passed through a 0.22 µm filter 
and  virions  were  harvested  by ultracentrifugation  in  a  Surespin  rotor (Sorval) at 
23,000 x g.
  Pellets were resuspended in 200 µL Opti-MEM, frozen in aliquots denoted 
vLssGCL12, vLssGCH12, vLH3cor63 and vSEW respectively and stored at -80°c.
2.2.2  Titration of lentivirus preparations by  Flow Cytometric  analysis of GFP+ 
  cells.
  293T cells were seeded on a 48-well plate (Nunc) at a density of 100,000/
well and were treated with 10 µL of freeze-thawed virus prep or 10 µL of 10-fold 
serial dilutions in Opti-MEM. On day 3 cells were trypsinised and passed through a 100
flow cytometer machine (Dako Cytomation CyAn ADP flow) to assess the number 
of  transducing  units  per  mL  of  virus  prep  (figure  3.9A).  Only values  for  cell 
populations of between 5% and 50% GFP+ were used for calculations to reduce the 
number of cells that had been multiply transduced.
2.2.3  Titre of LH3-expressing lvv by qPCR – DNA extraction
  Lentiviral  vectors  that  express  the  lysine-modifying  enzyme  lysyl-
hydroxylase  3 (LH3) were generated as described above using  the transfer vector 
pLH3cor63. Because this lvv does not express a fluorescent protein infectious titre 
could not be ascertained by simple flow cytometric analysis of transduced cells. One 
approach that has been widely used was to assay the amount of HIV P24 protein in a 
lentivirus prep,  but while  this  gives a  measure  of  the  number  of viral  particles 
present, it cannot give a reliable measure of infectious titre due to the possibility of 
“empty” or otherwise non-infectios virions. Quantatitive PCR, however, provides a 
direct measure of the number of transgenes integrated in the target cell DNA.
  293T cells, seeded in 48-well plates at 100,000 per well, were treated with 
10-fold serially diluted vLH3cor63 at a top concentration of a full 50 µL aliquot of 
frozen-thawed virus prep. On day 3 DNA was extracted by “salting out”. Briefly, on 
day 3 cells were washed with PBS  and lysed using  10-µL 1 mg/mL proteinase K 
(Merck, Nottingham, UK, Darmsdatd, Germany) in 750 µL 8 µM Tris-HCl pH8.2, 
0.32M NaCl, 1.87 µM EDTA at 37ºc overnight. On day 4, 200 µL 6M NaCl was 
vigorously  mixed  with  each  sample  in  a  1.5  mL  microcentrifuge  tube,  before 
spinning at 13,000 RPM for 10 mins. Supernatant was transferred to a 15-mL falcon 
tube and 2-mL 100% ethanol was added to precipitate DNA which was pelleted by 
spinning at 4,600 for 30 minutes. Pellets were washed in 70% ethanol, airdried and 
dissolved in dH2O overnight at 37°c.101
2.2.4  Measurement of integration number by qPCR – reaction set-up
  Determination  of  transgene  copy  number  was  performed  by  qPCR  on 
extracted  DNA  –  both  by  using  WPRE-complementary  primers  to  determine 
transgene  integration  number  and  also  mouse  β-actin-complementary primers  to 
determine cell number. 25 µL reactions were set up by mixing 20 µL β-actin reaction 
mix  (1100 µL Universal Master Mix, 19.8 µL β-actin forward primer, 19.8 µL β-
actin reverse primer, 4.4 µL β-actin probe, 440 µL H20), or 20 µL WPRE reaction 
mix  (1100  µL  Universal  Master  Mix,  19.8  µL WPRE  forward  primer,  19.8  µL 
WPRE reverse primer, 4.4 µL WPRE probe, 440 µL H20) with 5 µL extracted DNA. 
Sequence  copy number  was  determined  on  an Abi  Prism  7000  machine  using 
Sequence Detection software.102
2.3  In vitro protocols for analysis of novel fusion proteins
2.3.1  Transfection of fibroblasts with pGCL2 and GFP-only controls
  Aliquots of 10 µL  lipofectamine (Invitrogen, Paisley, UK) in 90 µL  Opti-
MEM were prepared and left at room temperature (RT) for 45 mins before addition 
of 100 µL 5pg/µL, 10-pg/µL, and 20 pg/µL pGCL2 in Opti-MEM were each mixed 
with  100  µL  lipofectamine  solution  and  left  at  RT for  a  further  15  mins  with 
occasional  agitation.  The  resulting  200-µL  solution  was  added  to  50,000  3T3 
fibroblasts adhered in a 48-well plate and washed with Opti-MEM, incubated for 4 
hours at 37°c, 5% CO2 before cell medium was added again.
2.3.2  Western Blot analysis of expressed constructs
  100,000  293T  cells,  stably  transduced  with  vLssGCL12,  vLssGCH12, 
vLH3cor63 or vSEW at MOI 25 were harvested using a cell-scraper three days post-
transduction  and  heated  at  98°c  for  10  mins  in  1  x  NuPAGE  sample  buffer  + 
reducing  agent  and  run  on  a  NuPAGE  Novex  Bis-Tris  4-12  %  gel  alongside 
NuPAGE  Plus2  pre-stained  standards  (Invitrogen,  Paisley,  UK).  Samples  were 
transfered to 0.45 µm Immobilon-P polyvinylidine difluoride membrane in an XCell 
II Blot module run at 30V for 1 hour. The membrane was blocked in 2% BSA/PBS 
overnight at 4°c. 
  Expression  of fluorescent proteins was detected by incubation with rabbit 
polyclonal  anti-eGFP at a 200-fold dilution in 1% BSA/PBS, 0.05% Tween for 2 
hours with shaking. Expression of LH3 was detected via incubation O/N with whole 
rabbit anti-LH3 serum  (Ruotsalainen et al. 2006a) diluted 1:10 in 1% BSA/PBS, 
0.05% Tween.
  After 4 washes in 1% BSA/PBS, 0.05% Tween, the membrane was incubated 
with HRP-conjugated donkey anti-rabbit IgG (GE, Buckinghamshire) for 2 hours 
with shaking and, following  four more washes, developed by mixing 1 mL each of 
TMB Substrate Reagents A and B (BD Biosciences), incubating  on the membrane 103
for 30s before removing excess with an absorbent towel and viewing a 10 minute 
exposure under a UVIdoc gel documentation system (UVItec, Cambridge, UK).
2.3.3  Confocal Microscopy of 293T cells
  Slides were  prepared  to  view the  pattern  of  eGFP  expression  within  the 
stably transduced 293T cells. After adherence to polylysine slides (VWR), 1 hour, 
37°c,  5%  CO2,  cells  were  fixed  with  4%  paraformaldehyde  (PFA)  at  room 
temperature for 15 minutes, gently rinsed with PBS and then simultaneously blocked 
and permeablised with 1%BSA/PBS, 0.1% Triton 100 (SIGMA, Poole, UK), stained 
with Rhodamine-phalloidin (Molecular Probes, Invitrogen, Paisley, UK), that binds 
to and stains the actin cytoskeleton, diluted 1:100 in 1%BSA/PBS, 0.1% Triton 100 
and  washed 3  x  PBS, 0.1% Triton 100,  and  once  in  water  before  mounting  the 
coverslip. All confocal images were captured using a Leica SP confocal microscope.
2.3.4  Generation of Mouse Dendritic cells
  Bone marrow was gently extracted from both tibia and fibula of the rear legs 
from female DBA/1 mice, sacrificed using CO2, using a 23-gauge needle and 1 mL 
syringe.  A  single-cell  suspension  in  serum-free  RPMI  was  obtained  by  gently 
repeatedly passing  the  cell  suspension  through  the  needle,  and  finally straining 
through a nylon cell strainer. After centrifuging the cell suspension at 13,000 rpm for 
5 minutes at room temperature, the pellet was resuspended in red blood cell lysing 
buffer (SIGMA, Poole, UK) and incubated at 37°c for 5 minutes. 45 mL PBS was 
added and following another spin at 13,000 rpm for 5 minutes at room temperature, 
cells were seeded at 1 x 107 each into three T75 tissue culture flasks in 10-mL RPMI 
supplemented with  10% FBS,  20ng/mL rmGM-CSF,  and were  incubated  at 37°c 
with 5%CO2. 20ng/mL rmGM-CSF was also added and refreshed every 3 days.
  Where these mBM-DCs were to be transduced they were treated with lvv at a 
multiplicity of infection (MOI) of  20-25  on day 3, standardised on infectivity of 104
293T cells as measured by FACS  analysis of  293T cells  transduced by limiting 
dilutions of viral preps (see section 2.2.2).
2.3.5  Confocal microscopy of mBM-DCs
  Cells  were  fixed  in  4%  paraformaldehyde  for  15  minutes before  plasma 
membranes and  internal  cell  membranes  were  permeabilised  by incubating  with 
0.1% Triton X-100, 1% BSA/PBS at room temperature for 1 hour. Cells were stained 
with  either  rabbit  polyclonal  anti-EEA-1  (ab2900,  AbCam,  Cambridge,  UK)  or 
rabbit  polyclonal  anti-LAMP-1  (sc5570,  Santa  Cruz Biotechnology,  Heidelberg, 
Germany) at 1:100 in PBS/0.1% Triton X-100/1% BSA, with or without biotinylated 
goat anti-eGFP (Rockland, Gilbertsville,  PA, USA)  at 1:250  for 1  hour at room 
temperature. After 3 gentle washes with 0.1% Triton X-100 in PBS, all cells were 
stained  with  a  mixture  of  goat  anti-rabbit-Cy5  (Invitrogen,  Paisley,  UK)  and 
streptavidin-FITC (Becton-Dickinson)  in  PBS/0.1%  Triton  X-100/1%  BSA for  1 
hour  at room  temperature.  Following  another 3  gentle  washes with  0.1% Triton 
X-100 in PBS, slides were washed with dH2O and cover slips were mounted using 
Vector Shield (Vector Laboratories, Burlingame, CA, USA) that also contains DAPI 
nuclear stain. Cells were imaged using a Leica SP confocal microscope.
2.3.6  Antigen presentation by 3T3-I-Aq cells to CD4+ T cell hybridomas
  The  3T3 mouse  embryonic fibroblast cell  line had  been  previously stably 
transfected with the MHCII-DR I-Aq molecule by Dr K Laurie (denoted 3T3-I-Aq 
cells)(Gjertsson  et  al.  2009).  These  cells  were  used  as  APCs  in  the  initial 
investigation of CII259-273-presentation by cells expressing CII-LAMP and CII-DM. 
3T3-I-Aq  were  transduced  with  vCII-LAMP  or  vCII-DM  at  an  MOI  of  50. 
Untransduced 3T3-I-Aq cells, 3T3-I-Aq cells stably expressing CII-LAMP, CII-DM, 
eGFP or the Ii-CII construct were seeded in 48-well plates at an initial density of 
~50,000/well and left for 2 days. Untransduced 3T3-I-Aq cells were either treated 
with  100 µg/mL  whole  rat CII at the  time  of  seeding,  or were  treated with  CII 105
peptide 259-273, either unglycosylated, or with an O-linked galactose to hydroxy-
lysine  in  the  264  position,  at  10  µg/mL  directly before  addition  of  the  T  cell 
hybridomas. T cell hybridomas HDBR1, HCQ3, HCQ4, and HCQ10, each specific 
for MHCII-I-Aq  in complex  with  CII epitopes in various states of glycosylation 
were thawed and grown in DMEM/10% FBS for four or five days at 37º C, 5% CO2 
before addition to ~ 100,000 3T3-I-Aq cells at a ratio of 1:1. Most experiments were 
conducted in triplicate. Cells were co-cultured in 48-well plates for 2 days, frozen 
and  thawed and the  medium  assayed for IL-2 concentration by sandwich ELISA 
using mouse IL-2 ELISA DuoSet (R&D Systems, Minneapolis, MN, USA) on Nunc 
Maxisorp 96-well plates. 100 µL standards were prepared by 2-fold serial dilutions 
of a 2000ng/mL high-standard.
  After  incubation  with  detection  agent,  streptavidin-conjugated  HRP  at  a 
dilution of 1:1000, substrate solutions A and B were mixed 1:1 and 100-µL added to 
each well after 3 thorough washes. The colour reaction was stopped by addition of 
50 µL 1 M HNO3. Optic density was measured by subtracting the absorbance at 450 
nm  from the  absorbance at 540 nm  using  a FLUOstar Optima microplate  reader 
(BMG Labtech, Aylesbury, UK).
2.3.7  Antigen presentation by mBM-DCs to CD4+ T cell hybridomas
  100,000 primary mBM-DCs, prepared as described above in section 2.3.3, 
were  transduced  or treated  with  rat CII on  day 3  and  co-cultured  with  100,000 
hybridomas  HCQ3  or  HCQ4  on  day  six.  Following  two  days’  co-culture,  IL-2 
response was measured by sandwich ELISA as described above.
2.3.8  Cll253-273 presentation in cells coexpressing LH3
  150,000 3T3-I-Aq fibroblasts were seeded into each well of a 12-well plate 
and incubated in 2 mL DMEM - 10% FBS overnight at 37°c with 5% CO2. Cells 
were washed in Opti-MEM prior to transduction or treatment with rat CII in 100 µL   
Opti-MEM; 10 µL vCII-LAMP (MOI = 50) or 20 µL vMOG-LAMP (MOI = 50) 106
either with or without 10 µL vLH3cor63 was added to the transduction wells and 10 
µL 5mg/mL native rat CII dissolved in 0.1 M acetic acid to the control well. 20 µL 
OPTI-MEM was added to the  mock-transduced well. After 4 hours incubation at 
37°c with 5% CO2 2 mL DMEM supplemented with 10% FBS was added to each 
well.107
2.4  Assay of protective action of lvv in mouse collagen-induced arthritis
2.4.1  Preparation of lvv for use in vivo
  Viral  vectors  intended  for  mouse  injection  were  prepared  exactly  as 
described above in section 2.2.1 except that the virus pellets were resuspended in 1 
mL PBS prior to freezing  at -80º. Shipment to the Department of Rheumatology at 
the  University of  Gothenburg  was  made  on  dry ice  using  DHL  world  delivery 
service.
2.4.2  Injection of  lvv into DBA/1 mice
  Male DBA/1 mice aged 7-10 weeks were used for the in vivo experiments 
and were maintained 10-to-a-cage under standard conditions at the animal facility at 
the  Department of  Rheumatology at  the  University  of  Gothenburg.  All  animal 
manipulations were performed under a local ethical permission and according to the 
local ethical rules for animal experimentation at the University of Gothenburg. 
  Administration of vCII-LAMP or vMOG-LAMP was by tail vein injection 28 
days prior to CIA induction (ie day -28). 5 x 106 infectious lvv, as measured through 
flow cytometry of transducd 293 T cells (see section 2.2.2), were injected into the 
tail vein in a total volume of 200 µL (diluted in PBS where necessary). Although 
only this one dosage was used, higher dosages were avoided as immunisation as 
opposed to tolerisation might occur. Dose escalation studies may form part of future 
work but were beyond the scope of this study.
2.4.3  Arthritis induction and evaluation
  The  arthritis  induction  protocol  was  based  on  that  developed  by Rikard 
Holmdahl (Holmdahl et al. 1985a). On day 0, 28 days after vaccination with vCII-
LAMP  or  vMOG-LAMP,  9  DBA/1  mice  in  each  group  were  immunised 
intradermally with  100  µL  rat  CII  emulsified  in  0.1M acetic  acid  (VWR)  and 
complete Freund’s advuvant (SIGMA, Poole, UK-Aldrich, Sweden). A second dose 108
of 100 µL rat CII emulsified in 0.1M acetic acid on day 21 was supplemented with 
incomplete  Freund’s  adjuvant  and  administered  i.p.  21  days  after  the  primary 
immunisation.
  Mice  were  graded  for  arthritic  score  based  on  previously  described 
observational  protocol,  originally used  to  score  septic  arthritis  (Abdelnour  et al. 
1993) but also used to determine disease severity in CIA (Gjertsson et al. 2009). 
Similar scoring systems have also been used in other studies of CIA (Hegen et al. 
2006) (Milici et al. 2008). Briefly, arthritis was defined as visible erythema and/or 
swelling of a limb/joint or digit. A score of 1 was assigned to a limb showing mild 
swelling and/or erythema, 2 for a limb displaying moderate swelling and erythema 
and a score of 3 assigned to any limb with marked swelling and erythema, allowing 
for a theoretical maximum score of 18 per mouse. Digits with clear swelling and/or 
erythema were assigned a score of 0.25. Scoring  of severity of arthritis using  this 
method  allows  direct  comparasson  of  the  results  obtained  with  those  from  the 
previous study (Gjertsson et al. 2009).109
2.5  Analysis of samples obtained from experimental animals
  Blood samples were taken on day 28 post CII immunisation and immediately 
before sacrifice. Spleen and lymph nodes were harvested directly after sacrifice.
2.5.1  In vitro T cell stimulation and proliferation assay
  Single-cell suspensions were obtained by gently pressing the draining lymph 
nodes  or  quartered  spleens  through  70  µm  nylon  cell-strainer  (BD  Bioscience, 
Bedford, MA, USA) in PBS. After incubation with red blood cell lysis buffer (10 
mM KHCO3, 150 mM NH4Cl 0.1 mM EDTA) (SIGMA, Poole, UK) at 37ºc for 10 
minutes, cells were cultured in Iscoves medium at 106 cells per mL in 12-well plates. 
Cells were cultured without stimuli, or in the presence of CII (50 µg/mL) or 1.25 µg/
mL Concanavalin A (Con A). Supernatant was harvested after 72 hours at which 
time 1 µCi [3H]-thymidine was added to each well. Plates were cultured for another 
20 hours before harvest. Each sample was tested in triplicate.
  T  cell  stimulations  and  thymidine  incorporation  assays  were  kindly 
performed by Inger Gjertsson at the  Department of Rheumatology, University of 
Gothenburg.
2.5.2  ELISA measurement of cytokines
  Supernatant  from  the  stimulated  splenic  and  lymph  node  cultures  was 
harvested  after  72  hours  and  frozen  in  aliquots.  IL-17,  IL-10  and  TGF-β 
concentrations were assayed using ELISA kits from eBiosciences (San Diego, CA, 
USA) by following the provided protocol.
2.5.3  ELISA measurement of mouse serum antibody titre 
  Approximately 300 µL tail  vein  blood was collected on day 28 of mouse 
experiment 1,  seven days  after  booster injection,  and again  immediately prior  to 
termination of the experiment (on day 39 for experiment 1, day 42 for experiment 2). 
After 2 hours coagulation at RT samples were microcentrifuged for 10 minutes at 110
6,000 RPM. Up to 150 µL serum was harvested and frozen. Following initial thaw, 
the  samples  were  measured  into  30  µL  aliquots before  re-freezing  for  later  use. 
Sandwich  ELISAs,  described  below,  were performed to determine antibody titre. 
IgM levels were assayed only using aliquots that had not undergone a second freeze; 
IgM-assays were performed on samples directly after the primary thaw.
  96-well Maxi-sorb plates (Nunc) were coated with 100 µL either 10 µg/mL 
rat CII in PBS or 2 µg/mL of unconjugated capture antibody specific for IgG2A or 
IgG2B in 0.5M sodium carbonate-bicarbonate pH 9.6 by incubating overnight at 4°c. 
Plates were washed 3 times with PBS containing 0.05% Tween-20 and were then 
blocked for 1 hour at RT using 200-µL 1% BSA in PBS.
  Mouse sera, transported back to London on dry ice, were diluted in PBS at 
the  following  dilutions  for  determination  of  each  isotype:  IgM:  1:200,  1:1000, 
1:5000, 1:25,000; Total IgG: 1:1000, 1:5000, 1:25,000, 1:125,000; IgG2A: 1:1000, 
1:5000, 1:25,000, 1:125,000; IgG2B: 1:1000, 1:5000, 1:25,000, 1:125,000.
  IgG2A and IgG2B isotype standards were prepared in duplicate at 1µg/mL 
and  serially  diluted  in  3-fold  dilutions  to  give  a  standard  curve  for  assays 
determining total IgG2a/IgG2b levels as opposed to CII-specific antibody titre.
  After  blocking  solution  was  removed  and  the  plates  were  washed  as 
described  above,  100  µL  sample  or  standard  dilution  was  added  per  well  and 
incubated at RT for  2 hours. After  a further wash, 100 µL biotinylated or  HRP-
conjugated isotype-specific detection antibody was applied to each plate for 1 or 2 
hours:
Biotin-anti-IgM (Pharmingen): 2µg/mL in PBS, 1 hour, RT.
Biotin-anti-IgG (DakoCytomation): 4µg/mL in PBS, 1 hour, RT.
HRP-anti-IgG2A (Pharmingen): 2µg/mL in PBS, 2 hours RT.
Biotin-anti-IgG2B (Pharmingen): 2µg/mL in PBS, 2 hours RT.
  Plates  incubated  with  biotinylated  detection  antibodies  were  washed  as 
described  above  and  incubated  for  a  further  1  hour  with  Streptavidin-HRP 
(Pharmingen)  diluted  to  1:1000  in  PBS.  Assays  were  developed  using  TMB 111
substrate reagents kit (BD Biosciences, San Diego, CA, USA). Substrate solutions A 
and B were mixed 1:1 and 100-µL added to each well after 3 thorough washes. The 
colour reaction was stopped by addition of 50 µL 1 N HNO3.
  Optic density was measured by subtracting the absorbance at 450 nm from 
the  absorbance  at 540  nm  using  a  FLUOstar  Optima  microplate  reader  (BMG 
Labtech, Aylesbury, UK).
2.6  Bio-electrospray
  3T3-I-Aq cells were transduced with vCII-LAMP at an MOI of 25 three days 
before passage through a steel needle with internal and external bore diameters of 6 
and 8 mm respectively. This was performed both in a “needle control” (nc) where no 
voltage was applied to the needle and for bio-electrospray the needle was charged to 
voltages  of  ±1-30  kV  using  the  FP-30  precision  high-voltage  power  supply 
(Glassman  Europe  Ltd,  Tadley,  UK),  drawing  a  maximum  current of  4  mA.  In 
experiments investigating  cell-structure  generation,  cell  media  was supplemented 
with 1% polyethylene oxide (PEO), average Mv ~  300,000 (SIGMA, Poole, UK). 
Cells were at a concentration of ~106/mL and were sprayed down into a beaker of 
PBS that was being mechanically stirred such that the stream of medium entered the 
PBS off-centre. Flow rates of 10 nL/s-100 µL/s were used by regulating the syringe-
depression speed using a PHD4400 (Harvard Apparatus Ltd., Kent, UK).
  For  co-culture  experiments  to  determine  the  ability  of  transduced,  bio-
electrosprayed cells to  retain T cell  hybridoma-stimulating  properties,  transduced 
3T3-I-Aq cells were processed at a voltage of 20 kV at a speed of 50 µL/s directly 
into a tissue-culture flask, before co-culture with HCQ4 hybridomas on day 1 for 2 
days.112
2.7  Statistical methods
  All data was analysed using GraphPad Prism 5.0. Two-tailed Student’s t tests 
were performed on all continuous data; antibody titres and IL-2 titres that can take 
any value  as  opposed  to  ordinal  data  that can  only have  particular  values. The 
statistical  significance  of  differences  in  ordinal  data,  such  as  arthritic  scores  of 
experimental DBA/1 mice were evaluated by performing two-tailed Mann-Whitney 
U tests. P values below 0.05 were considered significant. 113
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3  Generation and expression of fusion constructs
3.1  Introduction
  The  aim  of  this  project  was  to  induce  antigen-specific  tolerance  to  the 
CII259-273 peptide by way of driving MHCII-presentation of the CII259-273 peptide. To 
achieve this, novel fusion proteins that were designed to traffic the CII259-273 peptide 
down the endosomal pathway by virtue of an intracellular localization domain were 
to  be  expressed by lvv. Two  such domains were  tested for  their ability to drive 
peptide presentation in the context of MHCII, namely the LAMP-1 cytoplasmic/TM 
domain (the signal-anchor sequence) and the H2-DM signal-anchor sequence.
  H2-DM  is  the  mouse  homologue  of  the  human  HLA-DM  protein,  the 
molecular chaperone that catalyses removal of the Ii-derived CLIP domain from the 
antigen-binding  cleft  of  MHCII  molecules  and  thus  loading  of  peptides  for 
presentation.  To  perform  this  task,  H2-DM  is  trafficked  to  MHCII-containing 
compartments and so was thought to be an excellent candidate to efficiently deliver 
the  fusion protein to  sub-cellular regions relevant to MHCII-loading. LAMP-1 is 
associated  with  the  lysosomal  membrane.  MHCII-containing  compartments  are 
considered to be lysosome-like organelles (Santambrogio & Strominger 2006) and 
LAMP-1 has been used by other groups to efficiently target antigens for MHCII-
loading  (Wu  et  al.  1995;Bonehill,  Heirman,  &  Thielemans  2005).  Subcellular 
location  and  antigen-presentation  derived  from  LAMP-1-targeted  fusion  proteins 
(CII-LAMP)  and  H2-DM-targeted  fusion  proteins  (CII-DM)  are  compared  in 
Chapter 4,  whilst this chapter focuses on their generation and  modifications that 
were found to be necessary in order to achieve lvv-mediated expression.
3.1.1  Signal peptides and signal-anchor sequences
  A short,  typically  20-24  amino  acid  signal  peptide  at  the  N-terminus  is 
required for translocation to the ER on proteins bound for the endosomal pathway. 115
Translocation  occurs  via  binding  of  the  SRP  to  the  signal  peptide  on  nascent 
polypeptides as they are translated by the  ribosome that in turn interacts with  an 
SRP  receptor  in  the  membrane  of  the  ER.  The  Ribosome-SRP-SRP  receptor 
complex  then directs translation  of  the nascent protein through a  translocon,  also 
embedded  in the  ER lipid bilayer, that associates directly with the  ribosome  and 
channels the emerging polypeptide into the lumen of the ER resulting in a full-length 
polypeptide that folds within the ER (Wilkinson, Regnacq, & Stirling 1997).
  The signal peptides contain a hydrophobic core.   Following translation the 
signal  peptide  egresses  the  translocon  laterally,  becoming  anchored  in  the  ER 
membrane. In the case  of soluble or type  I TM proteins that are anchored to the 
membrane by a signal-anchor sequence present at the C-terminus, the signal peptide 
is  then  cleaved  by signal  peptidase  (with  type  II  TM proteins anchored  by the 
uncleaved signal peptide at the N-terminus). It is thought that the C-terminal signal-
anchor sequence  of type I TM proteins such as LAMP-1 and  H2-DM determine 
whether  the  protein  is  ultimately  destined  for  secretion  or  retention  within 
components of the endosomal pathway. 
 
3.1.2  IL-2 signal peptide and LAMP-1 signal peptide
  The  original  cloning  strategy utilized  a  plasmid,  pFUSE-hIgG4-Fc2,  that 
contained  a  sequence  that  encodes  the  signal  peptide  from  IL-2  immediately 
upstream  from  the  EcoRI  restriction  endonuclease  site  of  the  multiple  cloning 
sequence. As described  below,  sequences encoding  the  other  components  of  the 
fusion construct were inserted into this plasmid such that the IL-2 signal sequence 
constituted the 5’ end of the fusion construct giving rise to DNA plasmids pGCL29 
and  pGCH12.  lvv  prepared  to  express  proteins  derived  from  such  constructs, 
however, were repeatably unable to induce fluorescence in cells (figure 3.7).
  After the  exchange  of promoter and vector backbone  failed to resolve this 
problem, the  IL-2 signal sequence was exchanged for the sequence encoding  the 116
LAMP-1  signal  peptide. This enabled lvv-mediated  expression  of  fusion proteins 
detectable by FACS, microscopy and western blot.
3.1.3  CII259-273 peptide
  The immunodominant epitope in CIA is a T cell determinant derived from 
collagen  type  II;  a  core  region  corresponding  to  amino  acid  residues  260-270. 
Studies into the  immunogenicity and  tolerising  capabilities of such peptides have 
used  peptides  of  varying  length,  ranging  from  residue  256  to  residue  273.  The 
present study has used fusion proteins that incorporate amino acid residues 259-273, 
consistent with soluble, synthetic peptides that were used as positive controls for 
MHCII-peptide presentation. Additionally, 4-amino acid cathepsin S proteolysis site 
Leu-Arg-Met-Lys was encoded immediately preceding  the CII259-273 sequence  and 
the  second cathepsin S  site  Glu-Asp-Leu-Lys  to  facilitate  epitope  release  within 
MHCII-containing  compartments.  (However,  no  control  constructs  without  such 
proteolysis sites were made, and it is therefore not possible to determine to what 
extent these improved the peptide processing.)
3.1.4  eGFP label
  Identification  of  fusion  protein-expressing  cells  was  achieved  by 
fluorescence  microscopy and flow cytometry.  Fusion protein-expressing  cells are 
fluorescently active because the fusion protein includes an eGFP domain that emits 
visible  (green)  light when  excited  with  UV  light. This also enabled  intracellular 
imaging of regions of fusion protein accumulation within the cell.117
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Figure 3.1 Cartoon of fusion proteins (A) CII-LAMP, (B) CII-DM
Schematic  cartoon depicting  eGFP domain,  cathepsin S  sites  (pink  colour), 
CII259-273 peptide and LAMP-1/H2-DM signal anchor domains.
3.2  Generation of fusion constructs
  Sequences  encoding  fusion  proteins  were  constructed  using  standard 
molecular biology techniques as described in detail in Materials and methods and 
outlined  briefly below.  Generation  of  plasmids  encoding  CII-LAMP  is  initially 
described since cDNA for CII-DM was constructed later using equivalent methods 
(see  3.2.6 Exchange  of  IL-2ss for LAMP-1ss and  generation of  H2-DM-targeted 
construct)
3.2.1  PCR-amplification of eGFP and LAMP-1-signal-anchor domains
  Amplification  of  eGFP and  LAMP-1  signal-anchor  sequences  flanked  by 
convenient restriction endonuclease sites was achieved by performing a polymerase 
chain reaction (PCR); custom oligonucleotides that include convenient restriction 
sites  (see  Materials  and  Methods)  were  used  as  primers  on  an  existing  eGFP-










LAMP-1, section 2.2.2 above), respectively. Each PCR product was ‘cleaned’ using 
a Qiagen kit (figure 3.2)
     
3.2.2  Assembly of component sequences
  By including  an EcoRI site at the 5’ end of the eGFP forward primer, the 
clean PCR product (figure 3.2, lane 4) was inserted, in frame, into plasmid pFUSE-
hIgG4-Fc2 such that the IL-2 signal  sequence  was fused to  the  5’ end,  with the 
hEF1α-HTLV fusion promoter upstream. Other unique restriction sites included on 
each  PCR  primer,  detailed  in  Materials  and  methods,  were  used  to  insert  the 
LAMP-1 signal-anchor sequence downstream, deriving plasmid pGL1 (figure 3.2A, 
lane  1).  Finally,  annealed  51-bp oligonucleotides  encoding  the  CII259-273  peptide 
including  a  BamHI-compatible  overhang  on  the  5’  end  and  an  NcoI-compatible 
overhang  on  the  3’  end  were  inserted  between  eGFP  and  LAMP-1  domains. 
Successful insertion of the CII259-273 sequence was verified by analytical restriction 
endonucease digestion with BamHI and XhoI (figure  3.3A, lane 3), confirmed by 
DNA  sequencing,  and  denoted  pGCL2.  Additionally,  an  IL-2ss-eGFP  control 
construct, denoted pG10 was generated (figure 3.3C) by insertion of an eGFP PCR 
product generated using a reverse primer that included a stop codon into the pFUSE-
hIgG4-Fc2 vector.
Figure  3.2  Products  of  PCR  to  amplify 
eGFP  and  the signal-anchor  sequence of 
LAMP-1.  Signal-anchor  sequence  of 
LAMP-1  before  clean-up,  lane  1,  and  after 
clean-up, lane 2; eGFP cDNA before clean-up, 
lane 3, and after clean-up, lane 4.
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Figure 3.3 IL-2 signal sequence-containing fusion constructs. (A) BamHI-
XhoI  restriction  digestion  of  minipreps,  lanes  2-7,  following  CII259-273 
oligonucleotide insertion between eGFP and LAMP-1 domains of pGL1, lane 1. 
Molecular weight markers correspond to 100-bp, 200-bp, 300-bp, 400-bp, 500-
bp, 600-bp, 700-bp, 800-bp and 1 kb. (B) Cartoon of plasmid pGCL2 depicting 
the IL-2ss (yellow), eGFP domain (green), CII259-273 sequence (thick black) and 
the LAMP-1 TM anchor-peptide sequence (red).
(C) Schematic diagram of fusion constructs pGCL2 and pG10, cloned into the 
pFUSE-hIgG4-Fc2  plasmid  that contains  the  hEF1α-HTLV  fusion  promoter 
upstream of the interleukin-2 signal sequence (IL-2ss) at the 5’ end, adjacent to 
the  multiple  cloning  site  into  which  eGFP,  LAMP1  TM  and  CII  peptide/
cathepsin S site sequences were inserted. 
232 bp
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3.2.3  Transient  expression  of  fusion  construct  following transfection of  pGCL2 
  plasmid
  The  pGCL2  plasmid  encoding  the  LAMP-1-targeted  fusion  construct 
downstream from the hEF1α-HTLV fusion promoter was transfected into mouse 3T3 
fibroblasts using lipofectamine. Fluorescent microscopy was used to visualise eGFP
+  cells.  In  cells  transfected  with  pGCL2,  fluorescence  was  visible  in  a  region 
surrounding the nucleus, whereas in constructs expressing pG10, without a targeting 
domain, fluorescence is present throughout the cell (Figure 3.4).
(A)         (B)               (C)
Figure 3.4 Transient transfection of mouse 3T3 fibroblasts. (A) 3T3 cells 
transfected with eGFP-expressing plasmid pG10 display eGFP throughout the 
cell, with the brightest region appearing to be within the nucleus; (B) 3T3 cells 
transfected with pGCL2 display eGFP-fluorescence that appears to be excluded 
from the nucleus, but within the surrounding regions; (C) 3T3 cells treated with 
lipofectamine alone. Images taken at 40 X magnification.121
3.2.4  IL-2ss-containing fusion constructs in lentiviral backbone
  The fusion construct including the IL-2ss at the 5’ end and a stop codon at 
the  3’ end  was excised from  the  pGCL2  plasmid using  SfoI and XhoI restriction 
endonucleases and ligated into the pENTR1A backbone that had been digested at 
XmnI  and  XhoI  sites  located  either  side  of  the  kanamycin  resistance  gene.  The 
pENTR1A vector, provided by Invitrogen, Paisley, UK, is designed to recombine by 
homologous  recombination  with  lentiviral  backbone  pDEST  in  determined 
orientation  such  that  the  sffv  promoter  is  upstream  of  the  insert in  a  reaction 
catalysed by LR recombinase. The presence of the inserted fusion construct in the 
daughter plasmid  pGCL15 was verified by restriction  analysis and confirmed  by 
sequencing.  However,  after  3-plasmids  transfection  of  293T  cells  for  virus 
production, cells transfected with the pSEW control vector (expressing eGFP alone) 
were seen, under UV light, to express eGFP at high levels whereas cells transfected 
with  pGCL12 did  not visibly express fluorescent proteins.  The  virus preparation 
harvested  from  these  cells  was  unable  to  induce  visible  eGFP-fusion  protein 
expression similar to that seen with transient transfection with pGCL2 in target cells.
  Because construct expression had been observed under control of the hEF1α-
HTLV  promoter following  transfection with pGCL2, it was decided that inserting 
this in place of the sffv promoter might resolve the unexpected lack of fusion-protein 
expression from the lentiviral backbone in the pGCL15 plasmid. The most practical 
way to achieve this was to insert the entire hEF1α-HTLV-fusion construct cassettes 
from pGCL2 into pENTR1A and then perform the LR reaction to transfer this into a 
pDEST plasmid that had had the sffv promoter removed.
  This two-step procedure was performed and the sequence of the resulting 
plasmid,  pGCL29  was  confirmed.  The  pGCL29  plasmid  contains  the  IL-2ss-
containing fusion construct downstream from the hEF1α-HTLV fusion promoter in 
the pDEST backbone (figure 3.5).122
  The plasmid pGCL29 was used along with the packaging and coat plasmids 
to transfect HEK293T cells to prepare lentiviral vectors as described in Materials 
and methods. The pSEW plasmid, an eGFP-expressing transfer vector was also used 
to transfect HEK293T cells in separate flasks, again with the  packaging  and coat 
plasmids.
  Two days after transfection. the  293T cells transfected with pGCL29 cells 
appeared to be brightly expressing eGFP-tagged construct. These cells were imaged 
by fluorescence microscopy (figure 3.6). Cells transfected with pSEW also brightly 
expressed eGFP (data not shown).
Figure  3.5  Schematic  diagram  of 
pGCL29.  IL-2ss-containing  fusion 
construct  downstream  from  the 
hEF1α-HTLV fusion promoter 123
Figure 3.6 Transient  transfection  with pGCL29  induces  fluorescence in 
293T  cells.  Fluorescence  micrograph,  day  2, of  293T cells  transfected  with 
transfer  vector  pGCL29,  VSV-G  envelope  plasmid  pMD.G2  and  packaging 
plasmid pCMVdR8.74. Image taken at 20 X magnification.
  Supernatant from  the  pGCL29-  and  pSEW-transfected  cell  cultures  were 
harvested  and  sterile  filtered  through  0.22-µm-pore  filters  to  remove  cells  and 
cellular debris. Virus particles were  purified  by ultracentrifugation  and frozen  in 
aliquots, and denoted vGCL29 and vSEW, respectively. 
3.2.5  No expression of fusion proteins was detectable after treatment of 293T cells 
  with vGCL29
  10-µL aliquots of vGCL29 were  serially diluted and used to treat 100,000 
293T cells growing  in 24-well  plates. These  cells were cultured  for several  days 
without any sign of eGFP-fluorescence. Those 293T cells treated with purified virus 124
supernatant from the vSEW prep, however, did visibly express eGFP. To be sure that 
cells  treated  with  vGCL29  prep  were  not  just  expressing  eGFP-tagged  fusion 
proteins below the threshold of detection with the UV microscope, each cell culture 
treated with each serially diluted virus-prep sample was run on the flow cytometer 
(figure 3.7). Measurement of viral titre by transducing  293T cells and determining 
the proportion of fluorescent cells is the standard method used in the lab for lvv that 
express fluorescent proteins, so this was the method used by the present study.
       
         (A) 0.01 µL vGCL29              (B) 10 µL vGCL29
       
          (C) 0.01 µL vSEW                 (D) 0.1 µL vSEW
Figure 3.7 Flow cytometric analysis of 293T cells transduced with vGCL29 
and vSEW. 100,000 293T cells were treated with 0.01 µL vGCL29 (A), or 10 
µL vGCL29 (B). No increase in fluorescence was observed. 293T cells treated 
with 0.01-µL or 0.1 µL vSEW become 41% eGFP-positive (C) and 62% eGFP-
positive (D) by day 2.
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  Using the 41% positive proportion of 100,000 293T cells treated with 0.01 
µL vSEW  on day 0, a  titre  of 4 x  109 infectious virions per mL  was calculated. 
Successive attempts to generate virus using pGCL29 yielded no infections titre.
3.2.6  Exchange  of  IL-2ss  for  LAMP-1ss  and  generation  of  H2-DM-targeted 
  construct
  Two approaches to resolve the lack of fusion-protein expression via vGCL29 
were undertaken: Firstly, the fusion construct was cloned into a similar but different 
lentiviral  backbone,  pLNT.  This  did  not  resolve  the  lack  of  viral  expression, 
although cloning  directly into the  BamHI-XhoI-linearised  pLNT was found to  be 
easier than lvv-backbone generation via  the  pENTR1A-pDEST system. Secondly, 
two adaptations to the fusion construct itself were made; the exchange of the IL-2 
signal sequence for the LAMP-1 signal sequence and replacement of the LAMP-1 
TM/cytosolic signal-anchor domain for that from H2-DM.
3.2.7  Lentiviral expression of LAMP-1ss-fusion proteins
  Plasmids encoding constructs that contain the LAMP-1 signal sequence and 
either  the  LAMP-1  signal-anchor  (pLssGCL12,  figure  3.8  A,  B)  or the  H2-DM 
signal-anchor (pLssGCH12, figure 3.8 A, C) were used to generate virus preps vCII-
LAMP and vCII-DM respectively (table 3.1). 293T cells treated with either vCII-
LAMP or vCII-DM were found to express eGFP-tagged fusion proteins (figure 3.9 
A, B) and this expression was stable over time (figure 3.9 C).




Plasmid pLssGCL12 pLssGCH12 pSEW





Figure  3.8  pLssGCL12  and 
pLssGCH12  transfer vectors. 
(A)  Schematic  diagram  of 
pLssGCL12 and pLssGCH12; Rev-
response  element,  RRE;  central 
polypurine tract, cPPT; Woodchuck 
post-transcriptional  regulatory 
element, WPRE.
(B) Vector NTI map of pLssGCL12
(C) Vector NTI map of pLssGCH12
enhancer127
(A)  0.01 µL vCII-LAMP        0.1 µL vCII-LAMP      1 µL vCII-LAMP  10 µL vCII-LAMP
(B)                Std           CII-DM   CII-LAMP   eGFP    (C)
Figure  3.9  Transduced  293T  cells  fluoresce  and  western  blot  reveals 
degradation  of  CII-LAMP.  (A)  Titre  of  vCII-LAMP  by  flow  cytometry; 
percentage  eGFP-positive  293T cells  treated  with  serial  dilutions  of  vCII-
LAMP: 0.01 µL - 3.56%; 0.1 µL - 25.1%, giving a titre of 2.4 x 108/mL; 1 µL - 
65.3%; 10 µL - 86.9%.
(B) Western blot using anti-eGFP primary antibodies of whole cell lysates from 
50,000 vCII-DM, vCII-LAMP and  vSEW-transduced  293T cells 3 days after 
transduction.  Pre-stained  standards  alcohol  dehydrogenase  (39  kDa)  and 
carbonic anhydrase (28 kDa) confirm sample bands of expected size: CII-DM 
37 kDa, CII-LAMP 35 kDa and eGFP 27 kDa and appears to show degradation 
products for CII-LAMP-expressing cells.
(C)  Transgene  expression  over  time.  Mean  fluorescence  intensity  (MFI)  of 
293T cells transduced  with vCII-DM (×) or vCII-LAMP (•) was measured on 
day 3, day 10 and day 28. MFI of vSEW-transduced 293T cells ranges from 800 
to 1000 (data not shown).
28 kDa
vCII-DM      ×
vCII-LAMP  •
39 kDa128
  Titres  of  between  108  and  5  x  108  infectious  particles  per  mL  were 
consistently obtained for both vCII-LAMP and vCII-DM. 
 
3.2.8 C onfocal micrographs of 293T cells expressing CII-LAMP and CII-DM
  Having  shown  that vCII-LAMP and  vCII-DM were able  to induce  stable 
fluorescent protein expression in 293T cells, confocal microscopy was used to image 
these cells (figure 3.10). Actin filaments were stained with Rhodamine-phalloidin so 
that the overall extent and shape of the cell could be visualized.
        
(A)                 (B)
(C)
Figure  3.10  Visible  fluorescent  fusion  proteins 
within transduced  293T  cells.  (A)  CII-DM,  (B) 
CII-LAMP (C) eGFP. Cells  imaged  on day 3 after 
transduction and  were co-stained with Rhodamine-
phalloidin (top-left quadrants) to visualise the actin 
filaments and thus the structure of the cell. eGFP-
fluorescence  was  visualised  (top-right  quadrants) 
and  combined  (bottom-left).  Punctate  pattern  of 
eGFP location in panels (A) and (B) contrast with 
global expression in (C).129
3.3.1  Summary
  The aim of the work presented in this chapter was to demonstrate successful 
construction of chimeric constructs encoding fusion proteins designed to deliver an 
immunodominant  CII259-273  peptide  epitope  to  MHCII-containing  compartments. 
Further, stable expression of these fusion proteins was to be achieved by way of lvv-
transduction using lvv’s that express the fusion constructs.
  After  successful  use  of  standard  molecular  biological  techniques,  fusion 
constructs  encoding  CII-LAMP  and  CII-DM were  cloned  with  the  IL-2  signal 
sequence  at  the  5’  end.  Whilst  fluorescent  fusion  protein  expression  was 
demonstrated  following  transient  transfection  using  CII-LAMP-  or  CII-DM-
encoding plasmids, lvv’s initially prepared to express these constructs failed to do so. 
Replacing the IL-2 signal sequence for the LAMP-1 signal sequence resolved this 
and stable fusion construct expression was shown.
  The eGFP domain allowed fusion protein expression to be monitored over 
time  by  measuring  the  mean  fluorescence  intensity  of  transduced  293T  cells. 
Additionally anti-eGFP antibodies were used to reveal  bands of expected size  by 
Western blot and microscopy revealed subcellular distribution of fluorescent fusion 
proteins as being distinct from that of eGFP alone. The intracellular distribution of 
the fusion proteins is investigated further in Chapter 4.
3.3.2  Discussion
  Detection of eGFP-positive 3T3 fibroblasts after transient transfection was 
clearly a good indication that eGFP-containing fusion proteins were being expressed 
by these cells (Figure 3.3) whilst no fluorescence was detected in cells treated with 
lipofectamine  alone.  Whilst  fluorescence  was  visible  throughout  some  cells 
transduced  with  the  IL-2ss-eGFP  construct  pG10,  it  is  now  accepted  that  the 
prescence of the IL-2ss on this fusion protein should result in the secretion of the 
eGFP protein, an outcome that was not investigated but that may have provided an 130
insight  into  the  reason  for  non-detection  of  the  IL-2ss-eGFP-CII259-273-LAMP-1 
fusion protein after transduction with lvv generated using plasmid pGCL15.
  The  observation  of degradation products in  Western blot analysis  of  CII-
LAMP-expressing  cells,  but  not  apparent  in  samples  from  eGFP-  or  CII-DM-
expressing  cells (figure  3.8)  gives a  strong  indication that the  CII-LAMP fusion 
protein  is  being  processed  by  proteolysis.  This  may  contribute  to  the  greater 
efficiency of  CII259-273-presentation  seen in the chapters that follow.  Conclusions 
about the  intracellular mechanism  behind this data  are, however, limited because 
constructs lacking  the  cathepsin sites were not generated and  cathepsin-inhibitors 
were not used.131
Chapter 4.  Results II
In vitro characterisation of fusion proteins132
4  In vitro characterization of fusion proteins
4.1  Introduction
  Stable expression of fusion proteins was achieved following modifications of 
the chimeric transgene as described in chapter 3. Whilst replacing  the IL-2 signal 
peptide allowed lvv-mediated expression of CII-LAMP and CII-DM, the rest of the 
construct was unchanged from the original design that was intended to traffic the 
protein to MHCII-containing compartments (MIICs). Traffic to MIICs was intended 
to result in degradation and release of the CII259-273 epitope to allow it to be loaded 
onto  MHCII-I-Aq  molecules that it is  known  to  bind.  The  next question  to  be 
addressed was whether expression of these proteins in MHCII-I-Aq–positive cells 
resulted in cell surface-presentation of the CII259-273 peptide.
  Antigen presentation to CD4+ T cells by APCs proceeds after  proteolytic 
processing  of material from the endocytic pathway into peptides that may then be 
loaded onto MHCII molecules. The 3T3-I-Aq fibroblast cell line was initially used 
to assay vCII-LAMP- and vCII-DM-driven CII259-273-presentaion. Treatment of these 
cells  with  either  vCII-LAMP  or  vCII-DM  was  found  to  induce  CII259-273-
presentation.  This  approach  was  then  extended  to  primary  mouse  BM-DCs. 
Intracellular location  of CII-LAMP and  CII-DM and  their  capacity for  inducing 
CII259-273-presentation in mBM-DCs was investigated and compared.
4.1.1  CII259-273 epitope-presentation to CD4+ T cell hybridomas
  The CII-LAMP and CII-DM fusion constructs were designed such that their 
expression in APCs should drive presentation of the CII259-273 epitope on  MHCII 
molecules in the following  way: An endosomal targeting domain was expected to 
traffick  to  the  late  endosomes where  cathepsin  S  cleavage  sites adjacent to  the 
CII259-273 14-mer were  expected  to release  the  peptide  epitope, making  it readily 
available  to  be  loaded  onto  the  MHCII  molecule  by  virtue  of  the  cellular 
components such as HLA-DM. HLA-DMαβ heterodimers have been found localised 133
to  pre-lysosomal  and  lysosomal  compartments  due  to  a  YTPL  motif  on  the 
cytoplasmic  tail  on  the  HLA-DMβ  polypeptide  (Marks  et  al.  1995).  Simillarly, 
LAMP-1-chimeras  are  known  to  localise  to  MHCII-containing  compartments 
(Arruda et al. 2006). The LAMP-1 and H2-DM chimeras investigated by the present 
study were designed to improve upon Ii-based chimeras previously investigated by 
Kenth  Gustafsson  and  colleagues (Gjertsson  et al. 2009).  To  detect and  make  a 
comparison between the potency of each lvv in driving  MHCII-presentation, I-Aq-
positive APCs were transduced with vCII-LAMP, vCII-DM or controls and were co-
cultured with CD4+ T cell hybridomas that respond to MHCII-I-Aq-bound CII259-273 
epitope  in  various  glycosylation  states.  As  discussed  previously  (see  1.2.6 
Posttranslational  modifications  of  CII  by  enzymes  such  as  LH3  alter  the 
immunogenicity of the immunodominant epitope), the lysine residue at position 264 
can be hydroxylated and further glycosylated and this happens extensively in native 
collagen. Different CD4+ T cell hybridomas have been previously shown to respond 










HDBR1 + +++ ++ - -
HCQ3 ++++ - - +++++ -
HCQ4 +++ ++++ +++ + -
HCQ10 +++++ - - +++++ +
Table 4.1 Summary of CD4+ T  cell hybridomas reactive to CII(Corthay et 
al. 1998). HCQ4 is strongly reactive against naked lysine 264 and  hydroxy-
lysine  whilst HDBR1 is  listed  as being  reactive only against hydroxy-lysine 
although our studies have found it to also react against the naked epitope. HCQ3 
and  HCQ10  are  both  strongly  reactive  to  the  galactosylated  form  of  the 
CII256-270 peptide.134
4.1.2  3T3-I-Aq fibroblasts as a useful antigen-presenting cell line
  Mouse  embryonic  NIH/  (3T3-I-Aq)  were  previously generated  by Dr  K 
Laurie in the laboratory and have been used as antigen presenting cells in previous 
studies of lvv-mediated CII259-273 presentation that used the invariant chain with the 
CII259-273 epitope  exchanged for the CLIP domain (CII-Ii) (Gjertsson et al. 2009). 
The advantage of using these cells is that as well as stably expressing the MHCII-I-
Aq molecule they are robust, fast-growing and easily transduced. 
4.2.1  3T3-I-Aq cells transduced with vCII-LAMP and vCII-DM present CII259-273 
  to CD4+ T cell hybridomas
  Initial experiments assessing the ability of the CII-LAMP and CII-DM fusion 
constructs to  drive  CII259-273  epitope  presentation  were  performed  by transducing 
3T3-I-Aq cells with vCII-LAMP or vCII-DM at an MOI of 25 three days before co-
culture with CD4+ T cell hybridomas. 3T3-I-Aq cells were also transduced with a 
CII-Ii-expressing lenti-vector (figure 4.1) to serve as a positive control and with an 
eGFP- expressing lentiviral vector that served as a vector (transduction) control.
  Hybridomas HDBR1, HCQ3, HCQ4 and HCQ10 were thawed and incubated 
in DMEM/10% FBS medium for 4 or 5 days until the cells began proliferating at 
which time they are suitable for 2 days co-culture with APCs. Due to varying culture 
times for different hybridomas before  proliferation, the first round of 3T3-I-Aq – 
hybridoma co-culture experiments only yielded a signal from 3-out-of-4 hybridoma 
lines (figure 4.1). The hybridoma cell line that proliferates most rapidly, HCQ3, had 
past the proliferation phase of growth and these cells were largely apoptotic by day 5 
when the other hybridomas were ready for co-culture. Hence, no IL-2 was detected 
in the medium from HCQ3-containing wells (data not shown).
  This initial result indicated that CII-LAMP or CII-DM expression in 3T3-I-
Aq cells results in CII259-273-presentation at levels that strongly stimulate responses 
from hybridomas HDBR1 and HCQ4.135
                  
  Figure 4.1 Stimulation of CII259-273-responsive hybridomas by vCII-LAMP- 
and vCII-DM-transduced 3T3-I-Aq cells indicates CII259-273-presentation. 
IL-2  production  measured  by  Sandwich  ELISA  and  presented  as  sample 
concentration, in pg/mL in the 100-µL well, is taken as a marker of hybridoma 
response.  HDBR1  responds  most strongly to the  CII-Ii-expressing  3T3-I-Aq 
cells  but responds  to 3T3-I-Aq  cells  treated  with rat CII or  the glycosylated 
CII259-273  peptide more strongly than to 3T3-I-Aq  cells treated  with the naked 
CII259-273  peptide,  demonstrating  a  lack  of  specificity  for  one  particular 
glycotype (both naked and glycosylated peptides kindly donated  by Professor 
Holmdahl) . HCQ4 is strongly selective for the naked  peptide and  HCQ10 is 
selective for glycosylated  isoforms. Hybridomas  incubated  with peptide aline 
(no 3T3-I-Aq) elicited no response (data not shown).136
  The  experiment presented in  figure  4.1  was repeated  with  the  full  set of 
hybridomas and with each well  in triplicate, allowing  hybridoma  responses to  be 
presented as given concentrations of IL-2 ± SEM. These data confirmed the initial 
findings  that  fusion  protein  expression  in  3T3-I-Aq  cells  can  drive  CII259-273-
presentation to CD4+ hybridomas (figure 4.2).
                  
Figure 4.2 Similar response profile of CD4+ T  cell hybridomas in second 
co-culture assay. HCQ3 and HCQ4 display a strong preference for 3T3-I-Aq 
cells  treated  with the glycolylated  peptide or the  naked  peptide respectively. 
However, in contrast to the data presented in figure 4.1, CII-LAMP-expressing 
3T3-I-Aq cells stimulate hybridoma HCQ4 more than CII-DM-expressing 3T3-
I-Aq cells.
  There are  points of similarity and  points of difference between these data 
presented  in  figures  4.1  and  4.2.  Both  HDBR1  and  HCQ4  respond  strongly  to 137
stimulation  with  3T3-I-Aq  cells  treated  with  the  naked  peptide  whilst  HCQ10 
responds  to  3T3-I-Aq  cells  treated  with  the  glycosylated  peptide.  The  overall 
magnitude  of  responses,  measured  by assaying  the  concentration  of  IL-2  in  the 
culture media, did vary between experiments and an example of this is found in the 
readings obtained from hybridoma HCQ10, both in the data presented here and in 
other  repeats  of  this  experiment  (data  not  shown).  Whilst  HCQ10  did  always 
respond to the glycosylated peptide by producing  IL-2 at levels far higher than in 
response to any other stimuli tested, the  amount of IL-2 produced in response  to 
3T3-I-Aq cells treated with the glycosylated peptide varies wildly from experiment 
to experiment. This is because the overall responsiveness of HCQ10 was found to be 
temperamental in its overall ability to produce IL-2.
  The  temperamental  nature  of  hybridoma  responses  is  not  confined  to 
HCQ10. High levels of IL-2 are produced by these hybridomas only whilst they are 
expanding  but  although  this  is  true  of  each  line,  HCQ10  were  found  to  be 
particularly sensitive.
  A second factor believed to give rise to variation between data from different 
experiments is the degree of confluence of 3T3-I-Aq cells, particularly in relation to 
their ability to process and present rat CII. Although care was taken to always seed 
the tissue culture plates with equal density of 3T3-I-Aq cells for each experiment, it 
was frequently noted  that they failed  to  effectively process and  present  rat CII. 
Although  frustrating,  it  is  not  altogether  surprising  as  3T3-I-Aq  cells  are  an 
embryonic mouse fibroblast cell line, made to stably express MHC-I-Aq molecule 
and are not professional APCs. Nonetheless, these initial antigen presentation studies 
show that CII-LAMP is able  to  drive  antigen  presentation  of the  unglycosylated 
CII259-273 peptide, inducing a response from HCQ4 hybridomas in the form of IL-2 
production  giving  an  excellent early indication  that  intracellular  trafficking  and 
proteolytic cleavage of the fusion protein occurs and that this is sufficient to result in 
CII259-273 presentation. 138
  Following  investigation  of  the  CII259-273-presenting  properties  of  vCII-
LAMP- and vCII-DM-transduced 3T3-I-Aq cells, mouse BM-DCs were transduced 
and observed. Initial studies investigated the intracellular localisation of each fusion 
protein.
4.2.2  Colocalisation  studies  of  fusion  proteins  with  intracellular  markers  in 
  mBM-  DCs
  Primary mouse  dendritic  cells were  generated  from  total  suspended  bone 
marrow  cell  cultures  with  20ng/ml  rmGM-CSF  as  described  in  Materials  and 
methods. After transduction with  either vCII-LAMP or  vCII-DM on  day 4,  cells 
were mounted on polylysine  slides and fixed and permeablised on day 7.   Initial 
studies  aimed  to  compare  the  degree  of  colocalisation  of  fusion  proteins  with 
endogenous  MHCII  to  see  if  either  LAMP-1  or  H2-DM-derived  intracellular 
trafficking domain display better targeting to MHCII-containing compartments. 139
     
  A)             B)
     
  C)            D)
Figure  4.3  Confocal  images  of  transduced  primary  mouse  BM-DCs 
costained for MHCII. Cells were  transduced  with vCII-DM (a, b) or vCII-
LAMP (c, d) and stained with DAPI nuclear stain (blue, first quadrant), and PE-
conjugated anti-MHCII-I-Aq (red, third quadrant). 
  The  data obtained by directly staining  the cells with PE-labled anti-mouse 
MHCII-I-Aq shows faint but punctuate regions of MHCII-I-Aq density. Neither CII-
LAMP nor  CII-DM appeared  to  strongly co-localise  with  MHCII. Whilst strong 
colocalisation with MHCII might suggest that fusion protein-derived antigen loading 140
would be possible, the absence of strict colocalisation does not preclude this. It is 
known that a large proportion of MHCII in immature DCs recycles from the plasma 
membrane  (Santambrogio  &  Strominger  2006)  and  it  is  conceivable  that  this 
accounts  for  the  MHCII  that  does  not  colocalise  with  the  eGFP-tagged  fusion 
proteins. It was therefore decided to investigate the degree of colocalisation between 
fusion proteins and other components of the endocytic pathway
  Fluorochrome-conjugated secondary antibodies were used in colocalisation 
studies of  fluorescent-green  fusion proteins with both Early endosomal antigen 1 
(EEA-1)  and  LAMP-1  to  enhance  the  signal  of  both  the  fusion  protein and  the 
intracellular  marker.  Biotinylated  Goat anti-eGFP primary antibody followed  by 
streptavidin-FITC secondary was used to increase eGFP signal (second quadrants, 
figures 4.4  and 4.5)  and  to  ensure  that even  partially degraded  or pH-quenched 
fluorescent proteins  are  detectable  after  fixing  and  permeablisation.  EEA-1  was 
visualised  using  rabbit polyclonal  anti-EEA-1  followed  by Cy5-conjugated  goat 
anti-rabbit (third quadrant, figure 4.4) whilst LAMP-1 was visualised by using rat 
monoclonal  anti-LAMP-1 primary stain followed by Cy5-conjugated goat anti-rat 
(third quadrant, figure 4.5).
4.2.3  Comparison  of  endosome  and  lysosome  colocalisation  of  CII-LAMP  and 
  CII-DM
  EEA-1 is an early-endosomal membrane protein essential for fusion between 
early endocytic vesicles.  Co-localisation with fluorescent proteins  would  indicate 
that  a  proportion  of  the  fusion  proteins  are  being  trafficked  through  the  early 
endosomal  compartments.  CII-DM was  observed  co-localising  with  EEA-1  to  a 
large  degree whereas CII-LAMP does not appear to display strong  colocalisation 
with EEA-1 (figure 4.4 A and B). In contrast, regions of high CII-DM density were 
not always found to colocalise with endogenous LAMP-1 (figure 4.5 C), whilst CII-
LAMP was usually found to colocalise strongly with endogenous LAMP-1 (figure 
4.5 A and B).141
 
     
  A)             B)
     
  C)            D)
Figure  4.4  Confocal  images  of  primary  mouse  BM-DCs  costained  for 
endosomal marker EEA-1. Cells were transduced with vCII-LAMP (A), vCII-
DM (B), veGFP (C), or untransduced (D) and stained with DAPI nuclear stain 
(blue,  first  quadrant),  rabbit  poly-clonal  anti-EEA-1  followed  by  Cy5-
conjugated goat anti-rabbit (red, third quadrant). EGFP signal was enhanced by 
staining  with biotinylated  goat anti-eGFP followed  by streptavidin-FITC. All 
images  are single-slice cross-sectional  images.  (Illumination of untransduced 
cells with the 488 laser, used to exite eGFP or FITC, did not result in a signal 
above background fluorescence, D, third quadrant).142
    
  A)            B)
    
  C)            D)
Figure  4.5  Confocal  images  of  transduced  primary  mouse  BM-DCs 
costained for lysosomal marker LAMP-1. Cells were transduced with vCII-
LAMP (A, B), vCII-DM (C, D) and stained with DAPI nuclear stain (blue, first 
quadrant), rat monoclonal anti-LAMP-1 followed by Cy5-conjugated goat anti-
rat  (red,  third  quadrant).  EGFP  signal  was  enhanced  by  staining  with 
biotinylated goat anti-eGFP followed by streptavidinated-FITC.
  Figures 4.4 and 4.5 suggest a difference in subcellular location of CII-LAMP 
and  CII-DM fusion  proteins  in  mouse  BM-DCs namely that fusion protein  CII-143
LAMP localises to the lysosome more strongly than CII-DM. The aim of this project 
was to use lvv to induce specific tolerance to the C259-273 peptide via presentation by 
APCs. Before  taking  either vector forward  for use in a  mouse study of tolerance 
induction in CIA, the efficacy of each lvv in driving C259-273-presentation in primary 
mouse APCs was compared, again using BM-DCs.
4.2.4  Mouse BM-DCs transduced with vCII-LAMP present CII259-273 to CD4+ T 
  cell hybridomas more efficiently than BM-DCs transduced with vCII-DM 
  Experiments  that  co-cultured  mBM-DCs  with  CD4+  hybridomas  were 
performed  to  compare  levels  of  CII259-273-presentation  by  BM-DCs  treated  with 
different lvv and peptides. Due to the difficulty in sychronising the growth of several 
hybridoma cell lines, the added time constraint of using  primary cells, and the fact 
that HCQ3 and HCQ4 are able to respond selectively to the glycosylated and naked 
CII259-273 peptides respectively, these hybridomas alone were selected for co-culture.
  Bone marrow extracted from the hind legs of DBA/1 mice was induced to 
differentiate  down  the  DC lineage  by culture  in the  presence  of  rmGM-CSF  as 
described in Materials and methods. On day 3 100,000 cells were seeded into 24-
well plates and either transduced at an MOI of 20 or treated with 100 µg  rat CII. 
Addition of hybridomas HCQ3 and HCQ4 was performed on day 5 at the time of 
addition of fresh either naked or gly-peptide controls.
  The first experiment was performed with or without addition of LPS one day 
after  DC  transduction/treatment  with  rat  CII  to  determine  whether  induced 
maturation might enhance antigen presentation (fig 4.6).
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Figure 4.6 Antigen presentation by mBM-DCs to CD4+ T  cell hybridomas 
with or without LPS. Both vCII-DM and vCII-LAMP-treated mBM-DCs induce 
a  response  from  HCQ4  hybridomas,  with  vCII-LAMP  inducing  a  response 
approximately five-fold stronger than vCII-DM, significantly higher (p = 0.013). 
Expression of neither CII-LAMP nor CII-DM in mBM-DCs induced stimulation 
of HCQ3 indicating  an absence of glycosylation of the CII259-273  epitope. Error 
bars represent SEM.
  These  data, obtained  from primary mouse BM-DCs show similarities and 
differences  from  the  data  obtained  from  3T3-I-Aq  cells  in  figures  4.1  and  4.2. 
Clearly, these cells are able to efficiently take up and present rat CII more efficiently 145
than 3T3-I-Aq cells. This is not surprising given that DCs are professional APCs. It 
is  clear  from  figure  4.5  that addition  of  LPS  one  day after  transduction  or  rat 
collagen-treatment does not enhance, but reduces antigen presentation. Hence, LPS 
was  not used  in  subsequent mBM-DC  antigen  presentation  assays.  Instead,  the 
experiment  was  repeated  using  the  naked  CII259-273  peptide  and  glycosylated 
CII259-273  peptide  controls  (figure  4.7).  Figure  4.5  suggests  that  mBM-DCs 
transduced with vCII-LAMP present the CII259-273 peptide to HCQ4 more efficiently 
than vCII-DM-transduced cells. This was also seen in figure 4.6.146
Figure 4.7 Antigen presentation by mBM-DCs to CD4+ T  cell hybridomas. 
IL-2  production-response  by  HCQ3  is  highly  selective  for  the  glycosylated 
peptide whilst HCQ4 responds instead to the naked peptide. vCII-LAMP induces 
a response four-fold greater than vCII-DM but both fusion proteins result only in 
presentation of  the naked  peptide. The  difference  in HCQ4 response  to vCII-
LAMP-treated mBM-DCs compared with the response to naked peptide-treated 
mBM-DCs is not considered significant (p = 0.22)
  The results of the antigen-presentation assays clearly demonstrate that vCII-
LAMP induces CII259-273-presentation with higher efficiency than an equal infectious 147
dose of vCII-DM. Therefore vCII-LAMP was selected for use in animal experiments 
described in chapter 5 that determine the efficacy of endosome/lysosome targeted T 
cell epitopes for specific tolerance induction.
  Whilst the experiments presented above have used eGFP-expressing lvv as a 
control and previous studies, in the case of Ii-based fusion proteins for intracellular 
targeting of the CII259-273 epitope, used an Ii-expressing lvv control (Gjertsson et al. 
2009) a more  relevant control in this study would  be  a lvv that delivers a fusion 
construct identical to CII-LAMP in every way but for the peptide between the two 
cathepsin  S  cleavage  sites.  Whilst “empty vector”  constructs,  lacking  a  peptide 
between  the  cathepsin  sites,  and  “scrambled  collagen”  constructs,  containing  a 
sequence that encodes the same amino acids as the CII259-273 15-mer but in a random 
order were cloned and viral vectors prepared, it was decided that the best control 
would  deliver  a  peptide  that also  binds the  MHCII I-Aq  molecule  but which  is 
irrelevant to CIA. The MOG79-90 peptide binds I-Aq molecules and is sufficient to 
cause experimental autoimmune encephalitis (EAE) in DBA/1 mice in the absence 
of  adjuvant  (Abdul-Majid  et  al.  2000).  A  construct  incorporating  a  sequence 
encoding  the  MOG79-90  peptide  between  the  cathepsin  S  cleavage  sites  was 
generated, denoted pMOG-LAMP, and lenti-viral vectors to deliver  this construct 
were prepared, denoted vMOG-LAMP.148
(A)
          (B) 
  The aim of this study is to show that lvv-mediated MHCII-presentation of a 
peptide can drive specific tolerance to that peptide. Recognition by a CD4+ T cell of 
any MHCII-bound peptide in the absence of costimulation may direct the T cell to 
become an immunosuppressive Treg  cell  as outlined above. Treg  cells exert their 
suppressive  effects  via  multiple  contact-dependent  and  contact-independent 
mechanisms some of which are not antigen-specific (La 2009). Hence, there is the 
possibility  that  lvv-driven  MHCII/peptide-presentation  might  induce  Treg 
Figure 4.8 Schematic  cartoon 
and  micrograph  of  pMOG-
LAMP.  (A)  DNA  plasmid 
identical to pCII-LAMP except 
for  the  peptide  region  that 
encodes  MOG 79-90.  (B) 
Confocal micrograph   at 1000-
fold  magnification  shows  the 
eGFP-tagged  (green,  second 
quadrant) pMOG-LAMP fusion 
protein  colocalises  with  rat 
monoclonal  anti-LAMP-1 
followed  by  Cy5-conjugated 
goat  anti-rat  (red,  third 
quadrant)  strongly  indicating 
that  the  full-length  protein  is 
being  expressed.  Blue,  first 
quadrant:  DAPI  nuclear  stain. 
Fourth quadrant: combined. 149
development that subsequently causes a non-specific immunosuppression reducing 
the  severity of autoimmune conditions such as CIA. By using  a  control  lentiviral 
construct that delivers a peptide that is not involved in CIA but is known to bind 
MHCII-I-Aq, such a global immunosuppression due to  potential bystander effects 
can be  excluded. The vMOG-LAMP vector was selected for the control group of 
mice to control for bystander suppression.
  Unfortunately  a  MOG79-90-responsive  CD4+  T  cell  hybridoma  was  not 
available to assay MHCII-presentation of the MOG79-90 epitope. A recent report of 
the use of soluble MHCII-I-Aq bound to the MOG79-90 peptide was also unable to 
directly or indirectly demonstrate the presence of MOG79-90  bound  to the  MHCII 
molecule (Batsalova et al. 2010). After vMOG-LAMP was generated and titred, it 
was  used,  alongside  vCII-LAMP,  to  transduce  mBM-DCs  which  were  then  co-
cultured with HCQ3 and HCQ4 T cell hybridomas to ensure it was unable to cause 
stimulation of CII259-273-reactive T cells (figure 4.8).150
Figure 4.9 MOG-LAMP-expressing mBM-DCs do not stimulate CD4+ T 
cell hybridomas HCQ3 and  HCQ4.  Neither HCQ3  nor  HCQ4  hybridoma 
responded to co-culture with vMOG-LAMP-treated mBM-DCs.151
4.3.1  Summary
  The  aim of the  work presented in this chapter was primarily to assess the 
ability of the novel lvv’s vCII-LAMP and vCII-DM, described in chapter 3, to induce 
surface  presentation  of  the  CII259-273  epitope.  Also  important  was  the  need  to 
compare the two fusion proteins’ ability to drive antigen presentation. These  tests 
were initially performed in the mouse fibroblast cell line 3T3-I-Aq.
  These  first  analyses  of  lvv-driven  antigen  presentation  utilised  all  four 
available CD4+ T cell hybridomas, reportedly responsive to distinct glycosylation 
states of the CII259-273 peptide. Figures 4.1 and 4.2, however, do not completely agree 
with the reported glycotype specificities as summarised in table 4.1. In particular 
HDBR1  was  found  to  strongly react  to  the  glycosylated  peptide  that carries  a 
galactosylated-hydroxylysine  at position  264  (the  consensus  glycotype  in  native 
collagen), contrary to its reported selectivity for hydroxylysine only. Based on these 
initial data, HCQ3  and HCQ4 were  selected  as sole  responder cells for use  with 
primary mouse APCs as these hybridomas alone give a reliable indication as to the 
relative  efficiency  of  naked  CII259-273  peptide  presentation  verses  glycosylated 
CII259-273  peptide  presentation.  These  hybridoma  lines  have  been  used  alone 
elsewhere to determine the glycosylation state of CII259-273 where they were used to 
show that the administration with glycosylated CII259-273 peptide in complex  with 
solublised  MHC-I-Aq  molecules  prevented  development  of  CIA  in  mice  and 
ameliorated  chronic  relapsing  disease  whereas  the  naked  CII259-273  peptide  in 
complex with solubilised MHC-I-Aq molecules had no such effect (Dzhambazov et 
al. 2006).
  Primary mBM-DCs  transduced  with  vCII-LAMP and  vCII-DM stimulate 
CII259-273-specific T cell hybridomas to produce IL-2 providing direct evidence that 
expression of  CII-LAMP or CII-DM in mouse APCs results in processing  of the 
fusion protein and  surface presentation of the  peptide on MHCII-I-Aq molecules. 
Confocal micrographs revealed a stronger localisation of CII-LAMP to lysosome-
like compartments and IL-2 production by HCQ4 in response to vCII-LAMP-treated 152
mBM-DCs was repeatedly shown to be 4 to 5 fold higher than in response to mBM-
DCs treated with equivalent infectious load of vCII-DM. Hence, vCII-LAMP was 
selected for the in vivo studies presented in chapter 5.
  Before  vCII-LAMP  was  tested  in  mice,  the  vMOG-LAMP  control  was 
designed to deliver  the  MOG79-90  peptide,  irrelevant in  autoimmune  arthritis  but 
known to bind the MHCII-I-Aq molecule. The vMOG-LAMP lvv was prepared and 
tested  alongside  vCII-LAMP  in  an  antigen-presentation  assay  to  CII-responsive 
hybridomas. As expected, vMOG-LAMP did not elicit an IL-2 secretion response 
from either hybridoma line.
4.3.2  Discussion
  One  potential  criticism  of  the  antigen-presentation  data  presented  in  this 
chapter is that the absolute values of IL-2 produced, by particular hybridomas and, 
in some cases, to particular antigen-presentation stimuli, were not always consistent 
between  different  experiments.  It  is  argued  here  that,  due  to  the  nature  of  the 
experimental  systems used, much of this variation was unavoidable. Further, it is 
believed that, despite variability of  IL-2-production in  response  to some  antigen-
presentation stimuli, the data obtained provides a strong enough indication that vCII-
LAMP is a  lvv capable  of  inducing  highly detectable  levels  of surface  CII259-273 
peptide presentation to take this lvv forward for testing iv vivo.
  The overall, maximal level of IL-2 production of a given hybridoma line was 
subject to  variation  between  experiments.  For  maximum  IL-2  production  to  be 
achieved,  these  hybridomas  need  to  be  co-cultured  with  APCs  during  rapid 
expansion, a phase of hybridoma growth that begins 2-5 days after thawing and lasts 
for 2-4 days depending  on the hybridoma line. As noted previously, this made the 
timing of hybridoma thaw critical for obtaining data. Unfortunately, sometimes, as in 
the  case  of  HCQ10 in  figure  4.2, one  hybridoma line  was not undergoing  rapid 
expansion at the time of co-culture and this resulted in the level of IL-2 production 
from the hybridoma varying by as much as 15-fold from experiment to experiment.153
  The timing of addition of rat CII to 3T3-I-Aq cells was similarly delicate with 
good processing and presentation of rat CII by these cells unreliable. What appears 
as a strong response from hybridomas HBDR1 and HCQ10 to rat CII presented by 
3T3-I-Aq cells in figure 4.1 was not repeated in figure 4.2. As noted in section 4.2.1 
this  unreliability  of  collagen  processing  and  MHC  class  II-presentation  is  not 
surprising in cells that are not professional APCs.
  Despite these limitations, overall, the data presented in this chapter, and in 
particular  the  antigen  presentation  data  obtained  from  the  primary  mBM-DCs 
strongly indicate  that the  fusion  proteins  CII-LAMP  and  CII-DM are  processed 
giving rise to strongly detectable surface MHC-I-Aq-CII259-273 peptide presentation 
with lvv vCII-LAMP inducing the stronger responses from HCQ4 hybridomas co-
cultured with transduced mBM-DCs.154
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5  Vaccination with vCII-LAMP is protective in CIA
5.1  Introduction
  Efficient MHCII-presentation of the CII259-273 epitope by primary, immature 
mBM-DCs transduced with vCII-LAMP was shown and discussed in chapter 4. It 
was hypothesised  that,  if  this virus  could  similarly drive  MHCII-presentation  of 
CII259-273 in vivo, this might induce specific tolerance to CII. The control virus used 
was vMOG-LAMP, also discussed in the previous chapter. This chapter presents the 
results of the in vivo experiments which show that vaccinantion with vCII-LAMP 
confers protection from CIA. Biological data were sought to elucidate the underlying 
mechanism of this protection. These data are also presented here.
5.2  Significant amelioration of CIA via tail vein injection of vCII-LAMP
  The experimental protocols used to test vCII-LAMP in the CIA mouse model 
of autoimmune arthritis closely followed those employed by the Ii-based CII259-273-
delivery study (Gjertsson et al. 2009) and were performed in collaboration with this 
group. In brief, adult male mice were vaccinated with 5 x  106 infectious units of 
either vCII-LAMP or vMOG-LAMP by tail vein injection. 28 days later, denoted 
day 0, the first rat CII injection was administered intradermally in Freund’s complete 
adjuvant with a booster (CII in Freund’s incomplete adjuvant) being administered on 
day 21  ip. Arthritic  disease  was  scored  by assessing  the  degree  of  swelling  or 
erythema  in  joints  and  digits;  an  inflamed  joint being  scored 1-3  depending  on 
severity and each inflamed digit receiving a score of 0.25.
  Groups of 10 mice were kept in a cage under standard conditions, one group 
being administered each with 5 x 106 infectious units of vCII-LAMP and the second 
group with 5 x 106 infectious units of vMOG-LAMP per mouse. The experiment was 
performed twice using the same reagents at the same time points. Arthritic score was 
also measured on the same days such that the data from each experiment could be 
compiled (figure 5.1). Termination of each experiment, the first after 39 days and the 156
second  after 42 days, immediately proceeded the first day that the  value  for the 
average arthritic score of the vCII-LAMP-treated mice increased by approximately 
one arthritic score unit.
Figure 5.1  Mean  arthritic  score from experiment  1,  experiment  2  and 
combined. 18 Mice were used  in experiment 1, nine in each group while 19 
mice were used in experiment 2, ten receiving vCII-LAMP and nine receiving 
the  vMOG-LAMP  control  virus.  All  mice  were  vaccinated  with  5  x  106 157
infectious  units  of recombinant lvv 28 days prior to CII/CFA administration. 
CII/IFA was  administered  on day  21.  The  data  from  each  experiment was 
collected  on equivalent days and compiled  to give the combined plot. Mann-
Whitney U test of time-points 35 and 37 have asociated p values of 0.0487 and 
0.0440 respectively. All other differences between the groups have associated p 
values of above 0.05.
  Whilst both  experiments  appear  to  clearly show  the  protective  effect  of 
vaccination with vCII-LAMP, only when data from both experiments are combined 
do the differences, as measured by performing the 2-tailed Mann-Whitney U test, 
become significant (with p values below 0.05). The time points at which the p values 
fall below this threshold were on days 35 and 37. Thus, together, these experiments 
demonstrate that lvv that express the novel fusion protein CII-LAMP provide DBA/1 
mice with significant protection from CIA at these time points. 
  Although  severity of  disease  was  largely  reduced,  there  was  no  overall 
reduction  in  disease  incidence. In  the  first experiment, three  vCII-LAMP-treated 
mice still showed no clinical signs of inflammation by the end of the experiment 
compared to two of the  mice treated with vMOG-LAMP. The  second experiment 
ended with one vMOG-LAMP-treated mouse unaffected with all mice in the vCII-
LAMP group showing some sign of inflammation, although two of these mice only 
had a clinical score of 0.25 meaning a single digit showed some redness. 
  The scale of measurement of arthritic score is not a true continuum as the 
values are averages of scores attributed to individual mice  that can vary only by 
increments of 0.25 or more. Furthermore, scores of 0.25 per inflamed digit and 1-3 
per  inflamed  joint  are  arbitrary ranking  values,  hence  this  is  an  ordinal  scale 
meaning  the data  is non-parametric. Therefore, the  statistical  analysis of variance 
appropriate for these data is a Mann Whitney U test. 
  It is deduced that the tolerisation induced in these mice is due to the CII259-273 
peptide that forms a part of the fusion protein expressed by vCII-LAMP, the only 
element that differs in the construct expressed by the otherwise identical lvv vMOG-158
LAMP. The mechanism by which expression of CII-LAMP affects tolerisation was 
investigated through analysis of biological data collected from blood samples at day 
28 and upon termination of each experiment.
5.3  Lymphoproliferation in response to rat CII
  A direct measurement of the degree of immunity an experimental animal has 
to an antigen is made by exposing splenocytes or lymph node cells to the antigen 
and  measuring  the  proliferative response.  The spleens and  draining  lymph  nodes 
were harvested from five mice from each group upon termination of experiment 1. 
Single-cell cultures were stimulated with either 50 µg/mL rat CII or 1.25 µg/mL of 
Con  A,  the  sugar-binding  lectin  and  lymphocyte  mitogen  (Mackler  1972)  as  a 
positive control.  Con A is a  useful  positive  control as it a  powerful  lymphocyte 
mitogen at concentrations in the order of 1.25 µg/mL as used here. After 72 hours 1 
µCi [3H]-thymidine was added and 20 hours later cells were washed and measured 
for [3H]-thymidine uptake, a measure of growth-rate. Differences in the proliferative 
response, as measured in  counts per minute  (CPM),  between  cells from  the  two 
different groups  of  mice  stimulated  with  the  same  stimuli  were  not significant, 
although there were some trends; both unstimulated cells from vCII-LAMP-treated 
mice and cells from vCII-treated mice stimulated with rat CII displayed lower levels 
of  [3H]-thymidine incorporation  than  cells from  the  vMOG-LAMP-treated  group 
exposed to the same stimuli. There was no such trend between cells from each group 
of mice that were stimulated with Con A as a  positive control for [3H]-thymidine 
uptake (figure 5.2).159
Figure 5.2 Cell proliferation in response to antigen or mitogen. 2 x 106 cells 
were stimulated with rat CII, Con A or no stimulation for 72 hours and a further 
20 hours in the  presence of tritiated thymidine. Cell growth is quantified by 
measuring  the uptake of radiolabeled thymidine in counts per minute (CPM). 
No significant differences were observed  between proliferation of cells  from 
vCII-LAMP-treated mice and vMOG-LAMP-treated mice exposed to the same 
stimulus.
  Although below the accepted significance threshold, analysing  the variance 
between  the  data  sets  ‘vCII-LAMP CII’ and  ‘vMOG-LAMP CII’ obtained  from 
lymph node cells by performing a 2-tailed Student’s t test give a p value of 0.074, 
indicating  a strong  trend. A trend of stronger proliferative responses was observed 
both in splenocytes and lymph node cells exposed to rat CII from vMOG-LAMP-
treated mice than cells from vMOG-LAMP-treated mice.
5.4  Cytokine assays
  Supernatants from lymph node cells that had been incubated with rat CII, 
Con  A or  left  unstimulated  were  harvested  after  72  hours  for  measurement  of 
cytokine  levels.  Titres of  IL-10,  IL-17  and TGF-β,  cytokines  highly relevant  in 
tolerance and autoimmunity, were measured using sandwich ELISA. TGF-β was not 160
present at levels detectable by the kits (above 20 pg/mL) whilst IL-10 and IL-17 was 
only detectable in those supernatants harvested from samples stimulated with Con A 
(figure 5.3). Splenocytes were also tested for TGF-β, IL-10 and IL-17 but in each 
case, the cytokine levels were lower than that for lymph node cells; all data points 
for IL-10 and IL-17 production in response to Con A were lower than 100 pg/mL 
and all other other points indistinguishable from background (data not shown).
Figure 5.3  ELISA of  IL-10 and  IL-17  produced  by stimulated  draining 
lymph node cells. Student’s t test analysis of the differences in IL-10 or IL-17 
levels in the supernatants from draining lymph node cells from vCII-LAMP and 
vMOG-LAMP-treated  mice stimulated  with the same antigen/mitogen reveals 
no significant differences between the groups (ie. all such p values greater than 
0.05).
  Although  many  cytokines  are  involved  in  both  CIA  and  RA,  many are 
produced within the  synovia of inflamed joints   (Brennan &  McInnes 2008) and 
were  thus  beyond  the  measure  of  this  study.  Other  cytokines  produced  by  re-
stimulated lymph node  cells or splenocytes that have  been measured in  previous 
studies  include  IFN-γ,  IL-4,  IL-6  and  IL-12  (Gjertsson  et  al.  2009).  As  the 
supernatants from lymph node cell and spleen cell restimulation were only available 
for the cytokine assay by ELISA towards the very end of the present study after time 161
and funds had technically expired, it was necessary to be very selective about which 
cytokines to measure.
  The  previous study by Gjertsson et  al  found no differences in IFN-γ  and 
IL-12  levels between  the  groups.  There  was also  no  difference  in  IL-17  levels 
between the groups in the Gjertsson et al study. However, as a crucial cytokine in 
autoimmunity it was decided to measure IL-17 levels to check that no differences 
were present in this case.
  IL-4 was not found at detectable levels in the Gjertsson et al study and was 
not selected here.
  IL-6 is not constitutively expressed but is readily induced by multiple stimuli 
and is found in sera of both RA patients and CIA mice (Park & Pillinger 2007). It 
could form a part of future research into the role of cytokine signaling  in FP-lvv-
induced antigen specific tolerance but was not amongst the  three cytokines tested 
here.
5.5  ELISA measurements of mouse serum antibody titre
  Sera  from tail-vein bleeds were  harvested at day 28  of experiment 1  and 
upon termination  of  both experiments. Samples were  serially diluted in PBS  and 
incubated  on  plates  coated  with  either  rat  CII  or  a  mouse-Ab-specific  capture 
antibody.  The  amount of  sera-derived Ab  was  then  determined  by using  HRP-
conjugated  detection  antibodies  (Sandwich  ELISA)  followed  by  blue-colour 
substrate.  No  CII-binding  standards  were  available  to  allow  determination  of 
absolute  concentration  of  CII-specific  Ab  serotypes,  so  only  comparative 
measurement  between  samples  collected  from  vCII-LAMP-treated  mice  with 
vMOG-LAMP-treated  mice  was possible.  Therefore,  the  raw  OD540-450  data  are 
plotted.  Because  dilution  factor and  colour-reaction time  both strongly affect the 
final OD540-450 and because the correspondence between concentration and OD540-450 
is only considered linear  up to OD540-450 values of approximately unity, care was 
taken to terminate the reactions well before saturation occurs such that the readings 162
still fall in or around the linear range, thus maximising the resolution of differences 
between  the  groups. A comparison  of  high and  low concentrations  of  the  same 
samples is presented in figures 5.4A and 5.4B to illustrate this.
Figure 5.4 ELISA of CII-bound IgM. A and B) High and low dilutions of the 
same samples taken at the end point of experiment 2; C) Samples collected at 
day 28, experiment 1; D) Samples collected at the endpoint of experiment 1. P 
values  are  calculated  using  the  two-tailed  Student’s  t  test  assuming  equal 
variance.
  Figures 5.4A and 5.4B illustrate how a further dilution of the same samples 
(figure 5.4B) reduces the OD540-450 values resolving differences between the groups, 163
thus lowering the p value. Figure 5.4C shows that in experiment 1, mice vaccinated 
with vCII-LAMP tended to have higher levels of CII-specific IgM on day 28, but 
this difference is not observed when the experiment is terminated on day 39 (figure 
5.4D).
  Figure 5.5 compares CII-specific  IgG levels from  the sera  of  vCII-LAMP 
and  vMOG-LAMP-treated mice  on day 28  from  experiment 1 (5.5A), and  upon 
termination of both experiments (5.5B and C)
  At  the  timepoint  at  which  experiment  2  was  terminated,  day 42,  mice 
vaccinated with vCII-LAMP have significantly lower CII-specific IgG titre. Because 
the IgG2A and IgG2B serotypes rather than IgG1 are able to bind complement and 164
have  a  strong  correlation  to  arthritic  disease,  the  titres  of  these  serotypes  were 
measured separately.
  In figure 5.6, a pattern of CII-specific IgG2A levels similar to the total CII-
specific IgG presented in figure 5.5, are seen. Again, titres in vCII-LAMP-treated 
mice are slightly higher at the mid-experiment time point (day 28, figure 5.6A), but 
this  trend  is  reversed  by  day  39  of  experiment  1  (figure  5.6B)  The  titre  is 
significantly higher in samples from vMOG-LAMP-treated mice at the end-point of 
the  second experiment (figure 5.6C). This pattern is again repeated in the IgG2B 
measurements (figure 5.7) although the differences are not significant.165
  Total Ab titres of different serotypes (not CII-specific) were also measured. 
The availability of mouse Ab standards for these ELISAs meant that absolute values 
could be extrapolated. No notable difference in total antibody load between the two 
groups of mice was observed, as illustrated by the total IgG2A and IgG2B counts 
presented in figure 5.8.166
Figure  5.8  ELISA  of  total IgG2A  and  IgG2B.  Samples  collected  at  the 
endpoint  of  experiment  1,  diluted  and  plate-captured  using  IgG2A-specific 
antibody or IgG2B-specific  antibody respectively. Following  incubation with 
HRP-conjugated detection antibodies, plates were washed and  incubated  with 
the BD Biosciences colour-reagent mix. Optic density was measured at 450 nm. 
P values  are calculated  using  the two-tailed  Student’s  t test assuming  equal 
variance.
5.5.1  Outliers
  Some  of  the  plots  above  have  points  that  could  be  considered  outliers. 
Removing  such points can cause the  student’s t test-calculated significance  of the 
remaining  data  to  increase  or  reduce  depending  on  the  spread  of  each  data-set 
compared to the difference between the means.
  For example, by removing the upper point from the IgM data from day 28, 
experiment one, the p value increases, because the reduction in spread is outweighed 
by the reduction in difference-of-means between the groups (fig 5.9). CII-bound IgG 
datasets provide an example of how removal of a data point can result in an increase 
in the significance of difference between the groups (figure 5.10)167
Figure 5.9 Removal of outlier from CII-bound IgM titre, experiment 1, day 
28. Before removal of outlying point (A) the student’s t test gives a p value of 
0.0613 whilst after removal of  the outlying  point (B)  the p value  increases 
slightly to 0.0657.
Figure 5.10 Removal of outlier from CII-bound IgG2B titre, experiment 1, 
day 39. (A)  Before  removal  of the  highest value in the  vCII-MOG-treated 
group, the p value is 0.0565. (B) After removal the p value is reduced to 0.0535
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  Whilst  it  is  sometimes  tempting  to  remove  data  points  that  fall  at  the 
extremities of a dataset, this should only be done if it is believed that the outlying 
value has been  caused either by a measurement error or by chance  that one data 
point  that  lies  two  or  more  standard  deviations  from  the  mean  of  a  normally 
distributed  population  has  been  included  in  the  measured  sample.  In  the  cases 
examined above, neither  of these reasons can be  assumed. A third reason for the 
appearance of outliers in a dataset is that the sample is taken from a heavy-tailed 
population, ie one that is not normally distributed.
  Student’s t tests are used to evaluate the significance of differences between 
two  sets  of  continuously variable  data  each  with  normal  distribution.  Whilst  a 
normal distribution is assumed, it is possible that the spread of antibody titres across 
individual  mice  is  not  normally  distributed  resulting  in  the  outlying  points 
occasionally observed  above. Although  this  argument  could  hold,  the  data  does 
appear to broadly fit a normal distribution and with the exception of CII-bound IgG 
presented in figure 5.5A, a case where the lowest-value data point from the vCII-
LAMP-treated group did not even lie very far from the remaining  data, removal of 
outliers does not greatly affect the interpretation of these data.169
5.6  Vector integration number
  Vector  integration number was determined by performing  qPCR  on DNA 
extracted from the liver, spleen and bone marrow from three mice from each group 
(experiment 1). Mouse β-actin-complementary primers and WPRE-complementary 
primers were used to determine cell number and transgene copy number respectively 
and the data obtained was analysed by an Abi Prism 7000 machine using Sequence 
Detection software. Transgene copies per cell are calculated by dividing the WPRE-
primer-derived value by the β-actin-derived value and multiplying by 2, the number 
of copies of β-actin per cell. These results are presented in table 5.1.
LI1 LI2 LI3 LII1 LII2 LII3
β-actin 17848 11151 16911 10403 20415 16090
WPRE 0.55 0.62 0.60 2.20 14.4 5.06
c/c - - - 4.2x10-4 1.4x10-3 6.3x10-4
BMI1 BMI2 BM3 BMII1 BMII2 BMII3
β-actin 9807 10914 9119 5403 2767 4373
WPRE 2.69 20.11 1.94 1.60 1.02 0.91
c/c 5.5x10-4 3.7x10-3 4.3x10-4 5.9x10-4 7.4x10-4 -
SI1 SI2 SI3 SII1 SII2 SII3
β-actin 9659 6543 12854 9862 13366 7623
WPRE 3.67 7.81 131 41.3 7.59 201
c/c 7.6x10-4 2.4x10-3 0.020 8.4x10-3 1.1x10-3 0.053
Table 5.1. Quantitive PCR data on vector integration from mouse tissues. 
DNA was extracted from livers (L), bone marrow (BM) and spleens (S) of three 
mice from the vCII-LAMP group (group I) or the vMOG-LAMP group (group 
II). Values for the H2O controls ranged from 0.5 to 1.1 WPRE. Hence, values 
below  1  are  considered  background  and  not  used  to  calculate  a  value  for 
transgene copies per cell. Analysis of differences between the groups using the 
two-tailed Student’s t test shows no significant difference between the groups.170
  Only very low vector copy numbers were detected by qPCR and this did not 
show a high integration-rate in the liver as expected. These data do, however, appear 
to confirm that there was no statistical difference in vector integration rates between 
the two groups of mice.
5.7.1  Summary
  The  data  presented  in  this  chapter  show  the  immunological  effects  of 
vaccination  of  male  DBA/1  mice  with  vCII-LAMP as compared to  the  vMOG-
LAMP control  lvv. The most important result was part-tolerisation to rat CII; the 
reason that these vectors were designed and made. Mice that were administered with 
a single iv dose of vCII-LAMP 28 days prior to arthritis induction suffered clinical 
arthritis at an average severity of approximately half that suffered by mice that had 
been administered the vMOG-LAMP control virus – an effect that was statistically 
significant. Attempts to elucidate the immunological mechanisms that underlie this 
effect were also partially successful.
  Efforts to measure cytokine production by lymphocytes ex vivo were limited 
by the detection threshold of the ELISA assay and proliferation assays performed on 
these lymphocytes did not reveal any significant differences between the groups of 
mice. Measurement of antibody titre, however, did show up differences that were 
most pronounced in the CII-specific IgG isotypes. IgG, and in particular, the IgG2A 
and IgG2B are known to correlate with clinical signs of arthritis in mice (Wooley et 
al. 1985;Banda et al. 2007).
  There was an unexpected trend towards higher α-CII titres of all isotypes in 
the vCII-LAMP-treated mice in samples taken at day 28. This could be because mice 
treated with  vCII-LAMP, having  had exposure  to the immunodominant CII259-273 
epitope derived from the transgene, might have been partially primed to respond to 
immunogens that contain the CII259-273 epitope, thus producing an antibody response 
more rapidly. By the endpoint of the experiments, however, this trend was reversed 
and  α-CII  titres  in  samples  taken  from  vMOG-LAMP-treated  animals  were 
significantly higher  mirroring  their higher  arthritic  scores.  These  complementary 171
data illustrate the partial but significant antigen-specific tolerisation to rat CII that 
vaccination with the novel lvv vCII-LAMP induces.
5.7.2  Discussion
  The  in  vivo experiments performed in  this chapter closely mirrored  those 
from a previous study presented by (Gjertsson et al. 2009). As in that study, mouse 
numbers were kept to a minimum in the present study. In the previous study two 
control groups were used, one receiving  an iv dose of eGFP-expressing lvv (LNT-
GFP), the other receiving a lvv that expressed an unmodified Ii protein including the 
CLIP domain (LNT-Ii-CLIP). No ‘untreated’ group of DBA/1 mice  was injected 
with ‘mock vector’ in either study.
  Splenocytes  from  the  LNT-Ii-CLIP-treated  group  were  found  to  show 
decreased proliferation compared to splenocytes from LNT-GFP-treated mice both 
when unstimulated and in response to CII-stimulation, however mice treated with 
LNT-Ii-CLIP were found to suffer from  more severe arthritis than those from the 
LNT-GFP-treated  group.  These  data  suggest that the  LNT-Ii-CLIP vector  has  an 
immunological  effect of its own. This is  consistent with  other prior  studies that 
found overexpression of the CLIP to have non-specific immunological effects (Rohn 
et al. 2004). Clearly, this limited the usefulness of LNT-Ii-CLIP as a control. The 
LNT-GFP control, whilst representing a valid control for administration of functional 
lvv  in  general,  expresses  the  eGFP  protein  that  is  not  related  to  LNT-Ii-CII. 
Additionally, eGFP itself is known to be immunogenic in some circumstances. For 
these reasons, a more suitable control was designed for the present study, namely 
vMOG-LAMP.
  Each component of the control lvv vMOG-LAMP is identical to that of the 
vCII-LAMP vector with the exception of the 15-aa CII259-273 peptide domain that is 
replaced by the 12-aa sequence that corresponds to the MOG79-90 peptide. Therefore 
this lvv is a control for the CII259-273 peptide-loading effect of vCII-LAMP only and 
does  not in any way address the  immune  effects  of lvv transduction  in  general. 172
Unfortunately,  given  the  limited  number  of  mice  available,  the  effects  of  lvv 
transduction per se on CIA could not be determined.
  Comparison of disease score  data between  the  studies  actually shows the 
present study to be less effective at ameliorating arthritis in the ‘treatment’ group as 
compared to the control lvv-treated mice, although this could be due to bystander 
suppression  effects  of  vaccination  with  the  vMOG-LAMP  control  vector.  As 
discussed in section 4.2.4, the vMOG-LAMP control was designed to eliminate the 
possibility  of  non-antigen-specific  bystander  effects  being  the  mediator  of 
amelioration of  CIA.  This  is because  vMOG-LAMP would deliver and  load the 
MOG79-90-peptide on MHCII-I-Aq molecules in the same way that vCII-LAMP loads 
the  CII259-273  peptide  for  MHCII-I-Aq-presentation.  Subsequent  recognition,  by 
MOG79-90-responsive T cells in the absence of costimulatory signals, could result in 
tolerogenic  immune  effects  that  could  non-specifically  reduce  inflammation  as 
outlined  in section  1.1.3.  Unfortunately,  as MOG79-90/I-Aq-responsive  hybridomas 
are not available, as in other studies (Batsalova et al. 2010), the presence of these 
complexes had to be assumed and could not be shown. Nevertheless, expression of 
the  eGFP-tagged fusion  proteins was inferred by the presence  of  fluorescence  in 
transduced cells.
  Measurement of TGF-β production by splenocytes from culled mice in the 
previous study, either without stimulation or in response to restimulation with CII, 
revealed a  significantly higher  production in  cells taken  from  LNT-Ii-CII-treated 
mice compared with cells from LNT-Ii-CLIP-treated mice (Gjertsson et al. 2009). 
The  elevated  levels of  TGF-β  production  was  taken to  indicate  a  skewing  to  a 
regulatory phenotype of those splenocytes. Equivalent experiments were performed 
during  the present study, both on splenocytes and draining lymph node cells. The 
stimulations themselves were kindly performed by Inger Gjertsson in Gothenburg 
with the  supernatants being  sent to UCL, UK for cytokine measurement ELISAs. 
Unfortunately TGF-β levels were not detectable above background in these samples. 
IL-10 and IL-17 were detected above background only in those samples stimulated 173
with  Con A (the  positive  control)  and  levels  detected in samples  obtained  from 
splenocytes were substantially lower than those measured in draining lymph node 
samples. Although the samples were shipped ‘on dry ice’ it is possible that there was 
a significant degradation of the cytokines within the samples between the time when 
they were harvested in Gothenburg  and the time when the  cytokine  concentration 
was measured in London.
  Another consideration for similar studies in future might be to assay levels of 
cytokines  from  blood  samples during  the  study to  try to  detect changing  levels 
during disease progression. This could give an indication as to which cytokines are 
mediating disease or therapeutic effects.
  Many antibody subtypes were measured in the present study. The difference 
in antibody titre between the two groups was significant only at the end-point (day 
42)  of the  second  experiment in  the  cases of  CII-specific  IgG2A and  total  CII-
specific IgG. These data resemble those presented by Gjertsson et al. that show CII-
specific  IgG2A levels to be  significantly lower in  LNT-Ii-CII  mice  compared  to 
LNT-Ii-CLIP-treated mice.
  Together, the data on the biological effects of iv vaccination of DBA/1 mice 
with vCII-LAMP presented in this chapter can be interpreted as showing the vCII-
LAMP vector as having a similar efficacy to LNT-Ii-CII in reducing anti-CII IgG2A   
titre and ameliorating CIA.174
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6  Further applications
6.1.1  Introduction to the need for an LH3-expressing vector
  The  reasons  behind  re-designing  the  CII259-273-delivering  fusion  proteins, 
using LAMP- or DM-based chimeras rather than Ii-based chimeras used previously   
were twofold (Gjertsson et al. 2009).
  Ii comprises one part of the trimer that forms the MHCII complex, the other 
polypeptide chains being I-Aα and I-Aβ (see figure 1.1). Firstly, replacing Ii as the 
delivery molecule  eliminates the  risk of  problems that might be caused by non-
physiological over-expression of a constituent part of the MHCII complex.
  Secondly, endogenous CII is heavily post-transcriptionally modified through 
hydroxylation and glycosylation by enzymes such as LH3 (Wang et al. 2009;Schegg 
et al. 2009). These modifications are known to occur at the lysine-264 residue and 
this is important for the immunogenicity of  the  CII259-273  peptide  (Corthay et al. 
1998;Corthay,  Backlund, &  Holmdahl  2001). The  degree of  glycosylation  of the 
CII259-273 peptide  that was presented by APCs transduced with the Ii-chimera was 
low as measured by the strong response of those CD4+ hybridoma lines responsive 
to  the  naked peptide  (eg  HCQ4)  and the poor  response of  glycosylated-peptide-
responsive lines (Gjertsson et al. 2009). It was thought that this could be because 
access of the glycosylation machinery to the nascent peptide might be limited by the 
fact that,  as  the  CII259-273  peptide  directly replaced  the  Ii  CLIP domain,  the  Ii-
chimera would fold into the MHCII complex, embedding the CII259-273 peptide in the 
peptide-binding  groove  before  significant post-transcriptional  modifications could 
occur. One solution, developed by James Devitt, was instead to fuse the CII259-273 
peptide to the carboxyl terminus of Ii, forming a lvv-expressed construct, known as 
SICW (sffv-Ii-CII259-273-WPRE). This approach did result in greater glycosylation of 
the  presented CII259-273 peptide  but brought with it the  drawback of  concomitant 
overexpression of the CLIP domain that is known to have non-specific, undesirable 
immunological effects (Rohn et al. 2004). It was hoped that by using the construct 176
design in the present study, namely a short TM domain from LAMP-1 or HLA-DM 
fused to the CII259-273 peptide, greater access might be afforded to the glycosylation 
machinery resulting  in a  greater overall degree of glycosylation of the  construct-
derived peptides. This, however, was not borne out by the antigen presentation data 
presented in chapter 4.
  LH3 is expressed globally during mouse embryo development and in most 
tissues either intra- or extra-cellularly (Salo et al. 2006). Procollagens are modified 
by LH3 within the lumen of the ER. It has been shown that eGFP-tagged LH3 (that 
was functional by exhibiting glucosyltransferase activity) was found predominantly 
in the ER, and also in the Golgi of transfected COS-7 cells (Heikkinen et al. 2000).
  It was hypothesised that co-expressing LH3 with the fusion constructs may 
enhance glycosylation. The cDNA of LH3 was cloned into the pLNT backbone and 
the lvv denoted vLH3cor63 was prepared.
6.1.2  Expression of LH3 – titration of vLH3cor63 by qPCR
  Titres of lvv that express eGFP-tagged fusion proteins were determined by 
flow  cytometry  but  this  was  not  possible  for  vLH3cor63.  Infectious  titre  of 
vLH3cor63 was determined by treating  wells containing  100,000 293T cells with 
serial dilutions of vLH3cor63 before harvesting cell DNA on day 3 and measuring 
the number of integrated vector by qPCR using WPRE-specific probe and primers 
(figure 6.1).177
Figure 6.1 Titre of infectious units of vLH3cor63 by qPCR . Values obtained 
using  dilutions  corresponding  to  5  x  10-3  µL, 5 x 10-2  µL and  0.5  µL are 
included; those values corresponding to 5 µL and 50 µL are excluded because 
they fall outside the linear range. A titre of 4 x 109 infectious units per mL was 
calculated.
  To  control  for  differences  in  the  sensitivity between flow cytometry and 
qPCR in detecting transgenes in a target cell, qPCR of vSEW of known titre of 109 
was performed alongside the titre of vLH3cor63 shown in figure 6.1. Analysis of 
infectious titre by qPCR of the vSEW preparation generated a calculated value of 5 x 
109 infectious units per mL – five-fold greater than the value calculated by flow 
cytometry. This was repeated also using vCII-DM and a five-fold discrepancy was 
consistently found. Hence for calculating experimental volumes and MOI’s, where 
the value for infectious titre was only available from qPCR, this value was reduced 
by 5-fold to achieve equivalent MOI’s.
  Although the sequence of LH3 cDNA in the pLNT backbone was confirmed 
by  sequencing  and  infectivity  of  the  vector  was  confirmed  by  qPCR,  protein 
expression could not be verified by fluorescence so western blot analysis was used 
to detect LH3 expression by transduced cells.178
6.1.3  Expression of LH3 – detection of LH3-expression by western blot
  Plates were seeded with 100,000 293T cells that were then transduced with 
vLH3cor63  at an  MOI of  25  and  cultured for  a further 4  days, passaging  when 
necessary. Cells were then harvested, lysed in reducing sample buffer and run on a 
polyacrylamide  gel  in  reducing  conditions.  After  transfer  onto  a  polyvinylidine 
membrane,  samples  were  probed  with  antibodies  reactive  to  human  β-actin  or 
diluted anti-serum  from rabbits immunised with LH3 (Ruotsalainen et al. 2006b) 
(figure  6.2). It was necessary to  expose  the  developing  polyvinylidine  difluoride 
membrane that had been probed with LH3-reactive sera for 30 minutes due to the 
weakness of the signal.
          (A)            (B)
  
  The calculated molecular mass of LH3 is approximately 85 kDa. A band of 
expected size is visible in the lane containing lysate from 293T cells transduced with 
vLH3cor63 (figure 6.2 lane A) but not in the sample lane from untransduced cells 
(figure 6.2 lane B).
6.1.4  Co-expression  of  LH3  in  3T3-I-Aq  cells  transduced  with  vCII-LAMP 
  results in glycosylation of the CII-259-273 peptide
  The  functional  assay  performed  with  the  vLH3cor63  vector  was  to  co-
transduce  the  cell  line  with  vLH3cor63  together  with  vCII-LAMP,  vSICW  (the 
vector expressing the CII259-273 peptide fused to the C-terminus of Ii) or vCII-MOG 
LH3
Β-actin
Figure  6.2  Western  blot  of  transduced 
293T cells with vLH3cor63.
(A) Transduced with vLH3cor63;
(B)  Untransduced.  Top  panel:  membrane 
probed  with  LH3-reactive  sera;  bottom 
panel:  membrane  probed  with  β-actin Ab; 
right-hand panel: pre-stained phosphorylase 
(above) and bovine serum albumin (below).179
and compare the antigen presentation data with that from 3T3-I-Aq cells transduced 







Figure 6.3 Antigen presentation of CII259-273 by 3T3-I-Aq cells transduced 
with vLH3cor63, vCII-LAMP and vMOG-LAMP. HCQ3 responds to rat CII 
(heavily glycosylated) and  to 3T3-I-Aq cells co-transduced  with vCII-LAMP 
and  vLH3cor63 but not to cells  transduced  with vCII-LAMP alone.  HCQ4 
responds to unmodified CII259-273 peptide and in this case is stimulated by both 
vCII-LAMP- and vSICW-treated cells, singly transduced or cotransduced with 
vLH3cor63.
P values  calculated  by 2-tailed  Student’s  t test:  *** denotes  p  <  0.001;  ** 
denotes p < 0.01;  * denotes p < 0.5; not significant (n/s) denotes p > 0.05180
  The data presented in figure 6.3 shows that by using lvv to express LH3 at 
the  same  time  as  the  CII259-273-containing  CII-LAMP,  the  CII259-273  peptide  is 
glycosylated to a significant degree before being presented.
6.1.5  Summary of vLH3cor63
  In  this  chapter,  generation  of  infectious  LH3-expressing  lvv  has  been 
demonstrated. It was also shown that such lvv-mediated expression of LH3 could be 
used to enhance O-glycosylation of lysine residues, in particular the lysine-264 of 
the  CII259-273   peptide, present in both  the CII-LAMP construct and the  Ii-fusion 
SICW.181
6.2.1  Introduction to Bio-electrospray
  Bio-electrospray  (BES)  is  a  jetting  technique  for  the  direct  physical 
manipulation of living cells (Jayasinghe 2007). Developed by Dr Jayasinghe at the 
department of engineering, UCL,  BES  and the  closely related technique  of  Cell 
Electrospinning  (CE)  pass cell suspensions through an  electrically charged large-
bore needle  such that the  solution is attracted  to a target at the  ground electrode 
(figure 6.4). From the droplet at the tip of the needle, a jet evolves that subsequently 
fragments  into  droplets  the  size  and  distribution  of  which  can  be  controlled  by 
varying the applied potential difference, the flow rate and liquid properties (Ganan-
Calvo & Gordillo 2001). If the cell suspension that passes out from the needle is an 
alginate solution of sufficient concentration, the cells are unable to egress from the 
resulting cell droplets (or other structures). When this technique was first applied to 
living cells, the viability of those cells were found to be unaffected, and it has since 
been  applied  to  different  cell  types  including  neurons  (Eagles,  Qureshi,  & 
Jayasinghe 2006), stem cells (Mongkoldhumrongkul, Flanagan, & Jayasinghe 2009) 
and even whole organisms (Clarke & Jayasinghe 2008;Geach et al. 2009).
        
  A)      B)
6.2.2  Combining Bio-electro spray with gene therapy
  In collaboration with Dr Jayasinghe we have for the first time shown that 
cells can be genetically manipulated using lvv before being physically manipulated 
through  BES  or  CE  to  form  multicellular  arrangements  of  gene-modified  cells 
Figure 6.4 Electrospray of  cellular 
suspensions  in stable  conditions  in 
A)  BES;  at  higher  voltages,  a 
narrower band of medium is ejected 
from  the  needle,  and  B)  CE;  at 
lower voltages the jet is spead more 
widely.182
(figure  6.5). More specifically, 3T3-I-Aq cells were  transduced with  vCII-LAMP 
and processed using BES or CE to form multicellular structures of cells that express 
the eGFP-containing  fluorescent fusion protein CII-LAMP. The result of changing 
the flow parameters to switch from BES to CE is that instead of forming cell-bearing 
droplets of near-uniform  size, cell-bearing  threads of different thicknesses can  be 
generated. These  techniques were  each  applied  to  3T3-I-Aq  cells  that had  been 
transduced with vCII-LAMP and suspended in alginate (figure 6.5).
   
 A)                  B)
Figure 6.5 Flourescent micrographs depicting structures formed from 3T3-I-Aq 
cells treated with vCII-LAMP generated by way of A) BES and B) CE.
  The aim of this work was to show that cells were not only viable after BES 
but were also able to retain the gene therapy-derived function, in this case antigen-
presentation of the CII259-273 peptide. This was assessed through co-culture of bio-
electrosprayed cells with HCQ4 T cell hybridomas followed by measurement of the 
concentration of secreted IL-2 by sandwich ELISA. Processing the cells using BES 
resulted  in  only  a  small  reduction  in  antigen-presentation  potency  (figure  6.6) 
although this reduction was significant when compared to the culture control (p = 
0.047).183
Figure 6.6 HCQ4 response  to  vCII-LAMP-treated  3T3-I-Aq  cells  after  bio-
electrospray (BES), passage through an un-charged needle (needle control, nc), 
culture control (cc), or in response to untransduced 3T3-I-Aq cells (n/t). 2-tailed 
Student’s t test, bes vs cc, p = 0.047.
6.2.3  Summary of bio-electrospray
  In this part of the project BES was shown to physically distribute genetically-
modified cells and it was evident that these cells retain their gene-therapy-acquired 
characteristics following BES. This means that they retained the ability to express 
fluorescent fusion protein  and  present the  immunodominant CII259-273  epitope  on 
MHCII molecules. This work could  enable  studies of the  best location within  an 
animal  for tolerogenic antigen expression. Multicellular bodies of APCs could be 
implanted into experimental animals at locations such as beside the spleen, lymph 
node  or  other  organs.  There  may  be  more  tolerogenic  or  more  immunogenic 
locations.184
6.3  Discussion
  This chapter has investigated the possibility of combining the lvv developed 
and tested in the previous chapters with other gene therapy lvv (the LH3-expressing 
vLH3cor63) or with biotechnology elements in development for tissue engineering 
(BES). It was found that the lvv that induce expression of the novel fusion proteins 
described  in  this  thesis,  when  used  in  concert  with  these  other  vectors  or 
technologies, were able to induce responses from CD4+ T cell hybridomas that were 
predicted and hoped for.
  When used with BES to produce multicellular bodies of antigen-presenting 
3T3-I-Aq  cells,  the  response  from  cocultured  responder  hybridomas  was  only 
slightly lower than the response to non-BES-processed controls. This opens avenues 
for  future  work  including  the  generation  of  layered  multicellular  structures  of 
different cell  types  to  investigate  or  mimic  the  types of  immunological  cell-cell 
interactions that occur in lymph nodes and other immune tissues and organs.
  When used with the LH3-expressing lvv vLH3cor63 the hybridoma response 
changed in precisely the way that was hoped. By exogenously co-expressing the key 
enzyme in the glycosylation process, LH3, alongside the novel fusion protein CII-
LAMP, the hybridoma line HCQ3 response was raised to a level not significantly 
different to that in response to 3T3-I-Aq cells presenting rat CII. This represents the 
achievement of one of the main goals of the design of this study, namely to generate 
a  lvv-mediated system for driving  presentation of CII259-273 peptides, a significant 
proportion of which appeared to be glycosylated. Whilst the original project design 
aimed  to  achieve  this  through  simple  expression  of  the  fusion  proteins,  it was 
eventually found to be necessary to co-express LH3 with the fusion proteins in this 
study  to  attain  levels  of  CII259-273  peptide  glycosylation  detectable  with  CD4+ 
hybridomas.
  This result is, to the best of our knowledge, the first time lvv co-transduction 
with  a  glycosylating  enzyme  has  induced  detectable  substrate  glycosylation. 
However,  this  data  was  obtained  in  a  3T3-derived  cell  line  only  and  was  not 185
confirmed  in  mBM-DCs.  Generation of  a  bicistronic  lvv that expresses both the 
fusion protein CII-LAMP and LH3 could form the next stage in further investigation 
of the use of lvv-driven presentation of glycosylated CII259-273 peptides.186
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7  General discussion
7.1  Achievements
  The current project has demonstrated several novel applications of existing 
principles. Transduction of APCs with FP-lvv was shown to result in fusion protein-
derived  peptide  presentation on  MHCII  molecules confirming  lvv as  a  means  to 
achieving  peptide-antigen  presentation.  Furthermore,  it  was  shown  that  direct 
injection of such FP-lvv into the tail veins of DBA-1 mice results in protection from 
arthritis that manifests as significant amelioration of disease at time-points of over 
nine weeks after lvv injection. This represents an improvement over previous studies 
and also a success for rational design in novel therapeutics.
  The previous studies that this work has improved upon used rational designs 
to induce MHCII-presentation of the CII259-273 peptide, immunodomminant in CIA, 
either by replacing the CLIP domain of Ii with the CII259-273 peptide (Gjertsson et al. 
2009) whilst a second, similar study fused the CII259-273 peptide to the luminal, C-
terminus of Ii, in the fusion construct denoted SICW. Other groups have used other 
retroviral vectors to express Ii-based chimeras that induce tolerance to other peptide 
antigens, namely the MOG40-55 peptide (Eixarch et al. 2009). The current project has 
rationally  designed  fusion  proteins  that  deliver  a  peptide  epitope  for  MHCII 
presentation not through conjugation to Ii, a constituent part of the MHCII trimer 
that folds within the ER, but simply through conjugation with short TM/cytosolic tail 
motifs from either of two other intracellular proteins, LAMP-1 and H2-DM that are 
known to traffic down the endosomal pathway. Hence, instead of inducing CII259-273 
presentation through direct targeting to the MHCII complex this project has achieved 
it through simple intracellular trafficking.
  Expression of the fusion proteins CII-LAMP or CII-DM in primary mBM-
DCs after transduction with equal infectious titres of lvv vCII-LAMP or vCII-DM 
allowed comparison of the two trafficking domains. Most importantly, these fusion 
proteins  were  compared  for  their  capacity to  induce  surface  presentation  of  the 188
CII259-273 peptide to MHCII-restricted T cell hybridomas. CII-LAMP-expression by 
the mBM-DCs resulted in stronger stimulation of the responding hybridomas leading 
to  the  conclusion  that conjugation to  the LAMP-1 TM/cytosolic  domain is more 
efficient in inducing MHCII-loading of the CII259-273 peptide. When vCII-LAMP was 
administered to DBA/1 mice iv, 28 days prior to CIA induction, it caused significant 
amelioration of disease and a significant reduction in CII-specific IgG at the time 
when the experiment was terminated. This is the first time lvv have been used to 
induce tolerance as a result of expressing such LAMP-l/peptide antigen chimeras.
  The  fusion  proteins  CII-LAMP  and  CII-DM are  not  expected  to  form 
complexes with MHCIl molecules in the way that Ii-based fusions might and so it 
was hoped that this might afford the glycosylation machinery greater access to the 
CII259-273  peptide  domain  of  CII-LAMP  and  CII-DM  giving  rise  to  greater 
glycosylation  than  the  modest  levels  presented  by  Gjertsson  et  al  in  their 
supplementary table.  The  prospect  of  enhanced  glycosylation  of  the  lysine-264 
residue was one of the key motives for designing novel CII259-273 peptide-delivering 
FP-lvv. However, when antigen-presentation data from T cell hybridomas reactive to 
CII259-273  peptide  in  the  naked,  unmodified  form  (HCQ4)  or  glycosylated  forms 
(HCQ3)  were  compared  with  data  obtained  from  APCs  expressing  vCII-LAMP, 
vCII-DM or  the  SICW  construct  (that  fuses  the  CII259-273  peptide  onto  the  C-
terminus of Ii) presented CIl259-273 peptide on cells transduced with the two novel 
FP-lvv were shown to be glycosylated to a much lesser extent (an example of this is 
shown by the data obtained from HCQ3 response to 3T3-I-Aq cells transduced with 
vCII-LAMP or vSICW in figure 6.3). To enhance the glycosylation of the CII259-273 
peptide domain of CII-LAMP, LH3 was cloned into the lvv backbone plasmid and 
the vLH3cor63 vector was prepared.
  Capable  of  hydroxylation,  galactoslytransferase  and  glucosyltransferase 
activity (Heikkinen et al. 2000;Wang et al. 2002) LH3 is able to modify collagen of 
different types (Wang, Valtavaara, & Myllyla 2000). LH3 knock-out in mice is lethal 
due  to  abnormal  collagen  type  IV  distribution  preventing  basement  membrane 189
formation  (Ruotsalainen  et  al.  2006c).  Expressed  globally in  embryonic  mouse 
tissues, LH3 is also detected at low levels in a broad range of adult mouse organs 
both intracellularly and extracellularly although which cell types express LH3 is not 
known (Salo et al. 2006). Presumably, given  the very low levels of glycosylated 
CII259-273 presented by DCs transduced with both the lvv described in this study and 
those  by Gjertsson et  al, LH3 expression in DCs at levels too low to efficiently 
glycosylate the nascent fusion proteins. The present study found that by using the lvv 
vLH3cor63  to  co-express  LH3,  the  glycosylation  state  of  the  CII259-273  peptide 
presented  by 3T3-I-Aq  cells  co-transduced with vCII-LAMP is  greatly enhanced 
(figure 6.3). To the best of our knowledge this is the first time that gene-delivery of a 
glycosylating  enzyme  has  been  shown  to  effect  a  detectable  increase  in  the 
glycosylation state of specific amino acid residues.
  Another notable finding  was the  difference in antibody titres between sera 
from  mice  vaccinated with vCII-LAMP and vMOG-LAMP. At the earliest time-
point at which samples were collected, day 28 of experiment 1, the trend of higher 
Ab  titres  in  the  vCII-LAMP  group compared  to  the  vMOG-LAMP  group was 
unexpected, but observed in every measurement of CII-specific antibody titre. As 
described  in  section  1.2.2  Antibody  response,  antibody  titre  does  not  always 
correlate with disease - indeed, mouse strains refractory to CIA secrete high titres of 
anti-CII  antibodies  in  response  to  rat CII  emulsified in CIA. The  trend  towards 
higher concentration of anti-CII Ab isotypes in mice vaccinated with vCII-LAMP at 
day  28  could  be  attributed  to  the  earlier  sub-immunising  exposure  to  the 
immunodominant  CII259-273  peptide  from  the  vCII-LAMP  vector.  Although 
ultimately having the effect of reducing the immune response to the immunising rat 
CII,  as this effect is  presumed  to  be  due  to  a  sub-immunogenic  priming  to  the 
CII259-273 epitope, it is conceivable that this also has the effect of reducing the time 
between rat CII-exposure and production of measurable titres of CII-specific Ab.
  Important in the pathogenesis of CIA are high titres of IgG, in particular the 
complement-fixing isotype IgG2A. Hence the titres of these isotypes were separately 190
measured.  However,  it  was  found  that  only  the  total  CII-specific  IgG  was 
significantly lower in vCII-LAMP mice when compared to mice vaccinated with the 
vMOG-LAMP  construct.  Whilst  the  lack  of  significant  differences  in  IgG2A 
precludes a statement on the mechanism by which vCII-LAMP exerts its protective 
action, the significant reduction of anti-CII IgG is a piece of key biological data that 
correlates with the reduced clinical score. Although the three time-points observed 
by this study - immediately at disease onset, and at the point of termination of each 
experiment 1 and 2 - are important, perhaps the best way to examine the relationship 
between tolerance induction, Ab production and disease  progression would be  to 
perform measurements upon the Ab concentration of sera collected at time-points of 
every two or three days throughout the experiment. Such an undertaking  was not 
considered possible within the context of this project.
7.2  Limitations
  Whilst  the  discovery  that  the  novel  FP-lvv  described  in  this  thesis  do 
significantly ameliorate  clinical  scores in  CIA constitutes  the  accomplishment of 
primary goal of this project, cellular interactions that must underlie the significant 
shift in the immunological behaviour of the  group of mice  vaccinated with vCII-
LAMP were  not  within  the  scope  of  the  project  and  thus not  fully  elucidated. 
Interactions between the MHCII-CII259-273 complex on transduced APCs with T cell 
hybridomas were demonstrated in vitro as being dependent upon transduction with 
CII259-273-delivering  FP-lvv such as vCII-LAMP, vCII-DM or vSICW. Whilst it is 
assumed that similar interactions between transduced I-Aq+ APCs and CD4+ T cells 
are  behind  the  antigen-specific  tolerogenicity  of  these  vectors,  this  was  not 
demonstrated with cells from vCII-LAMP-treated mice. It was thought that the low 
numbers of transduced cells in any one  tissue  following  iv administration would 
certainly preclude the induction of any detectable response from coculturing tissue-
derived cells with T cell hybridomas ex vivo. That mBM-DCs, transduced ex  vivo, 
are  able  to  strongly  stimulate  CD4+  T  cell  hybridomas  is  viewed  as  a  good 191
indication that transduction of APCs or APC progenitors in vivo would  result in 
anergising or otherwise tolerising interactions with CII259-273-reactive CD4+ T cells 
that  reduce  the  animal  sensitivity  to  immunisation  with  rat  CII.  It  would  be 
extremely  difficult  to  detect  such  transduced  cells  from  mice  on  the  basis  of 
fluorescence - even qPCR was only able to detect counts of vector-derived WPRE 
from mouse tissues just above background.
  Assessment of the precise reactions within experimental mice was never a 
stated aim  of  this study,  however cellular responses using  spleen or  lymph  node 
cultures to assess the differences in proliferative and cytokine-production responses 
between the groups of mice were sought once  it was shown that the  vCII-LAMP 
vector  had  a  significant protective  effect.  Neither,  however,  revealed  significant 
differences between the groups of mice, although, in the case of induced production 
of  TGF-beta,  IL-10  and  IL-17  in  response  to  rat  CII,  the  cytokine  levels  were 
broadly below the threshold of detection.
  The only significant biological data taken from the mice in this study was the 
difference  in CII-specific  IgG.  Whether this can  be  interpreted as indicating  that 
CIA is Ab-mediated, however is unclear. It is known that B cell-deficient mice are 
unable  to  develop  CIA,  so  the  difference  in  IgG  titre  is  highly  relevant  in 
pathogenesis. The mechanism by which this value is reduced has not been directly 
elucidated.  The  importance  of  CD4+ T cell  help in  antibody switching  and  the 
CII259-273-presentation by transduced APCs in vitro strongly suggests that reduced 
anti-CII IgG is a downstream effect of tolerogenic antigen presentation.
  Arguably, a limitation of this study and others like it, inherent in their design, 
is the limited similarity of an animal model to the human condition that it represents.   
Of course this is also true of CIA in DBA/1 mice. Other mouse models include AIA,   
CAIA and autologous CII-induced arthritis, discussed in section 1.2 and reviewed in 
(Williams 1998). Each also has disadvantages.  Susceptibility of mouse  strains  to 
CIA is dependent on MHCII type, a similarity to the correlation of susceptibility to 192
RA with HLA-DR1 and HLA-DR4. Indeed, the  crystal  structure of HLA-DR4 in 
complex with the human CII257-273 has been solved (Hurlbert & Izard, 2002).
  Whilst the MHCII-linked susceptibility is an advantage CIA has over models 
such as CAIA, the lack of MHC diversity in inbred mice is an obvious limitation of 
using  such animals as models  for human conditions.  Greater diversity,  however, 
would limit the repeatability of experimental data and in turn limit the usefulness of 
a  model  that may be  of a  closer  likeness to  human  RA. Such  reasons limit the 
usefulness of autologous CII-induced arthritis - disease progression varies greatly 
and  many  mice  do  not show  signs  of  clinical  arthritis  at  all.  Hence,  although 
heterologous CII-induced CIA as used in this study is the most widely used model, 
as with all animal models of human disease, it is not a perfect model. This, along 
with the safety issues associated with lvv do limit the transferability of this type of 
therapeautic  strategy  into  human  patients.  Nonetheless,  this  study  does  present 
significant additional insights as to the use of exogenously expressed, endosomally 
targeted fusion proteins in the induction of antigen specific tolerance.
7.3  Future work
  One  notable  achievement  of  this  study  was  the  successful  use  of  gene 
therapy-type methods to deliver the post-translationally modifying  LH3 enzyme to 
enhance  the  glycosylation  of  the  lysine-264  residue  of  the  CII259-273  peptide 
presented by transduced 3T3-I-Aq cells. This represents a novel finding in itself but, 
furthermore,  could be  important in  developing  gene  therapy protocols  to  induce 
tolerance to CII. When presented within the context of soluble MHCII molecules the 
CII259-273 peptide was only able to protect mice from CIA in its galactosylated form 
(Dzhambazov et al. 2006).
  The  data  showing  enhanced  glycosylation  following  cotransduction  with 
vLH3cor63 along with vCII-LAMP represents preliminary data on the use of LH3-
encoding vectors. In the context of the present study, the next question to be asked 
was whether similar results would be obtained in co-transduced mBM-DCs (or other 193
primary cells). Secondly, before translating  this approach into the mouse model, a 
strategy for ensuring  APCs in vivo would be transduced in such a  way that both 
transgenes would be expressed in the same cell must be  addressed. Both of these 
problems  were  approached  although  neither  was  completed  within  the  available 
time. Initial attempts to cotransduce mBM-DCs proved technically challenging  and 
erratic  probably  owing  to  the  relatively  low  efficiency  of  the  mBM-DC  co-
transductions per individual cell.
  Cotransduction of mBM-DCs or other primary APC ex vivo is one way to 
ensure a high proportion of APCs are co-transduced and will express both LH3 and 
CII-LAMP as long  as transductions are performed at relatively high MOIs. Such 
cells could then be  infused into syngenic  mice  and assessed for their tolerogenic 
effects. Administration of each vector iv would be insufficient to be  assured of a 
useful rate of co-transduction - only a very small population of cells are likely to be 
infected by both vectors. The only way in which an iv transduction protocol, similar 
to that used previously in this study, might be used would be if a single bicistronic 
vector expressing  both LH3 and CII-LAMP could be made. (Significant time was 
spent attempting to clone LH3 into a vector backbone containing the sffv promoter 
and  an  adjacent minimal  CMV  promoter that had  had  the  cDNA encoding  CII-
LAMP  inserted  beside  it.  Unfortunately,  clones  containing  LH3  could  not  be 
obtained). Together with Inger Gjertsson's collaboration in Gothenberg, these studies 
will be continued.
  Finally, the implications that this study has for future clinical trials in humans 
will  be  considered. The  safety aspects of current lvv clearly preclude  the  use  of 
vectors such as vCII-LAMP for use in non-lethal human diseases such as RA. The 
work presented here is, nonetheless, of interest to researchers planning future studies 
of novel therapeutic protocols for the treatment of autoimmune diseases. Firstly, it 
has been demonstrated that administrating vectors iv that express rationally-designed 
endosomal-targeted peptide-antigen-containing  fusion proteins can have  beneficial 
effects by reducing the severity of subsequent responses to that antigen. There is no 194
reason to believe that this effect would be limited to either the delivery vectors used 
in this study (integrating  lvv) nor to the model peptide antigen tested here. Whilst 
expression  levels  obtained  from  using  non-integrating  lvv are  often  significantly 
lower  (Karwacz  et al.  2009)  than  from  integrating  lvv  and,  currently,  attaining 
sustained expression after multiple rounds of cell replication appears distant, these 
problems are  not necessarily insurmountable. Furthermore,  it may prove  that for 
effective,  antigen  specific  modulation  of  immune  disorders,  continuous  antigen 
presentation may not be required. A pulse of tolerogenic peptide presentation may 
effectively prime the immune system to reduce the severity of subsequent responses 
to that antigen. A study of the fusion constructs described here, expressed by non-
integrating lvv administered iv to DBA/1 mice would be an obvious starting-point.
It may be that efficient priming of the immune system of the nature described here 
does  require  the  high-level  and  sustained  expression  profiles  currently  only 
achievable with integrating vector technologies. Even if this is the case, the antigen-
presenting  strategies  presented  in  this  thesis  might still  find  application  in  the 
treatment of human disease. Life-threatening  conditions such as cancer  and  HIV 
infection would often be much more amenable to treatment if only the host immune 
system were able to recognise and effectively respond to tumour- or virus-associated 
antigens. Whilst MHCII-presentation in this study has acted to increase tolerance to 
the presented antigen, some groups have already investigated co-expression of DC-
activating proteins alongside model antigens to enhance CD8 T cell responses to the 
antigen (Rowe 2009). A similar strategy, if used alongside MHCII-directing fusions 
such as CII-LAMP might act to immunise CD4 T cells rather than tolerise them.195
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1 CTT TAA GAC CAA TGA CTT ACA AGG CAG CTG TAG ATC TTA GCC ACT TTT TAA AAG AAA AGG
61 GGG GAC TGG AAG GGC TAA TTC ACT CCC AAC GAA GAC AAG ATC TGC TTT TTG CTT GTA CTG
121 GGT CTC TCT GGT TAG ACC AGA TCT GAG CCT GGG AGC TCT CTG GCT AAC TAG GGA ACC CAC
181 TGC TTA AGC CTC AAT AAA GCT TGC CTT GAG TGC TTC AAG TAG TGT GTG CCC GTC TGT TGT
241 GTG ACT CTG GTA ACT AGA GAT CCC TCA GAC CCT TTT AGT CAG TGT GGA AAA TCT CTA GCA
301 GCA TCT AGA ATT AAT TCC GTG TAT TCT ATA GTG TCA CCT AAA TCG TAT GTG TAT GAT ACA
361 TAA GGT TAT GTA TTA ATT GTA GCC GCG TTC TAA CGA CAA TAT GTA CAA GCC TAA TTG TGT
421 AGC ATC TGG CTT ACT GAA GCA GAC CCT ATC ATC TCT CTC GTA AAC TGC CGT CAG AGT CGG
481 TTT GGT TGG ACG AAC CTT CTG AGT TTC TGG TAA CGC CGT CCC GCA CCC GGA AAT GGT CAG
541 CGA ACC AAT CAG CAG GGT CAT CGC TAG CCA GAT CCT CTA CGC CGG ACG CAT CGT GGC CGG
601 CAT CAC CGG CGC CAC AGG TGC GGT TGC TGG CGC CTA TAT CGC CGA CAT CAC CGA TGG GGA
661 AGA TCG GGC TCG CCA CTT CGG GCT CAT GAG CGC TTG TTT CGG CGT GGG TAT GGT GGC AGG
721 CCC CGT GGC CGG GGG ACT GTT GGG CGC CAT CTC CTT GCA TGC ACC ATT CCT TGC GGC GGC
781 GGT GCT CAA CGG CCT CAA CCT ACT ACT GGG CTG CTT CCT AAT GCA GGA GTC GCA TAA GGG
841 AGA GCG TCG AAT GGT GCA CTC TCA GTA CAA TCT GCT CTG ATG CCG CAT AGT TAA GCC AGC
901 CCC GAC ACC CGC CAA CAC CCG CTG ACG CGC CCT GAC GGG CTT GTC TGC TCC CGG CAT CCG
961 CTT ACA GAC AAG CTG TGA CCG TCT CCG GGA GCT GCA TGT GTC AGA GGT TTT CAC CGT CAT
1021 CAC CGA AAC GCG CGA GAC GAA AGG GCC TCG TGA TAC GCC TAT TTT TAT AGG TTA ATG TCA
1081 TGA TAA TAA TGG TTT CTT AGA CGT CAG GTG GCA CTT TTC GGG GAA ATG TGC GCG GAA CCC
1141 CTA TTT GTT TAT TTT TCT AAA TAC ATT CAA ATA TGT ATC CGC TCA TGA GAC AAT AAC CCT
1201 GAT AAA TGC TTC AAT AAT ATT GAA AAA GGA AGA GTA TGA GTA TTC AAC ATT TCC GTG TCG
1261 CCC TTA TTC CCT TTT TTG CGG CAT TTT GCC TTC CTG TTT TTG CTC ACC CAG AAA CGC TGG
1321 TGA AAG TAA AAG ATG CTG AAG ATC AGT TGG GTG CAC GAG TGG GTT ACA TCG AAC TGG ATC
1381 TCA ACA GCG GTA AGA TCC TTG AGA GTT TTC GCC CCG AAG AAC GTT TTC CAA TGA TGA GCA
1441 CTT TTA AAG TTC TGC TAT GTG GCG CGG TAT TAT CCC GTA TTG ACG CCG GGC AAG AGC AAC
1501 TCG GTC GCC GCA TAC ACT ATT CTC AGA ATG ACT TGG TTG AGT ACT CAC CAG TCA CAG AAA
1561 AGC ATC TTA CGG ATG GCA TGA CAG TAA GAG AAT TAT GCA GTG CTG CCA TAA CCA TGA GTG
1621 ATA ACA CTG CGG CCA ACT TAC TTC TGA CAA CGA TCG GAG GAC CGA AGG AGC TAA CCG CTT
1681 TTT TGC ACA ACA TGG GGG ATC ATG TAA CTC GCC TTG ATC GTT GGG AAC CGG AGC TGA ATG
1741 AAG CCA TAC CAA ACG ACG AGC GTG ACA CCA CGA TGC CTG TAG CAA TGG CAA CAA CGT TGC
1801 GCA AAC TAT TAA CTG GCG AAC TAC TTA CTC TAG CTT CCC GGC AAC AAT TAA TAG ACT GGA
1861 TGG AGG CGG ATA AAG TTG CAG GAC CAC TTC TGC GCT CGG CCC TTC CGG CTG GCT GGT TTA
1921 TTG CTG ATA AAT CTG GAG CCG GTG AGC GTG GGT CTC GCG GTA TCA TTG CAG CAC TGG GGC
1981 CAG ATG GTA AGC CCT CCC GTA TCG TAG TTA TCT ACA CGA CGG GGA GTC AGG CAA CTA TGG
2041 ATG AAC GAA ATA GAC AGA TCG CTG AGA TAG GTG CCT CAC TGA TTA AGC ATT GGT AAC TGT
2101 CAG ACC AAG TTT ACT CAT ATA TAC TTT AGA TTG ATT TAA AAC TTC ATT TTT AAT TTA AAA
2161 GGA TCT AGG TGA AGA TCC TTT TTG ATA ATC TCA TGA CCA AAA TCC CTT AAC GTG AGT TTT
2221 CGT TCC ACT GAG CGT CAG ACC CCG TAG AAA AGA TCA AAG GAT CTT CTT GAG ATC CTT TTT
2281 TTC TGC GCG TAA TCT GCT GCT TGC AAA CAA AAA AAC CAC CGC TAC CAG CGG TGG TTT GTT
2341 TGC CGG ATC AAG AGC TAC CAA CTC TTT TTC CGA AGG TAA CTG GCT TCA GCA GAG CGC AGA
2401 TAC CAA ATA CTG TCC TTC TAG TGT AGC CGT AGT TAG GCC ACC ACT TCA AGA ACT CTG TAG
2461 CAC CGC CTA CAT ACC TCG CTC TGC TAA TCC TGT TAC CAG TGG CTG CTG CCA GTG GCG ATA
2521 AGT CGT GTC TTA CCG GGT TGG ACT CAA GAC GAT AGT TAC CGG ATA AGG CGC AGC GGT CGG
2581 GCT GAA CGG GGG GTT CGT GCA CAC AGC CCA GCT TGG AGC GAA CGA CCT ACA CCG AAC TGA
2641 GAT ACC TAC AGC GTG AGC ATT GAG AAA GCG CCA CGC TTC CCG AAG GGA GAA AGG CGG ACA
2701 GGT ATC CGG TAA GCG GCA GGG TCG GAA CAG GAG AGC GCA CGA GGG AGC TTC CAG GGG GAA
2761 ACG CCT GGT ATC TTT ATA GTC CTG TCG GGT TTC GCC ACC TCT GAC TTG AGC GTC GAT TTT
2821 TGT GAT GCT CGT CAG GGG GGC GGA GCC TAT GGA AAA ACG CCA GCA ACG CGG CCT TTT TAC
2881 GGT TCC TGG CCT TTT GCT GGC CTT TTG CTC ACA TGT TCT TTC CTG CGT TAT CCC CTG ATT
2941 CTG TGG ATA ACC GTA TTA CCG CCT TTG AGT GAG CTG ATA CCG CTC GCC GCA GCC GAA CGA
3001 CCG AGC GCA GCG AGT CAG TGA GCG AGG AAG CGG AAG AGC GCC CAA TAC GCA AAC CGC CTC
3061 TCC CCG CGC GTT GGC CGA TTC ATT AAT GCA GCT GTG GAA TGT GTG TCA GTT AGG GTG TGG
3121 AAA GTC CCC AGG CTC CCC AGC AGG CAG AAG TAT GCA AAG CAT GCA TCT CAA TTA GTC AGC
3181 AAC CAG GTG TGG AAA GTC CCC AGG CTC CCC AGC AGG CAG AAG TAT GCA AAG CAT GCA TCT
3241 CAA TTA GTC AGC AAC CAT AGT CCC GCC CCT AAC TCC GCC CAT CCC GCC CCT AAC TCC GCC
3301 CAG TTC CGC CCA TTC TCC GCC CCA TGG CTG ACT AAT TTT TTT TAT TTA TGC AGA GGC CGA
3361 GGC CGC CTC GGC CTC TGA GCT ATT CCA GAA GTA GTG AGG AGG CTT TTT TGG AGG CCT AGG
3421 CTT TTG CAA AAA GCT TGG ACA CAA GAC AGG CTT GCG AGA TAT GTT TGA GAA TAC CAC TTT
3481 ATC CCG CGT CAG GGA GAG GCA GTG CGT AAA AAG ACG CGG ACT CAT GTG AAA TAC TGG TTT
3541 TTA GTG CGC CAG ATC TCT ATA ATC TCG CGC AAC CTA TTT TCC CCT CGA ACA CTT TTT AAG
3601 CCG TAG ATA AAC AGG CTG GGA CAC TTC ACA TGA GCG AAA AAT ACA TCG TCA CCT GGG ACA235
3661 TGT TGC AGA TCC ATG CAC GTA AAC TCG CAA GCC GAC TGA TGC CTT CTG AAC AAT GGA AAG
3721 GCA TTA TTG CCG TAA GCC GTG GCG GTC TGT ACC GGG TGC GTT ACT GGC GCG TGA ACT GGG
3781 TAT TCG TCA TGT CGA TAC CGT TTG TAT TTC CAG CTA CGA TCA CGA CAA CCA GCG CGA GCT
3841 TAA AGT GCT GAA ACG CGC AGA AGG CGA TGG CGA AGG CTT CAT CGT TAT TGA TGA CCT GGT
3901 GGA TAC CGG TGG TAC TGC GGT TGC GAT TCG TGA AAT GTA TCC AAA AGC GCA CTT TGT CAC
3961 CAT CTT CGC AAA ACC GGC TGG TCG TCC GCT GGT TGA TGA CTA TGT TGT TGA TAT CCC GCA
4021 AGA TAC CTG GAT TGA ACA GCC GTG GGA TAT GGG CGT CGT ATT CGT CCC GCC AAT CTC CGG
4081 TCG CTA ATC TTT TCA ACG CCT GGC ACT GCC GGG CGT TGT TCT TTT TAA CTT CAG GCG GGT
4141 TAC AAT AGT TTC CAG TAA GTA TTC TGG AGG CTG CAT CCA TGA CAC AGG CAA ACC TGA GCG
4201 AAA CCC TGT TCA AAC CCC GCT TTA AAC ATC CTG AAA CCT CGA CGC TAG TCC GCC GCT TTA
4261 ATC ACG GCG CAC AAC CGC CTG TGC AGT CGG CCC TTG ATG GTA AAA CCA TCC CTC ACT GGT
4321 ATC GCA TGA TTA ACC GTC TGA TGT GGA TCT GGC GCG GCA TTG ACC CAC GCG AAA TCC TCG
4381 ACG TCC AGG CAC GTA TTG TGA TGA GCG ATG CCG AAC GTA CCG ACG ATG ATT TAT ACG ATA
4441 CGG TGA TTG GCT ACC GTG GCG GCA ACT GGA TTT ATG AGT GGG CCC CGG ATC TTT GTG AAG
4501 GAA CCT TAC TTC TGT GGT GTG ACA TAA TTG GAC AAA CTA CCT ACA GAG ATT TAA AGC TCT
4561 AAG GTA AAT ATA AAA TTT TTA AGT GTA TAA TGT GTT AAA CTA CTG ATT CTA ATT GTT TGT
4621 GTA TTT TAG ATT CCA ACC TAT GGA ACT GAT GAA TGG GAG CAG TGG TGG AAT GCC TTT AAT
4681 GAG GAA AAC CTG TTT TGC TCA GAA GAA ATG CCA TCT AGT GAT GAT GAG GCT ACT GCT GAC
4741 TCT CAA CAT TCT ACT CCT CCA AAA AAG AAG AGA AAG GTA GAA GAC CCC AAG GAC TTT CCT
4801 TCA GAA TTG CTA AGT TTT TTG AGT CAT GCT GTG TTT AGT AAT AGA ACT CTT GCT TGC TTT
4861 GCT ATT TAC ACC ACA AAG GAA AAA GCT GCA CTG CTA TAC AAG AAA ATT ATG GAA AAA TAT
4921 TCT GTA ACC TTT ATA AGT AGG CAT AAC AGT TAT AAT CAT AAC ATA CTG TTT TTT CTT ACT
4981 CCA CAC AGG CAT AGA GTG TCT GCT ATT AAT AAC TAT GCT CAA AAA TTG TGT ACC TTT AGC
5041 TTT TTA ATT TGT AAA GGG GTT AAT AAG GAA TAT TTG ATG TAT AGT GCC TTG ACT AGA GAT
5101 CAT AAT CAG CCA TAC CAC ATT TGT AGA GGT TTT ACT TGC TTT AAA AAA CCT CCC ACA CCT
5161 CCC CCT GAA CCT GAA ACA TAA AAT GAA TGC AAT TGT TGT TGT TAA CTT GTT TAT TGC AGC
5221 TTA TAA TGG TTA CAA ATA AAG CAA TAG CAT CAC AAA TTT CAC AAA TAA AGC ATT TTT TTC
5281 ACT GCA TTC TAG TTG TGG TTT GTC CAA ACT CAT CAA TGT ATC TTA TCA TGT CTG GAT CAA
5341 CTG GAT AAC TCA AGC TAA CCA AAA TCA TCC CAA ACT TCC CAC CCC ATA CCC TAT TAC CAC
5401 TGC CAA TTA CCT AGT GGT TTC ATT TAC TCT AAA CCT GTG ATT CCT CTG AAT TAT TTT CAT
5461 TTT AAA GAA ATT GTA TTT GTT AAA TAT GTA CTA CAA ACT TAG TAG TTG GAA GGG CTA ATT
5521 CAC TCC CAA AGA AGA CAA GAT ATC CTT GAT CTG TGG ATC TAC CAC ACA CAA GGC TAC TTC
5581 CCT GAT TAG CAG AAC TAC ACA CCA GGG CCA GGG GTC AGA TAT CCA CTG ACC TTT GGA TGG
5641 TGC TAC AAG CTA GTA CCA GTT GAG CCA GAT AAG GTA GAA GAG GCC AAT AAA GGA GAG AAC
5701 ACC AGC TTG TTA CAC CCT GTG AGC CTG CAT GGG ATG GAT GAC CCG GAG AGA GAA GTG TTA
5761 GAG TGG AGG TTT GAC AGC CGC CTA GCA TTT CAT CAC GTG GCC CGA GAG CTG CAT CCG GAG
5821 TAC TTC AAG AAC TGC TGA TAT CGA GCT TGC TAC AAG GGA CTT TCC GCT GGG GAC TTT CCA
5881 GGG AGG CGT GGC CTG GGC GGG ACT GGG GAG TGG CGA GCC CTC AGA TCC TGC ATA TAA GCA
5941 GCT GCT TTT TGC CTG TAC TGG GTC TCT CTG GTT AGA CCA GAT CTG AGC CTG GGA GCT CTC
6001 TGG CTA ACT AGG GAA CCC ACT GCT TAA GCC TCA ATA AAG CTT GCC TTG AGT GCT TCA AGT
6061 AGT GTG TGC CCG TCT GTT GTG TGA CTC TGG TAA CTA GAG ATC CCT CAG ACC CTT TTA GTC
6121 AGT GTG GAA AAT CTC TAG CAG TGG CGC CCG AAC AGG GAC TTG AAA GCG AAA GGG AAA CCA
6181 GAG GAG CTC TCT CGA CGC AGG ACT CGG CTT GCT GAA GCG CGC ACG GCA AGA GGC GAG GGG
6241 CGG CGA CTG GTG AGT ACG CCA AAA ATT TTG ACT AGC GGA GGC TAG AAG GAG AGA GAT GGG
6301 TGC GAG AGC GTC AGT ATT AAG CGG GGG AGA ATT AGA TCG CGA TGG GAA AAA ATT CGG TTA
6361 AGG CCA GGG GGA AAG AAA AAA TAT AAA TTA AAA CAT ATA GTA TGG GCA AGC AGG GAG CTA
6421 GAA CGA TTC GCA GTT AAT CCT GGC CTG TTA GAA ACA TCA GAA GGC TGT AGA CAA ATA CTG
6481 GGA CAG CTA CAA CCA TCC CTT CAG ACA GGA TCA GAA GAA CTT AGA TCA TTA TAT AAT ACA
6541 GTA GCA ACC CTC TAT TGT GTG CAT CAA AGG ATA GAG ATA AAA GAC ACC AAG GAA GCT TTA
6601 GAC AAG ATA GAG GAA GAG CAA AAC AAA AGT AAG ACC ACC GCA CAG CAA GCG GCC GCT GAT
6661 CTT CAG ACC TGG AGG AGG AGA TAT GAG GGA CAA TTG GAG AAG TGA ATT ATA TAA ATA TAA
6721 AGT AGT AAA AAT TGA ACC ATT AGG AGT AGC ACC CAC CAA GGC AAA GAG AAG AGT GGT GCA
6781 GAG AGA AAA AAG AGC AGT GGG AAT AGG AGC TTT GTT CCT TGG GTT CTT GGG AGC AGC AGG
6841 AAG CAC TAT GGG CGC AGC GTC AAT GAC GCT GAC GGT ACA GGC CAG ACA ATT ATT GTC TGG
6901 TAT AGT GCA GCA GCA GAA CAA TTT GCT GAG GGC TAT TGA GGC GCA ACA GCA TCT GTT GCA
6961 ACT CAC AGT CTG GGG CAT CAA GCA GCT CCA GGC AAG AAT CCT GGC TGT GGA AAG ATA CCT
7021 AAA GGA TCA ACA GCT CCT GGG GAT TTG GGG TTG CTC TGG AAA ACT CAT TTG CAC CAC TGC
7081 TGT GCC TTG GAA TGC TAG TTG GAG TAA TAA ATC TCT GGA ACA GAT TTG GAA TCA CAC GAC
7141 CTG GAT GGA GTG GGA CAG AGA AAT TAA CAA TTA CAC AAG CTT AAT ACA CTC CTT AAT TGA
7201 AGA ATC GCA AAA CCA GCA AGA AAA GAA TGA ACA AGA ATT ATT GGA ATT AGA TAA ATG GGC
7261 AAG TTT GTG GAA TTG GTT TAA CAT AAC AAA TTG GCT GTG GTA TAT AAA ATT ATT CAT AAT
7321 GAT AGT AGG AGG CTT GGT AGG TTT AAG AAT AGT TTT TGC TGT ACT TTC TAT AGT GAA TAG
7381 AGT TAG GCA GGG ATA TTC ACC ATT ATC GTT TCA GAC CCA CCT CCC AAC CCC GAG GGG ACC
7441 CGA CAG GCC CGA AGG AAT AGA AGA AGA AGG TGG AGA GAG AGA CAG AGA CAG ATC CAT TCG236
7501 ATT AGT GAA CGG ATC TCG ACG GTC GCC AAA TGG CAG TAT TCA TCC ACA ATT TTA AAA GAA
7561 AAG GGG GGA TTG GGG GGT ACA GTG CAG GGG AAA GAA TAG TAG ACA TAA TAG CAA CAG ACA
7621 TAC AAA CTA AAG AAT TAC AAA AAC AAA TTA CAA AAA TTC AAA ATT TTC GGG TTT ATT ACA
7681 GGG ACA GCA GAG ATC CAG TTT GGA TCG ATA AGC TTG ATA TCG AAT TCC TGC AGC CCC GAT
7741 AAA ATA AAA GAT TTT ATT TAG TCT CCA GAA AAA GGG GGG AAT GAA AGA CCC CAC CTG TAG
7801 GTT TGG CAA GCT AGC TGC AGT AAC GCC ATT TTG CAA GGC ATG GAA AAA TAC CAA ACC AAG
7861 AAT AGA GAA GTT CAG ATC AAG GGC GGG TAC ATG AAA ATA GCT AAC GTT GGG CCA AAC AGG
7921 ATA TCT GCG GTG AGC AGT TTC GGC CCC GGC CCG GGG CCA AGA ACA GAT GGT CAC CGC AGT
7981 TTC GGC CCC GGC CCG AGG CCA AGA ACA GAT GGT CCC CAG ATA TGG CCC AAC CCT CAG CAG
8041 TTT CTT AAG ACC CAT CAG ATG TTT CCA GGC TCC CCC AAG GAC CTG AAA TGA CCC TGC GCC
8101 TTA TTT GAA TTA ACC AAT CAG CCT GCT TCT CGC TTC TGT TCG CGC GCT TCT GCT TCC CGA
8161 GCT CTA TAA AAG AGC TCA CAA CCC CTC ACT CGG CGC GCC AGT CCT CCG ACA GAC TGA GTC
8221 GCC CGG GGG GGA TCC GTC CTC CGG CCT CGG CTG CGT CGC GCC ATG GCG GCC CCC GGC GCC
          M   A   A   P   G   A
8281 CGG CGG CCG CTG CTC CTG CTG CTG CTG GCA GGC CTT GCA CAT GGC GCC TCA GCA CTC TTT
      R   R   P   L   L   L   L   L   L   A   G   L   A   H   G   A   S   A   L   F
8341 GAG AAT TCG ATG GTC AGC AAG GGC GAG GAG CTG TTC ACC GGG GTG GTG CCC ATC CTG GTC
      E   N   S   M   V   S   K   G   E   E   L   F   T   G   V   V   P   I   L   V
8401 GAG CTG GAC GGC GAC GTA AAC GGC CAC AAG TTC AGC GTG TCC GGC GAG GGC GAG GGC GAT
      E   L   D   G   D   V   N   G   H   K   F   S   V   S   G   E   G   E   G   D
8461 GCC ACC TAC GGC AAG CTG ACC CTG AAG TTC ATC TGC ACC ACC GGC AAG CTG CCC GTG CCC
      A   T   Y   G   K   L   T   L   K   F   I   C   T   T   G   K   L   P   V   P
8521 TGG CCC ACC CTC GTG ACC ACC CTG ACC TAC GGC GTG CAG TGC TTC AGC CGC TAC CCC GAC
      W   P   T   L   V   T   T   L   T   Y   G   V   Q   C   F   S   R   Y   P   D
8581 CAC ATG AAG CAG CAC GAC TTC TTC AAG TCC GCC ATG CCC GAA GGC TAC GTC CAG GAG CGC
      H   M   K   Q   H   D   F   F   K   S   A   M   P   E   G   Y   V   Q   E   R
8641 ACC ATC TTC TTC AAG GAC GAC GGC AAC TAC AAG ACC CGC GCC GAG GTG AAG TTC GAG GGC
      T   I   F   F   K   D   D   G   N   Y   K   T   R   A   E   V   K   F   E   G
8701 GAC ACC CTG GTG AAC CGC ATC GAG CTG AAG GGC ATC GAC TTC AAG GAG GAC GGC AAC ATC
      D   T   L   V   N   R   I   E   L   K   G   I   D   F   K   E   D   G   N   I
8761 CTG GGG CAC AAG CTG GAG TAC AAC TAC AAC AGC CAC AAC GTC TAT ATC ATG GCC GAC AAG
      L   G   H   K   L   E   Y   N   Y   N   S   H   N   V   Y   I   M   A   D   K
8821 CAG AAG AAC GGC ATC AAG GTG AAC TTC AAG ATC CGC CAC AAC ATC GAG GAC GGC AGC GTG
      Q   K   N   G   I   K   V   N   F   K   I   R   H   N   I   E   D   G   S   V
8881 CAG CTC GCC GAC CAC TAC CAG CAG AAC ACC CCC ATC GGC GAC GGC CCC GTG CTG CTG CCC
      Q   L   A   D   H   Y   Q   Q   N   T   P   I   G   D   G   P   V   L   L   P
8941 GAC AAC CAC TAC CTG AGC ACC CAG TCC GCC CTG AGC AAA GAC CCC AAC GAG AAG CGC GAT
      D   N   H   Y   L   S   T   Q   S   A   L   S   K   D   P   N   E   K   R   D
9001 CAC ATG GTC CTG CTG GAG TTC GTG ACC GCC GCC GGG ATC ACT CTC GGC ATG GAC GAG CTG
      H   M   V   L   L   E   F   V   T   A   A   G   I   T   L   G   M   D   E   L
9061 TAC AAG CTT CGC ATG AAG GGA TCC GGC ATC GCT GGC TTC AAA GGT GAA CAA GGC CCC AAG
      Y   K   L   R   M   K   G   S   G   I   A   G   F   K   G   E   Q   G   P   K
9121 GGA GAA CCT TCA TGG GAG AAT CTG AAG AGC GGG ACC TCT GAG CCC ATC CGC GGG GAC TGG
      G   E   P   S   W   E   N   L   K   S   G   T   S   E   P   I   R   G   D   W
9181 ACA CCT GGG CTG TCC CCC ATC CAG ACA GTG AAG GTC TCT GTG TCT GCA GCC ACC CTG GGC
      T   P   G   L   S   P   I   Q   T   V   K   V   S   V   S   A   A   T   L   G
9241 CTG GGC TTC ATC ATC TTC TGT GTT GGC TTC TTC AGA TGG CGC AAG TCT CAT TCC TCC AGC
      L   G   F   I   I   F   C   V   G   F   F   R   W   R   K   S   H   S   S   S
9301 TAC ACT CCT CTC CCC GGA TCC ACC TAC CCA GAA GGA CGG CAC TAG CTC GAG AGG CCT GGT
      Y   T   P   L   P   G   S   T   Y   P   E   G   R   H   Z
9361 ACC ACG CGT GCG GCC GCG ACT CTA GAG TCG ACC TGC AGG CAT GCA AGC TTG ATA TCA AGC
9421 TTA TCG ATG AAT GTC AAT AAA ACA AAA TGG TGG GGC AAT CAT CTA CAT TTC ATG GGA TAT
9481 GTG ATT ACT AGT TCA GGT GTA TTG CCA CAA GAC AAA CAT GTT AAG AAA ATT TCC CGT TAT
9541 TTG CAC TCT GTT CCT GTT AAT CAA CCT CTG GAT TAC AAA ATT TGT GAA AGA TTG ACT GGT
9601 ATT CTT AAC TAT GTT GCT CCT TTT ACG CTA TGT GGA TAC GCT GCT TTA ATG CCT TTG TAT
9661 CAT GCT ATT GCT TCC CGT ATG GCT TTC ATT TTC TCC TCC TTG TAT AAA TCC TGG TTG CTG
9721 TCT CTT TAT GAG GAG TTG TGG CCC GTT GTC AGG CAA CGT GGC GTG GTG TGC ACT GTG TTT
9781 GCT GAC GCA ACC CCC ACT GGT TGG GGC ATT GCC ACC ACC TGT CAG CTC CTT TCC GGG ACT
9841 TTC GCT TTC CCC CTC CCT ATT GCC ACG GCG GAA CTC ATC GCC GCC TGC CTT GCC CGC TGC
9901 TGG ACA GGG GCT CGG CTG TTG GGC ACT GAC AAT TCC GTG GTG TTG TCG GGG AAG CTG ACG
9961 TCC TTT CCA TGG CTG CTC GCC TGT GTT GCC ACC TGG ATT CTG CGC GGG ACG TCC TTC TGC
10021 TAC GTC CCT TCG GCC CTC AAT CCA GCG GAC CTT CCT TCC CGC GGC CTG CTG CCG GCT CTG
10081 CGG CCT CTT CCG CGT CTT CGC CTT CGC CCT CAG ACG AGT CGG ATC TCC CTT TGG GCC GCC
10141 TCC CCG CCT GAT CGA TAC CGT CGA CCT CGA237
DNA Sequence Translated - DNADynamo File pLssGCL12
1 CTT TAA GAC CAA TGA CTT ACA AGG CAG CTG TAG ATC TTA GCC ACT TTT TAA AAG AAA AGG
61 GGG GAC TGG AAG GGC TAA TTC ACT CCC AAC GAA GAC AAG ATC TGC TTT TTG CTT GTA CTG
121 GGT CTC TCT GGT TAG ACC AGA TCT GAG CCT GGG AGC TCT CTG GCT AAC TAG GGA ACC CAC
181 TGC TTA AGC CTC AAT AAA GCT TGC CTT GAG TGC TTC AAG TAG TGT GTG CCC GTC TGT TGT
241 GTG ACT CTG GTA ACT AGA GAT CCC TCA GAC CCT TTT AGT CAG TGT GGA AAA TCT CTA GCA
301 GCA TCT AGA ATT AAT TCC GTG TAT TCT ATA GTG TCA CCT AAA TCG TAT GTG TAT GAT ACA
361 TAA GGT TAT GTA TTA ATT GTA GCC GCG TTC TAA CGA CAA TAT GTA CAA GCC TAA TTG TGT
421 AGC ATC TGG CTT ACT GAA GCA GAC CCT ATC ATC TCT CTC GTA AAC TGC CGT CAG AGT CGG
481 TTT GGT TGG ACG AAC CTT CTG AGT TTC TGG TAA CGC CGT CCC GCA CCC GGA AAT GGT CAG
541 CGA ACC AAT CAG CAG GGT CAT CGC TAG CCA GAT CCT CTA CGC CGG ACG CAT CGT GGC CGG
601 CAT CAC CGG CGC CAC AGG TGC GGT TGC TGG CGC CTA TAT CGC CGA CAT CAC CGA TGG GGA
661 AGA TCG GGC TCG CCA CTT CGG GCT CAT GAG CGC TTG TTT CGG CGT GGG TAT GGT GGC AGG
721 CCC CGT GGC CGG GGG ACT GTT GGG CGC CAT CTC CTT GCA TGC ACC ATT CCT TGC GGC GGC
781 GGT GCT CAA CGG CCT CAA CCT ACT ACT GGG CTG CTT CCT AAT GCA GGA GTC GCA TAA GGG
841 AGA GCG TCG AAT GGT GCA CTC TCA GTA CAA TCT GCT CTG ATG CCG CAT AGT TAA GCC AGC
901 CCC GAC ACC CGC CAA CAC CCG CTG ACG CGC CCT GAC GGG CTT GTC TGC TCC CGG CAT CCG
961 CTT ACA GAC AAG CTG TGA CCG TCT CCG GGA GCT GCA TGT GTC AGA GGT TTT CAC CGT CAT
1021 CAC CGA AAC GCG CGA GAC GAA AGG GCC TCG TGA TAC GCC TAT TTT TAT AGG TTA ATG TCA
1081 TGA TAA TAA TGG TTT CTT AGA CGT CAG GTG GCA CTT TTC GGG GAA ATG TGC GCG GAA CCC
1141 CTA TTT GTT TAT TTT TCT AAA TAC ATT CAA ATA TGT ATC CGC TCA TGA GAC AAT AAC CCT
1201 GAT AAA TGC TTC AAT AAT ATT GAA AAA GGA AGA GTA TGA GTA TTC AAC ATT TCC GTG TCG
1261 CCC TTA TTC CCT TTT TTG CGG CAT TTT GCC TTC CTG TTT TTG CTC ACC CAG AAA CGC TGG
1321 TGA AAG TAA AAG ATG CTG AAG ATC AGT TGG GTG CAC GAG TGG GTT ACA TCG AAC TGG ATC
1381 TCA ACA GCG GTA AGA TCC TTG AGA GTT TTC GCC CCG AAG AAC GTT TTC CAA TGA TGA GCA
1441 CTT TTA AAG TTC TGC TAT GTG GCG CGG TAT TAT CCC GTA TTG ACG CCG GGC AAG AGC AAC
1501 TCG GTC GCC GCA TAC ACT ATT CTC AGA ATG ACT TGG TTG AGT ACT CAC CAG TCA CAG AAA
1561 AGC ATC TTA CGG ATG GCA TGA CAG TAA GAG AAT TAT GCA GTG CTG CCA TAA CCA TGA GTG
1621 ATA ACA CTG CGG CCA ACT TAC TTC TGA CAA CGA TCG GAG GAC CGA AGG AGC TAA CCG CTT
1681 TTT TGC ACA ACA TGG GGG ATC ATG TAA CTC GCC TTG ATC GTT GGG AAC CGG AGC TGA ATG
1741 AAG CCA TAC CAA ACG ACG AGC GTG ACA CCA CGA TGC CTG TAG CAA TGG CAA CAA CGT TGC
1801 GCA AAC TAT TAA CTG GCG AAC TAC TTA CTC TAG CTT CCC GGC AAC AAT TAA TAG ACT GGA
1861 TGG AGG CGG ATA AAG TTG CAG GAC CAC TTC TGC GCT CGG CCC TTC CGG CTG GCT GGT TTA
1921 TTG CTG ATA AAT CTG GAG CCG GTG AGC GTG GGT CTC GCG GTA TCA TTG CAG CAC TGG GGC
1981 CAG ATG GTA AGC CCT CCC GTA TCG TAG TTA TCT ACA CGA CGG GGA GTC AGG CAA CTA TGG
2041 ATG AAC GAA ATA GAC AGA TCG CTG AGA TAG GTG CCT CAC TGA TTA AGC ATT GGT AAC TGT
2101 CAG ACC AAG TTT ACT CAT ATA TAC TTT AGA TTG ATT TAA AAC TTC ATT TTT AAT TTA AAA
2161 GGA TCT AGG TGA AGA TCC TTT TTG ATA ATC TCA TGA CCA AAA TCC CTT AAC GTG AGT TTT
2221 CGT TCC ACT GAG CGT CAG ACC CCG TAG AAA AGA TCA AAG GAT CTT CTT GAG ATC CTT TTT
2281 TTC TGC GCG TAA TCT GCT GCT TGC AAA CAA AAA AAC CAC CGC TAC CAG CGG TGG TTT GTT
2341 TGC CGG ATC AAG AGC TAC CAA CTC TTT TTC CGA AGG TAA CTG GCT TCA GCA GAG CGC AGA
2401 TAC CAA ATA CTG TCC TTC TAG TGT AGC CGT AGT TAG GCC ACC ACT TCA AGA ACT CTG TAG
2461 CAC CGC CTA CAT ACC TCG CTC TGC TAA TCC TGT TAC CAG TGG CTG CTG CCA GTG GCG ATA
2521 AGT CGT GTC TTA CCG GGT TGG ACT CAA GAC GAT AGT TAC CGG ATA AGG CGC AGC GGT CGG
2581 GCT GAA CGG GGG GTT CGT GCA CAC AGC CCA GCT TGG AGC GAA CGA CCT ACA CCG AAC TGA
2641 GAT ACC TAC AGC GTG AGC ATT GAG AAA GCG CCA CGC TTC CCG AAG GGA GAA AGG CGG ACA
2701 GGT ATC CGG TAA GCG GCA GGG TCG GAA CAG GAG AGC GCA CGA GGG AGC TTC CAG GGG GAA
2761 ACG CCT GGT ATC TTT ATA GTC CTG TCG GGT TTC GCC ACC TCT GAC TTG AGC GTC GAT TTT
2821 TGT GAT GCT CGT CAG GGG GGC GGA GCC TAT GGA AAA ACG CCA GCA ACG CGG CCT TTT TAC
2881 GGT TCC TGG CCT TTT GCT GGC CTT TTG CTC ACA TGT TCT TTC CTG CGT TAT CCC CTG ATT
2941 CTG TGG ATA ACC GTA TTA CCG CCT TTG AGT GAG CTG ATA CCG CTC GCC GCA GCC GAA CGA
3001 CCG AGC GCA GCG AGT CAG TGA GCG AGG AAG CGG AAG AGC GCC CAA TAC GCA AAC CGC CTC
3061 TCC CCG CGC GTT GGC CGA TTC ATT AAT GCA GCT GTG GAA TGT GTG TCA GTT AGG GTG TGG
3121 AAA GTC CCC AGG CTC CCC AGC AGG CAG AAG TAT GCA AAG CAT GCA TCT CAA TTA GTC AGC
3181 AAC CAG GTG TGG AAA GTC CCC AGG CTC CCC AGC AGG CAG AAG TAT GCA AAG CAT GCA TCT
3241 CAA TTA GTC AGC AAC CAT AGT CCC GCC CCT AAC TCC GCC CAT CCC GCC CCT AAC TCC GCC
3301 CAG TTC CGC CCA TTC TCC GCC CCA TGG CTG ACT AAT TTT TTT TAT TTA TGC AGA GGC CGA
3361 GGC CGC CTC GGC CTC TGA GCT ATT CCA GAA GTA GTG AGG AGG CTT TTT TGG AGG CCT AGG
3421 CTT TTG CAA AAA GCT TGG ACA CAA GAC AGG CTT GCG AGA TAT GTT TGA GAA TAC CAC TTT
3481 ATC CCG CGT CAG GGA GAG GCA GTG CGT AAA AAG ACG CGG ACT CAT GTG AAA TAC TGG TTT
3541 TTA GTG CGC CAG ATC TCT ATA ATC TCG CGC AAC CTA TTT TCC CCT CGA ACA CTT TTT AAG
3601 CCG TAG ATA AAC AGG CTG GGA CAC TTC ACA TGA GCG AAA AAT ACA TCG TCA CCT GGG ACA
3661 TGT TGC AGA TCC ATG CAC GTA AAC TCG CAA GCC GAC TGA TGC CTT CTG AAC AAT GGA AAG
3721 GCA TTA TTG CCG TAA GCC GTG GCG GTC TGT ACC GGG TGC GTT ACT GGC GCG TGA ACT GGG238
3781 TAT TCG TCA TGT CGA TAC CGT TTG TAT TTC CAG CTA CGA TCA CGA CAA CCA GCG CGA GCT
3841 TAA AGT GCT GAA ACG CGC AGA AGG CGA TGG CGA AGG CTT CAT CGT TAT TGA TGA CCT GGT
3901 GGA TAC CGG TGG TAC TGC GGT TGC GAT TCG TGA AAT GTA TCC AAA AGC GCA CTT TGT CAC
3961 CAT CTT CGC AAA ACC GGC TGG TCG TCC GCT GGT TGA TGA CTA TGT TGT TGA TAT CCC GCA
4021 AGA TAC CTG GAT TGA ACA GCC GTG GGA TAT GGG CGT CGT ATT CGT CCC GCC AAT CTC CGG
4081 TCG CTA ATC TTT TCA ACG CCT GGC ACT GCC GGG CGT TGT TCT TTT TAA CTT CAG GCG GGT
4141 TAC AAT AGT TTC CAG TAA GTA TTC TGG AGG CTG CAT CCA TGA CAC AGG CAA ACC TGA GCG
4201 AAA CCC TGT TCA AAC CCC GCT TTA AAC ATC CTG AAA CCT CGA CGC TAG TCC GCC GCT TTA
4261 ATC ACG GCG CAC AAC CGC CTG TGC AGT CGG CCC TTG ATG GTA AAA CCA TCC CTC ACT GGT
4321 ATC GCA TGA TTA ACC GTC TGA TGT GGA TCT GGC GCG GCA TTG ACC CAC GCG AAA TCC TCG
4381 ACG TCC AGG CAC GTA TTG TGA TGA GCG ATG CCG AAC GTA CCG ACG ATG ATT TAT ACG ATA
4441 CGG TGA TTG GCT ACC GTG GCG GCA ACT GGA TTT ATG AGT GGG CCC CGG ATC TTT GTG AAG
4501 GAA CCT TAC TTC TGT GGT GTG ACA TAA TTG GAC AAA CTA CCT ACA GAG ATT TAA AGC TCT
4561 AAG GTA AAT ATA AAA TTT TTA AGT GTA TAA TGT GTT AAA CTA CTG ATT CTA ATT GTT TGT
4621 GTA TTT TAG ATT CCA ACC TAT GGA ACT GAT GAA TGG GAG CAG TGG TGG AAT GCC TTT AAT
4681 GAG GAA AAC CTG TTT TGC TCA GAA GAA ATG CCA TCT AGT GAT GAT GAG GCT ACT GCT GAC
4741 TCT CAA CAT TCT ACT CCT CCA AAA AAG AAG AGA AAG GTA GAA GAC CCC AAG GAC TTT CCT
4801 TCA GAA TTG CTA AGT TTT TTG AGT CAT GCT GTG TTT AGT AAT AGA ACT CTT GCT TGC TTT
4861 GCT ATT TAC ACC ACA AAG GAA AAA GCT GCA CTG CTA TAC AAG AAA ATT ATG GAA AAA TAT
4921 TCT GTA ACC TTT ATA AGT AGG CAT AAC AGT TAT AAT CAT AAC ATA CTG TTT TTT CTT ACT
4981 CCA CAC AGG CAT AGA GTG TCT GCT ATT AAT AAC TAT GCT CAA AAA TTG TGT ACC TTT AGC
5041 TTT TTA ATT TGT AAA GGG GTT AAT AAG GAA TAT TTG ATG TAT AGT GCC TTG ACT AGA GAT
5101 CAT AAT CAG CCA TAC CAC ATT TGT AGA GGT TTT ACT TGC TTT AAA AAA CCT CCC ACA CCT
5161 CCC CCT GAA CCT GAA ACA TAA AAT GAA TGC AAT TGT TGT TGT TAA CTT GTT TAT TGC AGC
5221 TTA TAA TGG TTA CAA ATA AAG CAA TAG CAT CAC AAA TTT CAC AAA TAA AGC ATT TTT TTC
5281 ACT GCA TTC TAG TTG TGG TTT GTC CAA ACT CAT CAA TGT ATC TTA TCA TGT CTG GAT CAA
5341 CTG GAT AAC TCA AGC TAA CCA AAA TCA TCC CAA ACT TCC CAC CCC ATA CCC TAT TAC CAC
5401 TGC CAA TTA CCT AGT GGT TTC ATT TAC TCT AAA CCT GTG ATT CCT CTG AAT TAT TTT CAT
5461 TTT AAA GAA ATT GTA TTT GTT AAA TAT GTA CTA CAA ACT TAG TAG TTG GAA GGG CTA ATT
5521 CAC TCC CAA AGA AGA CAA GAT ATC CTT GAT CTG TGG ATC TAC CAC ACA CAA GGC TAC TTC
5581 CCT GAT TAG CAG AAC TAC ACA CCA GGG CCA GGG GTC AGA TAT CCA CTG ACC TTT GGA TGG
5641 TGC TAC AAG CTA GTA CCA GTT GAG CCA GAT AAG GTA GAA GAG GCC AAT AAA GGA GAG AAC
5701 ACC AGC TTG TTA CAC CCT GTG AGC CTG CAT GGG ATG GAT GAC CCG GAG AGA GAA GTG TTA
5761 GAG TGG AGG TTT GAC AGC CGC CTA GCA TTT CAT CAC GTG GCC CGA GAG CTG CAT CCG GAG
5821 TAC TTC AAG AAC TGC TGA TAT CGA GCT TGC TAC AAG GGA CTT TCC GCT GGG GAC TTT CCA
5881 GGG AGG CGT GGC CTG GGC GGG ACT GGG GAG TGG CGA GCC CTC AGA TCC TGC ATA TAA GCA
5941 GCT GCT TTT TGC CTG TAC TGG GTC TCT CTG GTT AGA CCA GAT CTG AGC CTG GGA GCT CTC
6001 TGG CTA ACT AGG GAA CCC ACT GCT TAA GCC TCA ATA AAG CTT GCC TTG AGT GCT TCA AGT
6061 AGT GTG TGC CCG TCT GTT GTG TGA CTC TGG TAA CTA GAG ATC CCT CAG ACC CTT TTA GTC
6121 AGT GTG GAA AAT CTC TAG CAG TGG CGC CCG AAC AGG GAC TTG AAA GCG AAA GGG AAA CCA
6181 GAG GAG CTC TCT CGA CGC AGG ACT CGG CTT GCT GAA GCG CGC ACG GCA AGA GGC GAG GGG
6241 CGG CGA CTG GTG AGT ACG CCA AAA ATT TTG ACT AGC GGA GGC TAG AAG GAG AGA GAT GGG
6301 TGC GAG AGC GTC AGT ATT AAG CGG GGG AGA ATT AGA TCG CGA TGG GAA AAA ATT CGG TTA
6361 AGG CCA GGG GGA AAG AAA AAA TAT AAA TTA AAA CAT ATA GTA TGG GCA AGC AGG GAG CTA
6421 GAA CGA TTC GCA GTT AAT CCT GGC CTG TTA GAA ACA TCA GAA GGC TGT AGA CAA ATA CTG
6481 GGA CAG CTA CAA CCA TCC CTT CAG ACA GGA TCA GAA GAA CTT AGA TCA TTA TAT AAT ACA
6541 GTA GCA ACC CTC TAT TGT GTG CAT CAA AGG ATA GAG ATA AAA GAC ACC AAG GAA GCT TTA
6601 GAC AAG ATA GAG GAA GAG CAA AAC AAA AGT AAG ACC ACC GCA CAG CAA GCG GCC GCT GAT
6661 CTT CAG ACC TGG AGG AGG AGA TAT GAG GGA CAA TTG GAG AAG TGA ATT ATA TAA ATA TAA
6721 AGT AGT AAA AAT TGA ACC ATT AGG AGT AGC ACC CAC CAA GGC AAA GAG AAG AGT GGT GCA
6781 GAG AGA AAA AAG AGC AGT GGG AAT AGG AGC TTT GTT CCT TGG GTT CTT GGG AGC AGC AGG
6841 AAG CAC TAT GGG CGC AGC GTC AAT GAC GCT GAC GGT ACA GGC CAG ACA ATT ATT GTC TGG
6901 TAT AGT GCA GCA GCA GAA CAA TTT GCT GAG GGC TAT TGA GGC GCA ACA GCA TCT GTT GCA
6961 ACT CAC AGT CTG GGG CAT CAA GCA GCT CCA GGC AAG AAT CCT GGC TGT GGA AAG ATA CCT
7021 AAA GGA TCA ACA GCT CCT GGG GAT TTG GGG TTG CTC TGG AAA ACT CAT TTG CAC CAC TGC
7081 TGT GCC TTG GAA TGC TAG TTG GAG TAA TAA ATC TCT GGA ACA GAT TTG GAA TCA CAC GAC
7141 CTG GAT GGA GTG GGA CAG AGA AAT TAA CAA TTA CAC AAG CTT AAT ACA CTC CTT AAT TGA
7201 AGA ATC GCA AAA CCA GCA AGA AAA GAA TGA ACA AGA ATT ATT GGA ATT AGA TAA ATG GGC
7261 AAG TTT GTG GAA TTG GTT TAA CAT AAC AAA TTG GCT GTG GTA TAT AAA ATT ATT CAT AAT
7321 GAT AGT AGG AGG CTT GGT AGG TTT AAG AAT AGT TTT TGC TGT ACT TTC TAT AGT GAA TAG
7381 AGT TAG GCA GGG ATA TTC ACC ATT ATC GTT TCA GAC CCA CCT CCC AAC CCC GAG GGG ACC
7441 CGA CAG GCC CGA AGG AAT AGA AGA AGA AGG TGG AGA GAG AGA CAG AGA CAG ATC CAT TCG
7501 ATT AGT GAA CGG ATC TCG ACG GTC GCC AAA TGG CAG TAT TCA TCC ACA ATT TTA AAA GAA
7561 AAG GGG GGA TTG GGG GGT ACA GTG CAG GGG AAA GAA TAG TAG ACA TAA TAG CAA CAG ACA239
7621 TAC AAA CTA AAG AAT TAC AAA AAC AAA TTA CAA AAA TTC AAA ATT TTC GGG TTT ATT ACA
7681 GGG ACA GCA GAG ATC CAG TTT GGA TCG ATA AGC TTG ATA TCG AAT TCC TGC AGC CCC GAT
7741 AAA ATA AAA GAT TTT ATT TAG TCT CCA GAA AAA GGG GGG AAT GAA AGA CCC CAC CTG TAG
7801 GTT TGG CAA GCT AGC TGC AGT AAC GCC ATT TTG CAA GGC ATG GAA AAA TAC CAA ACC AAG
7861 AAT AGA GAA GTT CAG ATC AAG GGC GGG TAC ATG AAA ATA GCT AAC GTT GGG CCA AAC AGG
7921 ATA TCT GCG GTG AGC AGT TTC GGC CCC GGC CCG GGG CCA AGA ACA GAT GGT CAC CGC AGT
7981 TTC GGC CCC GGC CCG AGG CCA AGA ACA GAT GGT CCC CAG ATA TGG CCC AAC CCT CAG CAG
8041 TTT CTT AAG ACC CAT CAG ATG TTT CCA GGC TCC CCC AAG GAC CTG AAA TGA CCC TGC GCC
8101 TTA TTT GAA TTA ACC AAT CAG CCT GCT TCT CGC TTC TGT TCG CGC GCT TCT GCT TCC CGA
8161 GCT CTA TAA AAG AGC TCA CAA CCC CTC ACT CGG CGC GCC AGT CCT CCG ACA GAC TGA GTC
8221 GCC CGG GGG GGA TCC GTC CTC CGG CCT CGG CTG CGT CGC GCC ATG GCG GCC CCC GGC GCC
          M   A   A   P   G   A
8281 CGG CGG CCG CTG CTC CTG CTG CTG CTG GCA GGC CTT GCA CAT GGC GCC TCA GCA CTC TTT
      R   R   P   L   L   L   L   L   L   A   G   L   A   H   G   A   S   A   L   F
8341 GAG AAT TCG ATG GTC AGC AAG GGC GAG GAG CTG TTC ACC GGG GTG GTG CCC ATC CTG GTC
      E   N   S   M   V   S   K   G   E   E   L   F   T   G   V   V   P   I   L   V
8401 GAG CTG GAC GGC GAC GTA AAC GGC CAC AAG TTC AGC GTG TCC GGC GAG GGC GAG GGC GAT
      E   L   D   G   D   V   N   G   H   K   F   S   V   S   G   E   G   E   G   D
8461 GCC ACC TAC GGC AAG CTG ACC CTG AAG TTC ATC TGC ACC ACC GGC AAG CTG CCC GTG CCC
      A   T   Y   G   K   L   T   L   K   F   I   C   T   T   G   K   L   P   V   P
8521 TGG CCC ACC CTC GTG ACC ACC CTG ACC TAC GGC GTG CAG TGC TTC AGC CGC TAC CCC GAC
      W   P   T   L   V   T   T   L   T   Y   G   V   Q   C   F   S   R   Y   P   D
8581 CAC ATG AAG CAG CAC GAC TTC TTC AAG TCC GCC ATG CCC GAA GGC TAC GTC CAG GAG CGC
      H   M   K   Q   H   D   F   F   K   S   A   M   P   E   G   Y   V   Q   E   R
8641 ACC ATC TTC TTC AAG GAC GAC GGC AAC TAC AAG ACC CGC GCC GAG GTG AAG TTC GAG GGC
      T   I   F   F   K   D   D   G   N   Y   K   T   R   A   E   V   K   F   E   G
8701 GAC ACC CTG GTG AAC CGC ATC GAG CTG AAG GGC ATC GAC TTC AAG GAG GAC GGC AAC ATC
      D   T   L   V   N   R   I   E   L   K   G   I   D   F   K   E   D   G   N   I
8761 CTG GGG CAC AAG CTG GAG TAC AAC TAC AAC AGC CAC AAC GTC TAT ATC ATG GCC GAC AAG
      L   G   H   K   L   E   Y   N   Y   N   S   H   N   V   Y   I   M   A   D   K
8821 CAG AAG AAC GGC ATC AAG GTG AAC TTC AAG ATC CGC CAC AAC ATC GAG GAC GGC AGC GTG
      Q   K   N   G   I   K   V   N   F   K   I   R   H   N   I   E   D   G   S   V
8881 CAG CTC GCC GAC CAC TAC CAG CAG AAC ACC CCC ATC GGC GAC GGC CCC GTG CTG CTG CCC
      Q   L   A   D   H   Y   Q   Q   N   T   P   I   G   D   G   P   V   L   L   P
8941 GAC AAC CAC TAC CTG AGC ACC CAG TCC GCC CTG AGC AAA GAC CCC AAC GAG AAG CGC GAT
      D   N   H   Y   L   S   T   Q   S   A   L   S   K   D   P   N   E   K   R   D
9001 CAC ATG GTC CTG CTG GAG TTC GTG ACC GCC GCC GGG ATC ACT CTC GGC ATG GAC GAG CTG
      H   M   V   L   L   E   F   V   T   A   A   G   I   T   L   G   M   D   E   L
9061 TAC AAG CTT CGC ATG AAG GGA TCC GGC ATC GCT GGC TTC AAA GGT GAA CAA GGC CCC AAG
      Y   K   L   R   M   K   G   S   G   I   A   G   F   K   G   E   Q   G   P   K
9121 GGA GAA CCT TCA TGG GAG AAT CTG AAG GGG TCT GTG GAA GAG TGT GTT CAG GAT GGT AAC
      G   E   P   S   W   E   N   L   K   G   S   V   E   E   C   V   Q   D   G   N
9181 AAC ATG TTG ATC CCC ATT GCT GTG GGC GGT GCC CTG GCA GGG CTG GTC CTC ATC GTC CTC
      N   M   L   I   P   I   A   V   G   G   A   L   A   G   L   V   L   I   V   L
9241 ATT GCC TAC CTC ATT GGC AGG AAG AGG AGT CAC GCC GGC TAT CAG ACC ATC TAG CTC GAG
      I   A   Y   L   I   G   R   K   R   S   H   A   G   Y   Q   T   I   Z
9301 AGG CCT GGT ACC ACG CGT GCG GCC GCG ACT CTA GAG TCG ACC TGC AGG CAT GCA AGC TTG
9361 ATA TCA AGC TTA TCG ATG AAT GTC AAT AAA ACA AAA TGG TGG GGC AAT CAT CTA CAT TTC
9421 ATG GGA TAT GTG ATT ACT AGT TCA GGT GTA TTG CCA CAA GAC AAA CAT GTT AAG AAA ATT
9481 TCC CGT TAT TTG CAC TCT GTT CCT GTT AAT CAA CCT CTG GAT TAC AAA ATT TGT GAA AGA
9541 TTG ACT GGT ATT CTT AAC TAT GTT GCT CCT TTT ACG CTA TGT GGA TAC GCT GCT TTA ATG
9601 CCT TTG TAT CAT GCT ATT GCT TCC CGT ATG GCT TTC ATT TTC TCC TCC TTG TAT AAA TCC
9661 TGG TTG CTG TCT CTT TAT GAG GAG TTG TGG CCC GTT GTC AGG CAA CGT GGC GTG GTG TGC
9721 ACT GTG TTT GCT GAC GCA ACC CCC ACT GGT TGG GGC ATT GCC ACC ACC TGT CAG CTC CTT
9781 TCC GGG ACT TTC GCT TTC CCC CTC CCT ATT GCC ACG GCG GAA CTC ATC GCC GCC TGC CTT
9841 GCC CGC TGC TGG ACA GGG GCT CGG CTG TTG GGC ACT GAC AAT TCC GTG GTG TTG TCG GGG
9901 AAG CTG ACG TCC TTT CCA TGG CTG CTC GCC TGT GTT GCC ACC TGG ATT CTG CGC GGG ACG
9961 TCC TTC TGC TAC GTC CCT TCG GCC CTC AAT CCA GCG GAC CTT CCT TCC CGC GGC CTG CTG
10021 CCG GCT CTG CGG CCT CTT CCG CGT CTT CGC CTT CGC CCT CAG ACG AGT CGG ATC TCC CTT
10081 TGG GCC GCC TCC CCG CCT GAT CGA TAC CGT CGA CCT CGA240
DNA Sequence Translated - DNADynamo File pMOG-LAMP
1 CTT TAA GAC CAA TGA CTT ACA AGG CAG CTG TAG ATC TTA GCC ACT TTT TAA AAG AAA AGG
61 GGG GAC TGG AAG GGC TAA TTC ACT CCC AAC GAA GAC AAG ATC TGC TTT TTG CTT GTA CTG
121 GGT CTC TCT GGT TAG ACC AGA TCT GAG CCT GGG AGC TCT CTG GCT AAC TAG GGA ACC CAC
181 TGC TTA AGC CTC AAT AAA GCT TGC CTT GAG TGC TTC AAG TAG TGT GTG CCC GTC TGT TGT
241 GTG ACT CTG GTA ACT AGA GAT CCC TCA GAC CCT TTT AGT CAG TGT GGA AAA TCT CTA GCA
301 GCA TCT AGA ATT AAT TCC GTG TAT TCT ATA GTG TCA CCT AAA TCG TAT GTG TAT GAT ACA
361 TAA GGT TAT GTA TTA ATT GTA GCC GCG TTC TAA CGA CAA TAT GTA CAA GCC TAA TTG TGT
421 AGC ATC TGG CTT ACT GAA GCA GAC CCT ATC ATC TCT CTC GTA AAC TGC CGT CAG AGT CGG
481 TTT GGT TGG ACG AAC CTT CTG AGT TTC TGG TAA CGC CGT CCC GCA CCC GGA AAT GGT CAG
541 CGA ACC AAT CAG CAG GGT CAT CGC TAG CCA GAT CCT CTA CGC CGG ACG CAT CGT GGC CGG
601 CAT CAC CGG CGC CAC AGG TGC GGT TGC TGG CGC CTA TAT CGC CGA CAT CAC CGA TGG GGA
661 AGA TCG GGC TCG CCA CTT CGG GCT CAT GAG CGC TTG TTT CGG CGT GGG TAT GGT GGC AGG
721 CCC CGT GGC CGG GGG ACT GTT GGG CGC CAT CTC CTT GCA TGC ACC ATT CCT TGC GGC GGC
781 GGT GCT CAA CGG CCT CAA CCT ACT ACT GGG CTG CTT CCT AAT GCA GGA GTC GCA TAA GGG
841 AGA GCG TCG AAT GGT GCA CTC TCA GTA CAA TCT GCT CTG ATG CCG CAT AGT TAA GCC AGC
901 CCC GAC ACC CGC CAA CAC CCG CTG ACG CGC CCT GAC GGG CTT GTC TGC TCC CGG CAT CCG
961 CTT ACA GAC AAG CTG TGA CCG TCT CCG GGA GCT GCA TGT GTC AGA GGT TTT CAC CGT CAT
1021 CAC CGA AAC GCG CGA GAC GAA AGG GCC TCG TGA TAC GCC TAT TTT TAT AGG TTA ATG TCA
1081 TGA TAA TAA TGG TTT CTT AGA CGT CAG GTG GCA CTT TTC GGG GAA ATG TGC GCG GAA CCC
1141 CTA TTT GTT TAT TTT TCT AAA TAC ATT CAA ATA TGT ATC CGC TCA TGA GAC AAT AAC CCT
1201 GAT AAA TGC TTC AAT AAT ATT GAA AAA GGA AGA GTA TGA GTA TTC AAC ATT TCC GTG TCG
1261 CCC TTA TTC CCT TTT TTG CGG CAT TTT GCC TTC CTG TTT TTG CTC ACC CAG AAA CGC TGG
1321 TGA AAG TAA AAG ATG CTG AAG ATC AGT TGG GTG CAC GAG TGG GTT ACA TCG AAC TGG ATC
1381 TCA ACA GCG GTA AGA TCC TTG AGA GTT TTC GCC CCG AAG AAC GTT TTC CAA TGA TGA GCA
1441 CTT TTA AAG TTC TGC TAT GTG GCG CGG TAT TAT CCC GTA TTG ACG CCG GGC AAG AGC AAC
1501 TCG GTC GCC GCA TAC ACT ATT CTC AGA ATG ACT TGG TTG AGT ACT CAC CAG TCA CAG AAA
1561 AGC ATC TTA CGG ATG GCA TGA CAG TAA GAG AAT TAT GCA GTG CTG CCA TAA CCA TGA GTG
1621 ATA ACA CTG CGG CCA ACT TAC TTC TGA CAA CGA TCG GAG GAC CGA AGG AGC TAA CCG CTT
1681 TTT TGC ACA ACA TGG GGG ATC ATG TAA CTC GCC TTG ATC GTT GGG AAC CGG AGC TGA ATG
1741 AAG CCA TAC CAA ACG ACG AGC GTG ACA CCA CGA TGC CTG TAG CAA TGG CAA CAA CGT TGC
1801 GCA AAC TAT TAA CTG GCG AAC TAC TTA CTC TAG CTT CCC GGC AAC AAT TAA TAG ACT GGA
1861 TGG AGG CGG ATA AAG TTG CAG GAC CAC TTC TGC GCT CGG CCC TTC CGG CTG GCT GGT TTA
1921 TTG CTG ATA AAT CTG GAG CCG GTG AGC GTG GGT CTC GCG GTA TCA TTG CAG CAC TGG GGC
1981 CAG ATG GTA AGC CCT CCC GTA TCG TAG TTA TCT ACA CGA CGG GGA GTC AGG CAA CTA TGG
2041 ATG AAC GAA ATA GAC AGA TCG CTG AGA TAG GTG CCT CAC TGA TTA AGC ATT GGT AAC TGT
2101 CAG ACC AAG TTT ACT CAT ATA TAC TTT AGA TTG ATT TAA AAC TTC ATT TTT AAT TTA AAA
2161 GGA TCT AGG TGA AGA TCC TTT TTG ATA ATC TCA TGA CCA AAA TCC CTT AAC GTG AGT TTT
2221 CGT TCC ACT GAG CGT CAG ACC CCG TAG AAA AGA TCA AAG GAT CTT CTT GAG ATC CTT TTT
2281 TTC TGC GCG TAA TCT GCT GCT TGC AAA CAA AAA AAC CAC CGC TAC CAG CGG TGG TTT GTT
2341 TGC CGG ATC AAG AGC TAC CAA CTC TTT TTC CGA AGG TAA CTG GCT TCA GCA GAG CGC AGA
2401 TAC CAA ATA CTG TCC TTC TAG TGT AGC CGT AGT TAG GCC ACC ACT TCA AGA ACT CTG TAG
2461 CAC CGC CTA CAT ACC TCG CTC TGC TAA TCC TGT TAC CAG TGG CTG CTG CCA GTG GCG ATA
2521 AGT CGT GTC TTA CCG GGT TGG ACT CAA GAC GAT AGT TAC CGG ATA AGG CGC AGC GGT CGG
2581 GCT GAA CGG GGG GTT CGT GCA CAC AGC CCA GCT TGG AGC GAA CGA CCT ACA CCG AAC TGA
2641 GAT ACC TAC AGC GTG AGC ATT GAG AAA GCG CCA CGC TTC CCG AAG GGA GAA AGG CGG ACA
2701 GGT ATC CGG TAA GCG GCA GGG TCG GAA CAG GAG AGC GCA CGA GGG AGC TTC CAG GGG GAA
2761 ACG CCT GGT ATC TTT ATA GTC CTG TCG GGT TTC GCC ACC TCT GAC TTG AGC GTC GAT TTT
2821 TGT GAT GCT CGT CAG GGG GGC GGA GCC TAT GGA AAA ACG CCA GCA ACG CGG CCT TTT TAC
2881 GGT TCC TGG CCT TTT GCT GGC CTT TTG CTC ACA TGT TCT TTC CTG CGT TAT CCC CTG ATT
2941 CTG TGG ATA ACC GTA TTA CCG CCT TTG AGT GAG CTG ATA CCG CTC GCC GCA GCC GAA CGA
3001 CCG AGC GCA GCG AGT CAG TGA GCG AGG AAG CGG AAG AGC GCC CAA TAC GCA AAC CGC CTC
3061 TCC CCG CGC GTT GGC CGA TTC ATT AAT GCA GCT GTG GAA TGT GTG TCA GTT AGG GTG TGG
3121 AAA GTC CCC AGG CTC CCC AGC AGG CAG AAG TAT GCA AAG CAT GCA TCT CAA TTA GTC AGC
3181 AAC CAG GTG TGG AAA GTC CCC AGG CTC CCC AGC AGG CAG AAG TAT GCA AAG CAT GCA TCT
3241 CAA TTA GTC AGC AAC CAT AGT CCC GCC CCT AAC TCC GCC CAT CCC GCC CCT AAC TCC GCC
3301 CAG TTC CGC CCA TTC TCC GCC CCA TGG CTG ACT AAT TTT TTT TAT TTA TGC AGA GGC CGA
3361 GGC CGC CTC GGC CTC TGA GCT ATT CCA GAA GTA GTG AGG AGG CTT TTT TGG AGG CCT AGG
3421 CTT TTG CAA AAA GCT TGG ACA CAA GAC AGG CTT GCG AGA TAT GTT TGA GAA TAC CAC TTT
3481 ATC CCG CGT CAG GGA GAG GCA GTG CGT AAA AAG ACG CGG ACT CAT GTG AAA TAC TGG TTT
3541 TTA GTG CGC CAG ATC TCT ATA ATC TCG CGC AAC CTA TTT TCC CCT CGA ACA CTT TTT AAG
3601 CCG TAG ATA AAC AGG CTG GGA CAC TTC ACA TGA GCG AAA AAT ACA TCG TCA CCT GGG ACA
3661 TGT TGC AGA TCC ATG CAC GTA AAC TCG CAA GCC GAC TGA TGC CTT CTG AAC AAT GGA AAG
3721 GCA TTA TTG CCG TAA GCC GTG GCG GTC TGT ACC GGG TGC GTT ACT GGC GCG TGA ACT GGG241
3781 TAT TCG TCA TGT CGA TAC CGT TTG TAT TTC CAG CTA CGA TCA CGA CAA CCA GCG CGA GCT
3841 TAA AGT GCT GAA ACG CGC AGA AGG CGA TGG CGA AGG CTT CAT CGT TAT TGA TGA CCT GGT
3901 GGA TAC CGG TGG TAC TGC GGT TGC GAT TCG TGA AAT GTA TCC AAA AGC GCA CTT TGT CAC
3961 CAT CTT CGC AAA ACC GGC TGG TCG TCC GCT GGT TGA TGA CTA TGT TGT TGA TAT CCC GCA
4021 AGA TAC CTG GAT TGA ACA GCC GTG GGA TAT GGG CGT CGT ATT CGT CCC GCC AAT CTC CGG
4081 TCG CTA ATC TTT TCA ACG CCT GGC ACT GCC GGG CGT TGT TCT TTT TAA CTT CAG GCG GGT
4141 TAC AAT AGT TTC CAG TAA GTA TTC TGG AGG CTG CAT CCA TGA CAC AGG CAA ACC TGA GCG
4201 AAA CCC TGT TCA AAC CCC GCT TTA AAC ATC CTG AAA CCT CGA CGC TAG TCC GCC GCT TTA
4261 ATC ACG GCG CAC AAC CGC CTG TGC AGT CGG CCC TTG ATG GTA AAA CCA TCC CTC ACT GGT
4321 ATC GCA TGA TTA ACC GTC TGA TGT GGA TCT GGC GCG GCA TTG ACC CAC GCG AAA TCC TCG
4381 ACG TCC AGG CAC GTA TTG TGA TGA GCG ATG CCG AAC GTA CCG ACG ATG ATT TAT ACG ATA
4441 CGG TGA TTG GCT ACC GTG GCG GCA ACT GGA TTT ATG AGT GGG CCC CGG ATC TTT GTG AAG
4501 GAA CCT TAC TTC TGT GGT GTG ACA TAA TTG GAC AAA CTA CCT ACA GAG ATT TAA AGC TCT
4561 AAG GTA AAT ATA AAA TTT TTA AGT GTA TAA TGT GTT AAA CTA CTG ATT CTA ATT GTT TGT
4621 GTA TTT TAG ATT CCA ACC TAT GGA ACT GAT GAA TGG GAG CAG TGG TGG AAT GCC TTT AAT
4681 GAG GAA AAC CTG TTT TGC TCA GAA GAA ATG CCA TCT AGT GAT GAT GAG GCT ACT GCT GAC
4741 TCT CAA CAT TCT ACT CCT CCA AAA AAG AAG AGA AAG GTA GAA GAC CCC AAG GAC TTT CCT
4801 TCA GAA TTG CTA AGT TTT TTG AGT CAT GCT GTG TTT AGT AAT AGA ACT CTT GCT TGC TTT
4861 GCT ATT TAC ACC ACA AAG GAA AAA GCT GCA CTG CTA TAC AAG AAA ATT ATG GAA AAA TAT
4921 TCT GTA ACC TTT ATA AGT AGG CAT AAC AGT TAT AAT CAT AAC ATA CTG TTT TTT CTT ACT
4981 CCA CAC AGG CAT AGA GTG TCT GCT ATT AAT AAC TAT GCT CAA AAA TTG TGT ACC TTT AGC
5041 TTT TTA ATT TGT AAA GGG GTT AAT AAG GAA TAT TTG ATG TAT AGT GCC TTG ACT AGA GAT
5101 CAT AAT CAG CCA TAC CAC ATT TGT AGA GGT TTT ACT TGC TTT AAA AAA CCT CCC ACA CCT
5161 CCC CCT GAA CCT GAA ACA TAA AAT GAA TGC AAT TGT TGT TGT TAA CTT GTT TAT TGC AGC
5221 TTA TAA TGG TTA CAA ATA AAG CAA TAG CAT CAC AAA TTT CAC AAA TAA AGC ATT TTT TTC
5281 ACT GCA TTC TAG TTG TGG TTT GTC CAA ACT CAT CAA TGT ATC TTA TCA TGT CTG GAT CAA
5341 CTG GAT AAC TCA AGC TAA CCA AAA TCA TCC CAA ACT TCC CAC CCC ATA CCC TAT TAC CAC
5401 TGC CAA TTA CCT AGT GGT TTC ATT TAC TCT AAA CCT GTG ATT CCT CTG AAT TAT TTT CAT
5461 TTT AAA GAA ATT GTA TTT GTT AAA TAT GTA CTA CAA ACT TAG TAG TTG GAA GGG CTA ATT
5521 CAC TCC CAA AGA AGA CAA GAT ATC CTT GAT CTG TGG ATC TAC CAC ACA CAA GGC TAC TTC
5581 CCT GAT TAG CAG AAC TAC ACA CCA GGG CCA GGG GTC AGA TAT CCA CTG ACC TTT GGA TGG
5641 TGC TAC AAG CTA GTA CCA GTT GAG CCA GAT AAG GTA GAA GAG GCC AAT AAA GGA GAG AAC
5701 ACC AGC TTG TTA CAC CCT GTG AGC CTG CAT GGG ATG GAT GAC CCG GAG AGA GAA GTG TTA
5761 GAG TGG AGG TTT GAC AGC CGC CTA GCA TTT CAT CAC GTG GCC CGA GAG CTG CAT CCG GAG
5821 TAC TTC AAG AAC TGC TGA TAT CGA GCT TGC TAC AAG GGA CTT TCC GCT GGG GAC TTT CCA
5881 GGG AGG CGT GGC CTG GGC GGG ACT GGG GAG TGG CGA GCC CTC AGA TCC TGC ATA TAA GCA
5941 GCT GCT TTT TGC CTG TAC TGG GTC TCT CTG GTT AGA CCA GAT CTG AGC CTG GGA GCT CTC
6001 TGG CTA ACT AGG GAA CCC ACT GCT TAA GCC TCA ATA AAG CTT GCC TTG AGT GCT TCA AGT
6061 AGT GTG TGC CCG TCT GTT GTG TGA CTC TGG TAA CTA GAG ATC CCT CAG ACC CTT TTA GTC
6121 AGT GTG GAA AAT CTC TAG CAG TGG CGC CCG AAC AGG GAC TTG AAA GCG AAA GGG AAA CCA
6181 GAG GAG CTC TCT CGA CGC AGG ACT CGG CTT GCT GAA GCG CGC ACG GCA AGA GGC GAG GGG
6241 CGG CGA CTG GTG AGT ACG CCA AAA ATT TTG ACT AGC GGA GGC TAG AAG GAG AGA GAT GGG
6301 TGC GAG AGC GTC AGT ATT AAG CGG GGG AGA ATT AGA TCG CGA TGG GAA AAA ATT CGG TTA
6361 AGG CCA GGG GGA AAG AAA AAA TAT AAA TTA AAA CAT ATA GTA TGG GCA AGC AGG GAG CTA
6421 GAA CGA TTC GCA GTT AAT CCT GGC CTG TTA GAA ACA TCA GAA GGC TGT AGA CAA ATA CTG
6481 GGA CAG CTA CAA CCA TCC CTT CAG ACA GGA TCA GAA GAA CTT AGA TCA TTA TAT AAT ACA
6541 GTA GCA ACC CTC TAT TGT GTG CAT CAA AGG ATA GAG ATA AAA GAC ACC AAG GAA GCT TTA
6601 GAC AAG ATA GAG GAA GAG CAA AAC AAA AGT AAG ACC ACC GCA CAG CAA GCG GCC GCT GAT
6661 CTT CAG ACC TGG AGG AGG AGA TAT GAG GGA CAA TTG GAG AAG TGA ATT ATA TAA ATA TAA
6721 AGT AGT AAA AAT TGA ACC ATT AGG AGT AGC ACC CAC CAA GGC AAA GAG AAG AGT GGT GCA
6781 GAG AGA AAA AAG AGC AGT GGG AAT AGG AGC TTT GTT CCT TGG GTT CTT GGG AGC AGC AGG
6841 AAG CAC TAT GGG CGC AGC GTC AAT GAC GCT GAC GGT ACA GGC CAG ACA ATT ATT GTC TGG
6901 TAT AGT GCA GCA GCA GAA CAA TTT GCT GAG GGC TAT TGA GGC GCA ACA GCA TCT GTT GCA
6961 ACT CAC AGT CTG GGG CAT CAA GCA GCT CCA GGC AAG AAT CCT GGC TGT GGA AAG ATA CCT
7021 AAA GGA TCA ACA GCT CCT GGG GAT TTG GGG TTG CTC TGG AAA ACT CAT TTG CAC CAC TGC
7081 TGT GCC TTG GAA TGC TAG TTG GAG TAA TAA ATC TCT GGA ACA GAT TTG GAA TCA CAC GAC
7141 CTG GAT GGA GTG GGA CAG AGA AAT TAA CAA TTA CAC AAG CTT AAT ACA CTC CTT AAT TGA
7201 AGA ATC GCA AAA CCA GCA AGA AAA GAA TGA ACA AGA ATT ATT GGA ATT AGA TAA ATG GGC
7261 AAG TTT GTG GAA TTG GTT TAA CAT AAC AAA TTG GCT GTG GTA TAT AAA ATT ATT CAT AAT
7321 GAT AGT AGG AGG CTT GGT AGG TTT AAG AAT AGT TTT TGC TGT ACT TTC TAT AGT GAA TAG
7381 AGT TAG GCA GGG ATA TTC ACC ATT ATC GTT TCA GAC CCA CCT CCC AAC CCC GAG GGG ACC
7441 CGA CAG GCC CGA AGG AAT AGA AGA AGA AGG TGG AGA GAG AGA CAG AGA CAG ATC CAT TCG
7501 ATT AGT GAA CGG ATC TCG ACG GTC GCC AAA TGG CAG TAT TCA TCC ACA ATT TTA AAA GAA
7561 AAG GGG GGA TTG GGG GGT ACA GTG CAG GGG AAA GAA TAG TAG ACA TAA TAG CAA CAG ACA242
7621 TAC AAA CTA AAG AAT TAC AAA AAC AAA TTA CAA AAA TTC AAA ATT TTC GGG TTT ATT ACA
7681 GGG ACA GCA GAG ATC CAG TTT GGA TCG ATA AGC TTG ATA TCG AAT TCC TGC AGC CCC GAT
7741 AAA ATA AAA GAT TTT ATT TAG TCT CCA GAA AAA GGG GGG AAT GAA AGA CCC CAC CTG TAG
7801 GTT TGG CAA GCT AGC TGC AGT AAC GCC ATT TTG CAA GGC ATG GAA AAA TAC CAA ACC AAG
7861 AAT AGA GAA GTT CAG ATC AAG GGC GGG TAC ATG AAA ATA GCT AAC GTT GGG CCA AAC AGG
7921 ATA TCT GCG GTG AGC AGT TTC GGC CCC GGC CCG GGG CCA AGA ACA GAT GGT CAC CGC AGT
7981 TTC GGC CCC GGC CCG AGG CCA AGA ACA GAT GGT CCC CAG ATA TGG CCC AAC CCT CAG CAG
8041 TTT CTT AAG ACC CAT CAG ATG TTT CCA GGC TCC CCC AAG GAC CTG AAA TGA CCC TGC GCC
8101 TTA TTT GAA TTA ACC AAT CAG CCT GCT TCT CGC TTC TGT TCG CGC GCT TCT GCT TCC CGA
8161 GCT CTA TAA AAG AGC TCA CAA CCC CTC ACT CGG CGC GCC AGT CCT CCG ACA GAC TGA GTC
8221 GCC CGG GGG GGA TCC GTC CTC CGG CCT CGG CTG CGT CGC GCC ATG GCG GCC CCC GGC GCC
          M   A   A   P   G   A
8281 CGG CGG CCG CTG CTC CTG CTG CTG CTG GCA GGC CTT GCA CAT GGC GCC TCA GCA CTC TTT
      R   R   P   L   L   L   L   L   L   A   G   L   A   H   G   A   S   A   L   F
8341 GAG AAT TCG ATG GTC AGC AAG GGC GAG GAG CTG TTC ACC GGG GTG GTG CCC ATC CTG GTC
      E   N   S   M   V   S   K   G   E   E   L   F   T   G   V   V   P   I   L   V
8401 GAG CTG GAC GGC GAC GTA AAC GGC CAC AAG TTC AGC GTG TCC GGC GAG GGC GAG GGC GAT
      E   L   D   G   D   V   N   G   H   K   F   S   V   S   G   E   G   E   G   D
8461 GCC ACC TAC GGC AAG CTG ACC CTG AAG TTC ATC TGC ACC ACC GGC AAG CTG CCC GTG CCC
      A   T   Y   G   K   L   T   L   K   F   I   C   T   T   G   K   L   P   V   P
8521 TGG CCC ACC CTC GTG ACC ACC CTG ACC TAC GGC GTG CAG TGC TTC AGC CGC TAC CCC GAC
      W   P   T   L   V   T   T   L   T   Y   G   V   Q   C   F   S   R   Y   P   D
8581 CAC ATG AAG CAG CAC GAC TTC TTC AAG TCC GCC ATG CCC GAA GGC TAC GTC CAG GAG CGC
      H   M   K   Q   H   D   F   F   K   S   A   M   P   E   G   Y   V   Q   E   R
8641 ACC ATC TTC TTC AAG GAC GAC GGC AAC TAC AAG ACC CGC GCC GAG GTG AAG TTC GAG GGC
      T   I   F   F   K   D   D   G   N   Y   K   T   R   A   E   V   K   F   E   G
8701 GAC ACC CTG GTG AAC CGC ATC GAG CTG AAG GGC ATC GAC TTC AAG GAG GAC GGC AAC ATC
      D   T   L   V   N   R   I   E   L   K   G   I   D   F   K   E   D   G   N   I
8761 CTG GGG CAC AAG CTG GAG TAC AAC TAC AAC AGC CAC AAC GTC TAT ATC ATG GCC GAC AAG
      L   G   H   K   L   E   Y   N   Y   N   S   H   N   V   Y   I   M   A   D   K
8821 CAG AAG AAC GGC ATC AAG GTG AAC TTC AAG ATC CGC CAC AAC ATC GAG GAC GGC AGC GTG
      Q   K   N   G   I   K   V   N   F   K   I   R   H   N   I   E   D   G   S   V
8881 CAG CTC GCC GAC CAC TAC CAG CAG AAC ACC CCC ATC GGC GAC GGC CCC GTG CTG CTG CCC
      Q   L   A   D   H   Y   Q   Q   N   T   P   I   G   D   G   P   V   L   L   P
8941 GAC AAC CAC TAC CTG AGC ACC CAG TCC GCC CTG AGC AAA GAC CCC AAC GAG AAG CGC GAT
      D   N   H   Y   L   S   T   Q   S   A   L   S   K   D   P   N   E   K   R   D
9001 CAC ATG GTC CTG CTG GAG TTC GTG ACC GCC GCC GGG ATC ACT CTC GGC ATG GAC GAG CTG
      H   M   V   L   L   E   F   V   T   A   A   G   I   T   L   G   M   D   E   L
9061 TAC AAG CTT CGC ATG AAG GGA TCC GGC ATC GCT GGC TTC AAA GGT GAA CAA GGC CCC AAG
      Y   K   L   R   M   K   G   S   G   I   A   G   F   K   G   E   Q   G   P   K
9121 GGA GAA CCT TCA TGG GAG AAT CTG AAG GGG TCT GTG GAA GAG TGT GTT CAG GAT GGT AAC
      G   E   P   S   W   E   N   L   K   G   S   V   E   E   C   V   Q   D   G   N
9181 AAC ATG TTG ATC CCC ATT GCT GTG GGC GGT GCC CTG GCA GGG CTG GTC CTC ATC GTC CTC
      N   M   L   I   P   I   A   V   G   G   A   L   A   G   L   V   L   I   V   L
9241 ATT GCC TAC CTC ATT GGC AGG AAG AGG AGT CAC GCC GGC TAT CAG ACC ATC TAG CTC GAG
      I   A   Y   L   I   G   R   K   R   S   H   A   G   Y   Q   T   I   Z
9301 AGG CCT GGT ACC ACG CGT GCG GCC GCG ACT CTA GAG TCG ACC TGC AGG CAT GCA AGC TTG
9361 ATA TCA AGC TTA TCG ATG AAT GTC AAT AAA ACA AAA TGG TGG GGC AAT CAT CTA CAT TTC
9421 ATG GGA TAT GTG ATT ACT AGT TCA GGT GTA TTG CCA CAA GAC AAA CAT GTT AAG AAA ATT
9481 TCC CGT TAT TTG CAC TCT GTT CCT GTT AAT CAA CCT CTG GAT TAC AAA ATT TGT GAA AGA
9541 TTG ACT GGT ATT CTT AAC TAT GTT GCT CCT TTT ACG CTA TGT GGA TAC GCT GCT TTA ATG
9601 CCT TTG TAT CAT GCT ATT GCT TCC CGT ATG GCT TTC ATT TTC TCC TCC TTG TAT AAA TCC
9661 TGG TTG CTG TCT CTT TAT GAG GAG TTG TGG CCC GTT GTC AGG CAA CGT GGC GTG GTG TGC
9721 ACT GTG TTT GCT GAC GCA ACC CCC ACT GGT TGG GGC ATT GCC ACC ACC TGT CAG CTC CTT
9781 TCC GGG ACT TTC GCT TTC CCC CTC CCT ATT GCC ACG GCG GAA CTC ATC GCC GCC TGC CTT
9841 GCC CGC TGC TGG ACA GGG GCT CGG CTG TTG GGC ACT GAC AAT TCC GTG GTG TTG TCG GGG
9901 AAG CTG ACG TCC TTT CCA TGG CTG CTC GCC TGT GTT GCC ACC TGG ATT CTG CGC GGG ACG
9961 TCC TTC TGC TAC GTC CCT TCG GCC CTC AAT CCA GCG GAC CTT CCT TCC CGC GGC CTG CTG
10021 CCG GCT CTG CGG CCT CTT CCG CGT CTT CGC CTT CGC CCT CAG ACG AGT CGG ATC TCC CTT
10081 TGG GCC GCC TCC CCG CCT GAT CGA TAC CGT CGA CCT CGA243
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